{
  "questions": [
    {
      "body": "What symptoms characterize the Muenke syndrome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23378035", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22446440", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22016144", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21844411", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21403567", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20592905", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20301588", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18000976", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17414289", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14963686"
      ], 
      "type": "summary", 
      "id": "52bf1d3c03868f1b0600000d", 
      "snippets": [
        {
          "offsetInBeginSection": 164, 
          "offsetInEndSection": 481, 
          "text": "Muenke syndrome is characterized by coronal craniosynostosis (bilateral more often than unilateral), hearing loss, developmental delay, and carpal and/or tarsal bone coalition. Tarsal coalition is a distinct feature of Muenke syndrome and has been reported since the initial description of the disorder in the 1990s. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23378035", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 133, 
          "text": "Muenke syndrome caused by the FGFR3 Pro250Arg mutation is associated with craniosynostosis, hearing loss, and various bony anomalies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22446440", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 242, 
          "text": "Muenke syndrome caused by the FGFR3(P250R) mutation is an autosomal dominant disorder mostly identified with coronal suture synostosis, but it also presents with other craniofacial phenotypes that include mild to moderate midface hypoplasia. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22016144", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1110, 
          "offsetInEndSection": 1207, 
          "text": "Sensorineural hearing loss at lower frequencies was found only in patients with Muenke syndrome. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21844411", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1388, 
          "offsetInEndSection": 1544, 
          "text": " Sensorineural hearing loss can occur in all 4 syndromes studied but is the primary cause of hearing loss in children and young adults with Muenke syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21844411", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 298, 
          "text": "The facial features of children with FGFR3Pro250Arg mutation (Muenke syndrome) differ from those with the other eponymous craniosynostotic disorders. We documented midfacial growth and position of the forehead after fronto-orbital advancement (FOA) in patients with the FGFR3 mutation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21403567", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 252, 
          "text": "The Muenke syndrome (MS) is characterized by unicoronal or bicoronal craniosynostosis, midfacial hypoplasia, ocular hypertelorism, and a variety of minor abnormalities associated with a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20592905", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 158, 
          "offsetInEndSection": 1281, 
          "text": "Muenke syndrome is characterized by considerable phenotypic variability: features may include coronal synostosis (more often bilateral than unilateral); synostosis of other sutures, all sutures (pansynostosis), or no sutures; or macrocephaly. Bilateral coronal synostosis typically results in brachycephaly (broad skull), although turribrachycephaly (a \"tower-shaped\" skull) or a cloverleaf skull can be observed. Unilateral coronal synostosis results in anterior plagiocephaly (asymmetry of the skull and face). Other craniofacial findings typically include: ocular hypertelorism, ptosis or proptosis (usually mild), midface hypoplasia, temporal bossing, and a highly arched palate. Strabismus is common. Extracranial findings can include: hearing loss (in 33%-100% of affected individuals); developmental delay (~33%); intellectual disability; carpal bone and/or tarsal bone fusions; brachydactyly, broad toes, broad thumbs, and/or clinodactyly; and radiographic findings of thimble-like (short and broad) middle phalanges and/or cone-shaped epiphyses. Phenotypic variability is considerable even within the same family. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20301588", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 224, 
          "text": "Muenke syndrome is an autosomal dominant disorder characterized by coronal suture craniosynostosis, hearing loss, developmental delay, carpal and tarsal fusions, and the presence of the Pro250Arg mutation in the FGFR3 gene. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18000976", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 655, 
          "offsetInEndSection": 762, 
          "text": "A majority of the patients (95%) demonstrated a mild-to-moderate, low frequency sensorineural hearing loss.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18000976", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 960, 
          "offsetInEndSection": 1222, 
          "text": "Increased digital markings were more severe posteriorly in Muenke patients than in non-Muenke patients. The Muenke patients with unilateral coronal synostosis showed a somewhat more severe asymmetry in the anterior part of the skull than the non-Muenke patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17414289", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 322, 
          "text": "Muenke syndrome is a genetically determined craniosynostosis that involves one or both coronal sutures. In some patients it is associated with skeletal abnormalities such as thimble-like middle phalanges, coned epiphysis, and/or neurological impairment, namely sensorineural hearing loss or mental retardation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14963686", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the inheritance pattern of Li\u2013Fraumeni syndrome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/7981072", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2190528", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9302689", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16772121"
      ], 
      "type": "factoid", 
      "id": "52bf208003868f1b06000019", 
      "snippets": [
        {
          "offsetInBeginSection": 524, 
          "offsetInEndSection": 745, 
          "text": "It therefore appears that the LFS phenotype has been conferred by an aberrant gene, showing a dominant pattern of inheritance, which may be acting to compromise normal p53 function rather than by a mutation in p53 itself.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7981072", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 725, 
          "offsetInEndSection": 1213, 
          "text": "In addition, there seem to be predispositions to a wider range of different, but well-defined neoplasms: e.g., adenocarcinomatosis of the colon and the endometrium, or the Li-Fraumeni/SBLA syndrome. The latter shows a spectrum of sarcoma, brain tumours, breast cancer, leukaemias, lung and adenocortical cancer. The genes leading to these types of dominantly inherited predispositions appear to be the tentatively so-called tumour suppressor genes, for which the Rb gene serves as a model", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2190528", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 150, 
          "text": "he Li-Fraumeni syndrome is a rare autosomal-dominant disease whose hallmark is a predisposition to a wide range of cancers among members of a family.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9302689", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 146, 
          "text": "Li-Fraumeni Syndrome (LFS) is characterized by early-onset carcinogenesis involving multiple tumor types and shows autosomal dominant inheritance.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16772121", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are the indications for alteplase?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23727456", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23463740", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23336348", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23251746", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19804685", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17656661", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15532135", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12450926", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11919252", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11794977", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11778213", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11772304", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9385884", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8521760", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7579782", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7549071", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10172049", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2689138"
      ], 
      "type": "list", 
      "id": "52bf209303868f1b0600001a", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 240, 
          "text": "In Japan, intravenous alteplase, a recombinant tissue-type plasminogen activator (rt-PA), was approved for an indication of ischemic stroke in 2005 on the basis of the results of a clinical trial with a unique dose of the drug (0.6 mg/kg). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23727456", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1858, 
          "offsetInEndSection": 2051, 
          "text": "Alteplase appears to show efficacy for treatment of thrombus-related venous catheter occlusion in pediatric patients; however, data regarding its use in occluded dialysis catheters are limited.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23463740", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 898, 
          "offsetInEndSection": 1171, 
          "text": "The trials used to support Food and Drug Administration approval of alteplase for central venous catheter (CVC) occlusions generally had low pediatric enrollment; however, additional small studies are available that support use of alteplase for this indication in children.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23463740", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 168, 
          "text": "To review the literature pertaining to the efficacy of alteplase for restoration of patency of occluded venous and dialysis catheters in pediatric patients. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23463740", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 190, 
          "text": "Intravenous thrombolysis with recombinant tissue Plasminogen Activator improves outcomes in patients treated early after stroke but at the risk of causing intracranial hemorrhage.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23336348", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 157, 
          "offsetInEndSection": 309, 
          "text": "Intravenous alteplase (recombinant tissue plasminogen activator) is the only approved thrombolytic agent at present indicated for acute ischaemic stoke.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23251746", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 1014, 
          "text": "This paper presents a summary of the evidence review group report into the clinical effectiveness and cost-effectiveness of alteplase for the treatment of acute ischaemic stroke, in accordance with the licensed indication, based upon the evidence submission from the manufacturer to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The submitted clinical evidence included several randomised controlled trials indicating that, in highly selected patients, alteplase administered at a licensed dose within 3 hours of the onset of acute ischaemic stroke is associated with a statistically significant reduction in the risk of death or dependency at 3 months compared with placebo, despite a significantly increased risk of symptomatic intracranial haemorrhage within the first 7-10 days. Data from the National Institute of Neurological Disorders and Stroke (NINDS) trial suggest that the benefit of treatment is sustained at 6 and 12 months.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19804685", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2560, 
          "offsetInEndSection": 2837, 
          "text": "The guidance issued by NICE in April 2007 as a result of the STA states that alteplase is recommended for the treatment of acute ischaemic stroke only when used by physicians trained and experienced in the management of acute stroke and in centres with the required facilities.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19804685", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 211, 
          "text": "Because of the risk of hemorrhage, especially in the brain, thrombolytic therapy with intravenous alteplase is restricted by guidelines, and only a small number of selected patients are being treated.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17656661", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1062, 
          "offsetInEndSection": 1280, 
          "text": "Alteplase can be given to patients with cervical artery dissection, seizure at onset and evidence of acute ischemia on brain imaging, and after carefully weighing risk and benefit in pregnancy and during menstruation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17656661", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 4, 
          "offsetInEndSection": 144, 
          "text": "Alteplase is the first thrombolytic drug to be approved in France for the treatment of ischaemic stroke within three hours of symptom onset.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15532135", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 209, 
          "offsetInEndSection": 376, 
          "text": "However, the Cochrane systematic review of thrombolysis for acute ischaemic stroke suggests that alteplase is the most promising treatment for acute ischaemic stroke. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12450926", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 10, 
          "offsetInEndSection": 256, 
          "text": " To determine whether cryopreserved solutions of the thrombolytic agent alteplase could be used as a safe, effective, and economically reasonable alternative to urokinase in patients presenting with occluded central venous access devices (CVADs).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11919252", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 266, 
          "offsetInEndSection": 370, 
          "text": "Alteplase has been reported as an efficacious alternative to urokinase for treatment of occluded CVADs. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11919252", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 908, 
          "offsetInEndSection": 1044, 
          "text": "Patients presenting with occluded CVADs received a sufficient volume of the thawed alteplase solution to fill the occluded catheter(s). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11919252", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1475, 
          "offsetInEndSection": 1760, 
          "text": "Cryopreserved 1-mg/mL aliquots of alteplase are safe and effective in the clearance of occluded CVADs when stored at -20 degrees C for 30 days. The ability to cryopreserve alteplase aliquots makes it an economically reasonable alternative to urokinase in the setting of CVAD occlusion.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11919252", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 222, 
          "offsetInEndSection": 489, 
          "text": "Of the thrombolytic agents and therapeutic protocols in use, alteplase 100 mg/2 hours seems to be the best compromise between the risk of bleeding and efficacy in reducing pulmonary resistances by 30 to 40% and relatively early pulmonary revascularisation of 40-50%. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11794977", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 230, 
          "text": "To explore the best regimen of treatment for acute pulmonary embolism(APE), and to evaluate the efficacy and safety of 2-h infusion of recombinant tissue-type plasminogen activator, Alteplase (rt-PA) and urokinase(UK). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11778213", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 983, 
          "offsetInEndSection": 1125, 
          "text": "A 2 h regimen of rt-PA or UK showed reliable efficacy and safety for treatment of APE. The indication of thrombolytic therapy can be extended.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11778213", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 114, 
          "text": "Tissue type plasminogen activator is available, through recombinant technology, for thrombolytic use as alteplase.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11772304", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 249, 
          "offsetInEndSection": 363, 
          "text": "Alteplase has been used successfully in evolving myocardial infarction (MI) to reopen occluded coronary arteries. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11772304", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 475, 
          "offsetInEndSection": 760, 
          "text": "Alteplase is most effective when given early in MI and is probably ineffective when given 12 h after the onset of symptoms. The effectiveness of alteplase in MI can be increased by front loading with a bolus of 15 mg, followed by an infusion of 50 mg over 30 min and 35 mg over 60 min.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11772304", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1017, 
          "offsetInEndSection": 1467, 
          "text": "A reduced dose of alteplase to increase coronary artery patency prior to angioplasty may be useful in MI. An exciting new indication for the use of alteplase is in stroke, where it has become the first beneficial intervention. Alteplase is used to reopen occluded cerebral vessels but is associated with an increased risk of intracerebral haemorrhage. Alteplase is beneficial if given within 3 h of the onset of stroke but not after this time period.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11772304", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1586, 
          "offsetInEndSection": 1813, 
          "text": "Clinical trials have not established a role for alteplase in the treatment of acute coronary syndromes or deep vein thrombosis. However, alteplase is useful in treating pulmonary thromboembolism and peripheral vascular disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11772304", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 277, 
          "text": "Our aim was to design and evaluate a new and easily administered recombinant tissue-type plasminogen activator (rt-PA) regimen for thrombolysis in acute myocardial infarction (AMI) based on established pharmacokinetic data that improve the reperfusion success rate. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9385884", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 289, 
          "offsetInEndSection": 430, 
          "text": "Rapid restoration of Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow is a primary predictor of mortality after thrombolysis in AMI.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9385884", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1912, 
          "offsetInEndSection": 2123, 
          "text": "The 60-min alteplase thrombolysis in AMI protocol achieved a TIMI grade 3 patency rate of 81.1% at 90 min with no indication of an increased bleeding hazard; it was associated with a 1.2% overall mortality rate.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9385884", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 244, 
          "offsetInEndSection": 1001, 
          "text": "Alteplase is now firmly established as a treatment of choice in the management of acute myocardial infarction. The efficacy of intravenous alteplase in the treatment of pulmonary thromboembolism has also been established and appears to be similar to that of streptokinase and urokinase in this indication and in arterial thrombotic occlusion. However, its use in this latter indication and in other vascular disorders has not been as extensively documented. Although trials demonstrating the efficacy of intravenous alteplase in patients with deep vein thrombosis and intra-arterial alteplase in patients with arterial thrombotic occlusion exist, reliable data on the efficacy of the fibrinolytic in ischaemic stroke and intracranial haemorrhage are scarce.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8521760", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1756, 
          "offsetInEndSection": 1965, 
          "text": "Further, preliminary data suggest efficacy in the therapy of deep vein thrombosis and arterial thrombotic occlusion, and alteplase has a proven place in the fibrinolytic treatment of pulmonary thromboembolism.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8521760", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 386, 
          "offsetInEndSection": 527, 
          "text": "The non-antigenic competitor for these two compounds for the indication of MI is alteplase (recombinant tissue plasminogen activator, rt-PA).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7579782", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1144, 
          "offsetInEndSection": 1270, 
          "text": " In the framework of tailored thrombolytic therapy, alteplase or urokinase appear to be the drugs of choice in these patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7579782", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 484, 
          "text": "Patients with a recent (less than 10 days) proximal deep vein thrombosis of the leg or pelvis are candidates for thrombolysis as the major benefit over heparin seems to be the prevention of the postphlebitic limb, an aim which is still not proven in a satisfactory manner. Nonocclusive thrombi appear to lyse more readily than occlusive thrombi. For this indication the optimal dose regimens for the three thrombolytic drugs (streptokinase, urokinase, alteplase) are not established. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7549071", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 679, 
          "offsetInEndSection": 1301, 
          "text": "To save 1 year of life, the costs of thrombolytic therapy using intravenous streptokinase, alteplase (recombinant tissue plasminogen activator; rt-PA) or anistreplase (anisoylated plasminogen streptokinase activator complex) under standard restricted indication criteria, vary from 1000 pounds British sterling to 1700 pounds British sterling in the UK, SEK3090 to 9660 in Scandinavia and $US35 000 to 800 000 in the US, depending on time delay in starting treatment after pain onset, size of infarct, thrombolytic agents used, study methodology, lists of clinical events considered in cost counting and the discount rate.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10172049", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1037, 
          "offsetInEndSection": 1390, 
          "text": "Thus, the results of the ETTT trial show that the used low dosages of alteplase administered intravenously over 3-7 days in heparinized patients cannot be recommended as a treatment for patients with deep venous thrombosis of lower limbs and/or pelvis. Further studies are needed to define a more suitable dosage regimen of alteplase in this indication.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1641820", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 941, 
          "offsetInEndSection": 1119, 
          "text": "Streptokinase, urokinase and alteplase have all been shown to accelerate the lysis of pulmonary emboli and to decrease pulmonary vascular obstruction and pulmonary hypertension. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2689138", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1669, 
          "offsetInEndSection": 1918, 
          "text": "The local treatment of acute arterial occlusion in limb arteries results in rapid clearing of the artery in 67% of patients treated with streptokinase; the corresponding success rates for urokinase and alteplase are 81% and 88 to 94%, respectively. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2689138", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Does Apolipoprotein E (ApoE) have anti-inflammatory activity?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23963646", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22326991"
      ], 
      "type": "yesno", 
      "id": "530cf4fe960c95ad0c000002", 
      "snippets": [
        {
          "offsetInBeginSection": 2, 
          "offsetInEndSection": 396, 
          "text": " have previously reported that apolipoprotein E (apoE), a protein component of very-low-density lipoproteins (VLDL) and high-density lipoproteins and a potent plasma-borne atheroprotective factor, exerts anti-inflammatory activity in macrophages by switching the activation profile from M1 (\"classic\") to M2 (\"alternative\") in a process involving signaling via low-density lipoprotein receptor ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23963646", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 206, 
          "offsetInEndSection": 248, 
          "text": "anti-inflammatory activity in macrophages ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23963646", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 243, 
          "offsetInEndSection": 360, 
          "text": "Small peptides corresponding to the receptor-binding region of apoE mimic the anti-inflammatory activity of the apoE ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22326991", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is the ACE inhibitor indicated for lung cancer treatment?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18837885", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22300564"
      ], 
      "type": "yesno", 
      "id": "530cf4fe960c95ad0c000005", 
      "snippets": [
        {
          "offsetInBeginSection": 104, 
          "offsetInEndSection": 311, 
          "text": "The angiotensin converting enzyme (ACE) inhibitors are used widely as antihypertensive agents, and it has been suggested that they decrease the risk of some cancers, although available data are conflicting. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18837885", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1182, 
          "offsetInEndSection": 1561, 
          "text": "Using cell viability and fluorescent activated cell sorting analysis tests, we demonstrated that captopril inhibited the viability of LNM35 cells by inducing apoptosis, providing insight about the mechanisms underlying its antitumorigenic activities. In view of these experimental findings, we conclude that captopril could be a promising option for the treatment of lung cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18837885", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 790, 
          "offsetInEndSection": 1181, 
          "text": "In order to determine the mechanism by which captopril inhibited tumor growth, we investigated the impact of this drug on cell proliferation, apoptosis, and angiogenesis. Immunohistochemical analysis demonstrated that captopril treatment significantly reduced the number of proliferating cells (Ki-67) in the tumor samples but was not associated with inhibition of tumor angiogenesis (CD31).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18837885", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 484, 
          "offsetInEndSection": 697, 
          "text": "Using this model, we demonstrated that daily IP administration of captopril (2.8 mg/mouse) for 3 weeks resulted in a remarkable reduction of tumor growth (58%, P < 0.01) and lymph node metastasis (50%, P= 0.088). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18837885", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 9, 
          "offsetInEndSection": 135, 
          "text": "Angiotensin-converting enzyme (ACE) inhibitors have been shown to mitigate radiation-induced lung injury in preclinical models", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22300564", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2023, 
          "offsetInEndSection": 2147, 
          "text": "ACE inhibitors may decrease the incidence of radiation pneumonitis in patients receiving thoracic radiation for lung cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22300564", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are the indications for hydrochlorothiazide?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23808745", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23767455", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23136355", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23116225", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22490507", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21718097", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9421695", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8227469"
      ], 
      "type": "list", 
      "id": "530cf4fe960c95ad0c000007", 
      "snippets": [
        {
          "offsetInBeginSection": 553, 
          "offsetInEndSection": 687, 
          "text": "The most frequently used diuretic in combination is again hydrochlorothiazide, which is combined with reninangiotensin system blockers", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23808745", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 985, 
          "offsetInEndSection": 1073, 
          "text": "Also a combination of two diuretics is popular -\u200a mainly hydrochlorothiazide + amiloride", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23808745", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 4, 
          "offsetInEndSection": 166, 
          "text": "article gives an overview of the risk factors for hypertension and the appropriate indication for using a fixed combination of telmisartan and hydrochlorothiazide", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23767455", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1576, 
          "offsetInEndSection": 1782, 
          "text": "Hydrochlorothiazide 25-200 mg daily, chlorothiazide 500 mg twice daily, and indapamide 2.5 mg daily provided long-term blood pressure reduction in patients with severe renal disease who were not on dialysis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23136355", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1828, 
          "offsetInEndSection": 2094, 
          "text": "This review provides an overview of the efficacy and safety of antihypertensive therapy based on olmesartan medoxomil\u2009\u00b1\u2009hydrochlorothiazide and amlodipine/olmesartan medoxomil in high-risk patient populations enrolled in studies that reported ambulatory BP endpoints", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23116225", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1746, 
          "offsetInEndSection": 1882, 
          "text": "In this regard, ARB-based SPCs are available in combination with the diuretic, hydrochlorothiazide (HCTZ) or the calcium CCB, amlodipine", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22490507", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1098, 
          "offsetInEndSection": 1312, 
          "text": "Telmisartan has a favourable safety and tolerability profile, and has demonstrated efficacious and long-lasting 24-hour BP reductions, whether as monotherapy or in combination with hydrochlorothiazide or amlodipine", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21718097", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 524, 
          "offsetInEndSection": 623, 
          "text": "The combination of irbesartan and hydrochlorothiazide resulted in additive antihypertensive effects", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9421695", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 444, 
          "offsetInEndSection": 561, 
          "text": "Patients with stable hypertension, not taking antihypertensive or NSAID medications, were treated with HCTZ 50 mg/day", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8227469", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2, 
          "offsetInEndSection": 173, 
          "text": "is study determined the effect of nonsteroidal anti-inflammatory drug (NSAID) administration on blood pressure in hypertensive patients taking hydrochlorothiazide (HCTZ). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8227469", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 932, 
          "offsetInEndSection": 1050, 
          "text": "Hydrochlorothiazide treatment decreased diastolic blood pressure to 83.1 +/- 5.6 mm Hg, and MAP to 101.1 +/- 6.5 mm Hg", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8227469", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can tetracyline affect tooth formation?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/3855899", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6829791", 
        "http://www.ncbi.nlm.nih.gov/pubmed/737550", 
        "http://www.ncbi.nlm.nih.gov/pubmed/5447715"
      ], 
      "type": "yesno", 
      "id": "530cf4fe960c95ad0c000009", 
      "snippets": [
        {
          "offsetInBeginSection": 149, 
          "offsetInEndSection": 379, 
          "text": "he results of that study, reported earlier (Rebich et al., 1983), indicated that over one-fifth of the American Indian children had discoloration of the dentition due to ingestion of tetracycline during the years of tooth formatio", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3855899", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 184, 
          "text": "ale Wistar rats prelabeled with tetracycline to mark surfaces of bone and tooth formation-mineralization were placed into orbit for 18.5 days aboard the Soviet COSMOS-1129 Biosatellit", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6829791", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 195, 
          "offsetInEndSection": 360, 
          "text": "It was concluded that the increased tetracycline incorporation reflected a higher rate of mineralization associated with faster tooth formation in the unimpeded toot", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/737550", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 237, 
          "text": "n this investigation an attempt has been made to determine the relationship between the staining of permanent teeth by tetracycline administered during the period of tooth formation with the dosage of the drug and the duration of therap", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/5447715", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 494, 
          "offsetInEndSection": 787, 
          "text": " definite relationship between total dosage and staining and duration of administration and staining was established; the condition occurred with greater frequency (in more than one-third of the children) when the total dosage exceeded 3 g. or the duration of treatment was longer than 10 days", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/5447715", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is zolpidem an antibiotic?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/9433391", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8098760", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1403792"
      ], 
      "type": "yesno", 
      "id": "530cf4fe960c95ad0c00000a", 
      "snippets": [
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 106, 
          "text": "Zolpidem is a short-acting imidazopyridine hypnotic drug that is metabolized mainly by CYP3A4.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9433391", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 461, 
          "offsetInEndSection": 719, 
          "text": "FGIN-1-27 and alpidem, like the neurosteroid 3 alpha,21-dehydroxy-5 alpha-pregnane-20-one (THDOC), clonazepam and zolpidem (the direct allosteric modulators of gamma-aminobutyric acidA receptors) delay the onset of isoniazid and metrazol-induced convulsions.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8098760", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 231, 
          "text": "olpidem is a new, short-acting hypnotic of imidazopyridine structure which binds selectively to a subpopulation of receptors involved in the action of benzodiazepines [omega 1 (BZ1) sites of the gamma-aminobutyric acidA receptors]", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8098760", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2, 
          "offsetInEndSection": 231, 
          "text": "lpidem is a new, short-acting hypnotic of imidazopyridine structure which binds selectively to a subpopulation of receptors involved in the action of benzodiazepines [omega 1 (BZ1) sites of the gamma-aminobutyric acidA receptors]", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1403792", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1334, 
          "offsetInEndSection": 1469, 
          "text": "In contrast, after repeated treatment with zolpidem, there was no change in its ability to produce sedative and anticonvulsant effects.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1403792", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which type of lung cancer is afatinib used for?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24086949", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23683257", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23664448", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18520300", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18408761"
      ], 
      "type": "factoid", 
      "id": "530cf4fe960c95ad0c00000b", 
      "snippets": [
        {
          "offsetInBeginSection": 611, 
          "offsetInEndSection": 891, 
          "text": "Afatinib is a novel irreversible inhibitor of the ErbB family members EGFR, tyrosine kinase-type cell surface receptors HER2 and HER4. It shows preclinical efficacy in NSCLC with common EGFR-activating mutations and the T790M mutation typically associated with EGFR TKI resistance", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24086949", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 540, 
          "offsetInEndSection": 978, 
          "text": "At present, only first-generation EGFR-tyrosine kinase inhibitors (TKIs) (erlotinib and gefitinib) are available for clinical use. Second-generation irreversible EGFR-TKIs, such as afatinib, are still in clinical trials. In current clinical practice, EGFR-TKI is the first-line treatment of choice for metastatic NSCLC patients with tumor EGFR mutation or as salvage therapy in NSCLC patients who received systemic chemotherapy previously", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683257", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 661, 
          "offsetInEndSection": 1249, 
          "text": "Afatinib is a small molecule covalently binding and inhibiting the EGFR, HER2 and HER4 receptor tyrosine kinases. In preclinical studies, afatinib not only inhibited the growth of models with common activating EGFR mutations, but was also active in lung cancer models harboring wild-type EGFR or the EGFR L858R/T790M double mutant. Clinical efficacy of afatinib has been extensively studied in the LUX-Lung study program. These trials showed promising efficacy in patients with EGFR-mutant NSCLC or enriched for clinical benefit from EGFR tyrosine kinase inhibitors gefitinib or erlotinib", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23664448", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1287, 
          "offsetInEndSection": 1394, 
          "text": "BIBW2992 is an irreversible EGFR TKI that also inhibits HER2 and vascular epidermal growth factor receptors", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18520300", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1396, 
          "offsetInEndSection": 1559, 
          "text": "In vitro work shows that this compound inhibits wild-type EGFR, EGFR exon 19 deletion, EGFR L858R, and EGFR T790M, the mutation associated with acquired resistance", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18520300", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 879, 
          "offsetInEndSection": 1104, 
          "text": "Here, we show that BIBW2992, an anilino-quinazoline designed to irreversibly bind EGFR and HER2, potently suppresses the kinase activity of wild-type and activated EGFR and HER2 mutants, including erlotinib-resistant isoforms", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18408761", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can desvenlafaxine be used at a dose of 50mg/day?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23881185", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23587982", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23517291", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22173281", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21067460", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20107296", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19407730", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19407711", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18507895"
      ], 
      "type": "yesno", 
      "id": "530cf4fe960c95ad0c00000c", 
      "snippets": [
        {
          "offsetInBeginSection": 1331, 
          "offsetInEndSection": 1466, 
          "text": "Long-term use of desvenlafaxine was safe and well tolerated, with a clinical benefit/risk profile similar to that in other populations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23587982", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2, 
          "offsetInEndSection": 286, 
          "text": "e objective of this study was to evaluate the long-term safety of desvenlafaxine for continuation treatment of major depressive disorder (MDD) in Japanese patients. This was a phase 3, multicenter, 10-month, open-label study with flexible dosing of desvenlafaxine (25, 50, 100 mg/day)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23587982", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 13, 
          "offsetInEndSection": 270, 
          "text": "n an effort to establish the lowest effective dose of desvenlafaxine (administered as desvenlafaxine succinate), we assessed the efficacy, safety, and tolerability of 10- and 50-mg/day desvenlafaxine vs placebo for the treatment of major depressive disorder", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23517291", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 893, 
          "offsetInEndSection": 1101, 
          "text": "Change from baseline to final evaluation in adjusted HAM-D(17) total scores was not significantly different comparing desvenlafaxine 10 mg/day (-9.28) and desvenlafaxine 50 mg/day (-8.92) with placebo (-8.42)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23517291", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1359, 
          "offsetInEndSection": 1449, 
          "text": "Overall rates of treatment-emergent adverse events with both doses were similar to placebo", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23517291", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1526, 
          "offsetInEndSection": 1783, 
          "text": "However, in a companion study reported separately, desvenlafaxine 50 mg, but not 25 mg, separated from placebo. Taken together, these studies suggest that 50 mg is the minimum effective dose of desvenlafaxine for the treatment of major depressive disorder. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23517291", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 394, 
          "offsetInEndSection": 515, 
          "text": "Patients were randomly assigned (2:1 ratio) to 12 weeks of double-blind treatment with desvenlafaxine 50 mg/day or placeb", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22905811", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2006, 
          "offsetInEndSection": 2208, 
          "text": "With the exception of orgasmic dysfunction in men without preexisting sexual dysfunction, no significant negative effect on sexual functioning was observed over 12 weeks of treatment with desvenlafaxine", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22905811", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 740, 
          "offsetInEndSection": 793, 
          "text": "Desvenlafaxine XR was dosed at 50 mg/day for 10 days.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22173281", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 539, 
          "offsetInEndSection": 645, 
          "text": "Desvenlafaxine therapy is initiated at the therapeutic dose (50 mg/day) without a need for dose titration.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21067460", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 370, 
          "offsetInEndSection": 764, 
          "text": "Clinical studies have investigated the efficacy of DVS in doses ranging from 50 to 400 mg/day for the treatment of MDD in adult outpatients. The effects of DVS 50 mg/day have been clearly distinguished from placebo in the reduction of MDD symptoms in such clinical trials. No additional therapeutic benefits were found at doses > 50 mg/day. The recommended dose of DVS ranges from 50 to 100 mg.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20107296", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 540, 
          "offsetInEndSection": 668, 
          "text": "Adult outpatients with major depressive disorder received desvenlafaxine doses ranging from 50-400 mg/day or placebo for 8 weeks", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19407730", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2422, 
          "offsetInEndSection": 2533, 
          "text": " At the recommended therapeutic dose of 50 mg/day, discontinuation due to adverse events was similar to placebo", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19407730", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 341, 
          "offsetInEndSection": 483, 
          "text": "atients received fixed (50, 100, 200, or 400 mg/day; n=1,342) or flexible doses (100-400 mg/day; n=463) of desvenlafaxine or placebo (n=1,108)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19407711", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1244, 
          "offsetInEndSection": 1493, 
          "text": "Desvenlafaxine demonstrated short-term efficacy for treating major depressive disorder across the range of doses studied. No evidence of greater efficacy was observed with doses >50 mg/day; a strong dose-response effect on tolerability was observed.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19407711", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 249, 
          "text": "To assess the efficacy, safety, and tolerability of 50- and 100-mg/day doses of desvenlafaxine (administered as desvenlafaxine succinate), a serotonin-norepinephrine reuptake inhibitor, for the treatment of major depressive disorder (MDD)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18507895", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 280, 
          "offsetInEndSection": 581, 
          "text": "Patients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) MDD and 17-item Hamilton Rating Scale for Depression (HAM-D(17)) scores > or =20 were randomly assigned to double-blind placebo or desvenlafaxine treatment (fixed dose of 50 mg/day or 100 mg/day) for 8 weeks.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18507895", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 931, 
          "offsetInEndSection": 1093, 
          "text": "Desvenlafaxine 50 mg was associated with a significantly greater adjusted mean change from baseline on the HAM-D(17) (-11.5) compared with placebo (-9.5, p=0.018)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18507895", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1701, 
          "offsetInEndSection": 1809, 
          "text": " These results demonstrate efficacy, safety, and tolerability of desvenlafaxine 50 mg/day for treating MDD. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18507895", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can ferric carboxymaltose be used to treat anemia in inflammatory bowel disease patients?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24114623", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24081613", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23889159", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23644823", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23078888", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22179489", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22023204", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21699794", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21340038", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21479141", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20648930", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19787830", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18371137"
      ], 
      "type": "yesno", 
      "id": "530cf4fe960c95ad0c00000d", 
      "snippets": [
        {
          "offsetInBeginSection": 641, 
          "offsetInEndSection": 805, 
          "text": "Intravenous iron should be preferred where oral iron is poorly tolerated or where it has failed in moderate to severe anemia, and in combination with erythropoietin", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24114623", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 938, 
          "offsetInEndSection": 1069, 
          "text": "Ferric carboxymaltose is much more convenient, and has been shown to be more effective than iron sucrose in a large randomized tria", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24114623", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 84, 
          "text": "nemia and iron deficiency anemia are very common in inflammatory bowel disease (IBD", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24114623", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 817, 
          "offsetInEndSection": 941, 
          "text": "Ferric carboxymaltose was associated with cost savings of 30-44\u00a0% per patient per treatment cycle compared to iron sucrose. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24081613", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 385, 
          "text": "Iron deficiency is common in pregnancy, postpartum, inflammatory bowel disease, chronic kidney disease, chronic heart failure, heavy uterine bleeding, cancer and following surgery. We estimate the budget impact (BI) on the Swiss mandatory health insurance associated with substituting iron sucrose (standard) with ferric carboxymaltose (new treatment) using real-life data.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24081613", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1438, 
          "offsetInEndSection": 1583, 
          "text": "reating iron deficiency involves substantial costs to the Swiss MHI which may be reduced by substituting iron sucrose with ferric carboxymaltose.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24081613", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 129, 
          "offsetInEndSection": 347, 
          "text": "e aim of this study was to observe, in a non-interventional way, how Swedish gastroenterologists adhere to guidelines in IBD outpatients treated with intravenous ferric carboxymaltose (FCM), and the result of treatment", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23889159", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1658, 
          "offsetInEndSection": 1766, 
          "text": "FCM lowers platelet counts and platelet activation in patients with IBD-associated secondary thrombocytosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23644823", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 588, 
          "offsetInEndSection": 777, 
          "text": "We performed a randomized, single-blinded placebo-controlled trial testing the effect of ferric carboxymaltose (FCM) in patients with IBD with secondary thrombocytosis (platelets > 450 G/L)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23644823", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 228, 
          "offsetInEndSection": 410, 
          "text": "e performed a randomized, placebo-controlled trial to determine if administration of ferric carboxymaltose (FCM) prevents anemia in patients with IBD and low levels of serum ferritin", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23078888", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1670, 
          "offsetInEndSection": 1749, 
          "text": "FCM prevents recurrence of anemia in patients with IBD, compared with placebo. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23078888", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 291, 
          "offsetInEndSection": 403, 
          "text": " A subgroup was analyzed regarding efficacy and side effects of iron supplementation with ferric carboxymaltose.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22179489", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1169, 
          "offsetInEndSection": 1332, 
          "text": "Iron deficiency and anemia are frequent in IBD patients. Treatment with ferric carboxymaltose is efficious, safe and well tolerated in iron-deficient IBD patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22179489", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 857, 
          "offsetInEndSection": 1001, 
          "text": " Intravenous iron avoids these concerns, especially with the development of ferric carboxymaltose, which allow up to 1000mg to be given rapidly.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22023204", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 71, 
          "text": "What is the optimal treatment for anemia in inflammatory bowel disease?", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22023204", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 237, 
          "offsetInEndSection": 441, 
          "text": "We compared the efficacy and safety of a novel fixed-dose ferric carboxymaltose regimen (FCM) with individually calculated iron sucrose (IS) doses in patients with inflammatory bowel disease (IBD) and IDA", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21699794", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1332, 
          "offsetInEndSection": 1447, 
          "text": "Study drugs were well tolerated and drug-related adverse events were in line with drug-specific clinical experience", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21699794", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1542, 
          "offsetInEndSection": 1706, 
          "text": " The simpler FCM-based dosing regimen showed better efficacy and compliance, as well as a good safety profile, compared with the Ganzoni-calculated IS dose regimen.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21699794", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1450, 
          "offsetInEndSection": 1701, 
          "text": "Ferric carboxymaltose can be rapidly administered in doses of 15 mg/kg body weight, up to a ceiling dose of 1000 mg. A test dose is not required, and it can be used more widely across a spectrum of iron deficiency and iron deficiency anemia indication", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21340038", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 425, 
          "offsetInEndSection": 970, 
          "text": " Intravenous iron offers a rapid means of iron repletion and is superior to oral iron in many circumstances, especially in the presence of anemia of chronic disease, where it appears to overcome the block to absorption of iron from the gastrointestinal tract and immobilization of stored iron. The clinical situations where high doses of iron are commonly required are reviewed. These include nondialysis-dependent chronic kidney disease, inflammatory bowel disease, obstetrics, menorrhagia, and anemia associated with cancer and its treatment. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21340038", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 268, 
          "offsetInEndSection": 723, 
          "text": "Ferric carboxymaltose can be administered at 15 mg/kg body weight to a maximum dose of 1000 mg, whereas iron isomaltoside 1000 can be administered at 20 mg/kg body weight. The ability to give high doses of iron is important in the context of managing iron deficiency anemia in a number of clinical conditions where demands for iron are high (including chronic blood loss associated with inflammatory bowel disease, menorrhagia, and chronic kidney disease)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21479141", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 456, 
          "text": "erric carboxymaltose (FCM, Ferinject) was effective and well tolerated in the treatment of iron-deficiency anemia (IDA) in nine, Phase III, randomized, controlled, multicenter trials in a diverse range of indications, including patients with inflammatory bowel disease (IBD), post-partum anemia (PPA) or abnormal uterine bleeding (AUB), chronic heart failure (CHF), non-dialysis-dependent chronic kidney disease (CKD) and those undergoing hemodialysis (HD", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20648930", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1306, 
          "offsetInEndSection": 1404, 
          "text": "In patients with IBD or PPA, improvements in Hb levels were more rapid with FCM than with FeSulf. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20648930", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2101, 
          "offsetInEndSection": 2263, 
          "text": "CM improved patient quality of life to an equivalent extent to oral FeSulf in patients with IBD or PPA, and to a greater extent than oral FeSulf in women with AUB", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20648930", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 949, 
          "offsetInEndSection": 1205, 
          "text": "Four different products are principally used in clinical practice, which differ in their pharmacokinetic properties and safety profiles: iron gluconate and iron sucrose (lower single doses), and iron dextran and ferric carboxymaltose (higher single doses).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19787830", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 104, 
          "text": "he prevalence of anemia across studies on patients with inflammatory bowel disease (IBD) is high (30%).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19787830", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 158, 
          "text": " novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18371137", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1356, 
          "offsetInEndSection": 1544, 
          "text": "FeCarb is effective and safe in IBD-associated anemia. It is noninferior to FeSulf in terms of Hb change over 12 wk, and provides a fast Hb increase and a sufficient refill of iron stores.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18371137", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1156, 
          "offsetInEndSection": 1342, 
          "text": "Treatment-related adverse events (AEs) occurred in 28.5% of the FeCarb and 22.2% of the FeSulf groups, with discontinuation of study medication due to AEs in 1.5% and 7.9%, respectively.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18371137", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 658, 
          "offsetInEndSection": 812, 
          "text": "The median Hb improved from 8.7 to 12.3 g/dL in the FeCarb group and from 9.1 to 12.1 g/dL in the FeSulf group, demonstrating noninferiority (P= 0.6967). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18371137", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the clinical indication of cardiac T1 mapping magnetic resonance?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24124732", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24043965", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24036385", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24011774", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23549230", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23498674", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23498672", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23408722", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22967246", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22720998", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22309452", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22279111", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19007595", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17659622", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12765114"
      ], 
      "type": "factoid", 
      "id": "530cf51d5610acba0c000001", 
      "snippets": [
        {
          "offsetInBeginSection": 1477, 
          "offsetInEndSection": 1672, 
          "text": "At present, ECV and native T1 mapping appear sufficiently robust for many diseases; yet more research is required before a large-scale application for clinical decision-making can be recommended.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24124732", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1878, 
          "offsetInEndSection": 2031, 
          "text": "Native T1 mapping as a novel criterion for the detection of acute myocarditis showed excellent and superior diagnostic performance compared with T2W-CMR.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24011774", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1603, 
          "offsetInEndSection": 1783, 
          "text": "In the present preliminary study, cardiac magnetic resonance postcontrast T1 time is associated with prognosis in HFPEF, suggesting postcontrast T1 as possible biomarker for HFPEF.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24036385", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 690, 
          "offsetInEndSection": 828, 
          "text": "Using T1 and T2 maps, the diagnosis of myocarditis can be made even in cases of global myocarditis with the help of quantitative analysis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24043965", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 669, 
          "offsetInEndSection": 919, 
          "text": "Recent findings show that ECV measurement can be correlated to the extent of diffuse fibrosis. Comparatively, molecular imaging targets specific biomarkers in the fibrosis formation pathway and provides enhanced sensitivity for imaging early disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23549230", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1416, 
          "offsetInEndSection": 2126, 
          "text": "T1 native was significantly longer in patients with cardiomyopathy compared with control subjects (p < 0.01). Conversely, post-contrast T1 values were significantly shorter in patients with cardiomyopathy at all time points (p < 0.01). ECV was significantly higher in patients with cardiomyopathy compared with controls at all time points (p < 0.01). Multivariate binary logistic regression revealed that T1 native could differentiate between healthy and diseased myocardium with sensitivity of 100%, specificity of 96%, and diagnostic accuracy of 98% (area under the curve 0.99; 95% confidence interval: 0.96 to 1.00; p < 0.001), whereas post-contrast T1 values and ECV showed lower discriminatory performance", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23498674", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1857, 
          "offsetInEndSection": 2094, 
          "text": "Noncontrast T1 mapping has high diagnostic accuracy for detecting cardiac AL amyloidosis, correlates well with markers of systolic and diastolic dysfunction, and is potentially more sensitive for detecting early disease than LGE imaging.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23498672", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 634, 
          "offsetInEndSection": 864, 
          "text": "Recently, the remarkable advances in CMR technique, such as T1 mapping, which can quantitatively evaluate myocardial status, showed potentials to overcome limitations of existing CMR sequences and to expand the application of CMR.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23408722", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2063, 
          "offsetInEndSection": 2165, 
          "text": "ECV mapping appears promising to complement LGE imaging in cases of more homogenously diffuse disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22967246", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1601, 
          "offsetInEndSection": 1735, 
          "text": "Non-contrast T1-mapping using ShMOLLI is a novel method for objectively detecting myocardial edema with a high diagnostic performance.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22720998", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1871, 
          "offsetInEndSection": 1961, 
          "text": "In acute MI, pre-contrast T1-mapping allows assessment of the extent of myocardial damage.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22309452", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1461, 
          "offsetInEndSection": 1655, 
          "text": "Extracellular volume fraction imaging can quantitatively characterize myocardial infarction, atypical diffuse fibrosis, and subtle myocardial abnormalities not clinically apparent on LGE images.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22279111", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1720, 
          "offsetInEndSection": 1859, 
          "text": "Contrast-enhanced CMRI T(1) mapping identifies changes in myocardial T(1) times in heart failure, which appear to reflect diffuse fibrosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007595", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 806, 
          "offsetInEndSection": 1169, 
          "text": "Acute and chronic MI exhibited different T(1) changes. Precontrast threshold T(1) maps detected segmental abnormalities caused by acute MI with 96% sensitivity and 91% specificity. Agreement between measurements of infarct size from T(1) mapping and DE imaging was higher in chronic than in acute infarcts. Precontrast T(1) maps enable the detection of acute MI. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17659622", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1397, 
          "offsetInEndSection": 1473, 
          "text": "T1 mapping can detect myocardial necrosis without the use of contrast media.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12765114", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which are the Yamanaka factors?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24150221", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23939864", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23704989", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23658991", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23612755", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23527808", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23166588", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22449255", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22357549", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22075965", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21839145", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21761058", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21640101", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21249204", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20144262", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19030024"
      ], 
      "type": "list", 
      "id": "53137541e3eabad021000010", 
      "snippets": [
        {
          "offsetInBeginSection": 462, 
          "offsetInEndSection": 505, 
          "text": "Yamanaka factors (OCT4, SOX2, MYC, and KLF4", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23704989", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 17, 
          "offsetInEndSection": 63, 
          "text": "Yamanaka factors' (Oct4, Sox2, Klf4 and c-Myc)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24150221", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 303, 
          "offsetInEndSection": 350, 
          "text": "Yamanaka factors (Oct4, Sox2, Klf4, and c-Myc) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23939864", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 815, 
          "offsetInEndSection": 862, 
          "text": "Yamanaka factors (c-myc, KLF4, Oct3/4 and SOX2)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23612755", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 824, 
          "offsetInEndSection": 877, 
          "text": "Yamanaka factors (i.e., Oct4, Sox2, Klf4, and c-Myc) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23658991", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 112, 
          "offsetInEndSection": 160, 
          "text": "Yamanaka factors (Oct3/4, Sox2, Klf4, and c-Myc)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23527808", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 839, 
          "offsetInEndSection": 886, 
          "text": "Yamanaka factors (OCT4, SOX2, KLF4, cMYC - OSKM", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23166588", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 676, 
          "offsetInEndSection": 726, 
          "text": "Oct4, Sox2, Klf4 and cMyc (4TF, Yamanaka factors) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22449255", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 807, 
          "offsetInEndSection": 854, 
          "text": "Yamanaka factors (Pou5f1, Myc, Klf4, and Sox2) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22357549", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 547, 
          "offsetInEndSection": 611, 
          "text": "c-Myc, Klf4, Oct3/4, and Sox2 (the so-called \"Yamanaka factors\")", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22075965", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1002, 
          "offsetInEndSection": 1049, 
          "text": "Yamanaka factors, Oct3/4, Sox2, Klf4, and c-Myc", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21839145", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 212, 
          "offsetInEndSection": 275, 
          "text": "Yamanaka factors, namely Sox2, Oct3/4 (Pou5f1), Klf4, and c-Myc", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21761058", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 154, 
          "offsetInEndSection": 218, 
          "text": "Oct4, Sox2, Klf4 and c-Myc, also known as the Yamanaka factors. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21640101", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 651, 
          "offsetInEndSection": 715, 
          "text": "Yamanaka factors (SOX2, OCT3/4, and KLF4, with or without c-MYC)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21249204", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 766, 
          "offsetInEndSection": 810, 
          "text": "Yamanaka factors Oct4, Sox2, Klf4, and c-Myc", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20144262", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 44, 
          "text": "amanaka factors (Oct3/4, Sox2, Klf4, c-Myc)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19030024", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which hormone abnormalities are characteristic to Pendred syndrome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23235354", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22116361", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22109890", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21511235", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20834201", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20822748", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20583162", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20501687", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20298745", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19692489", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19318451", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19205523", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19196800", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19189692", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18692402", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17697873", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17365057", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17120770", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16263499", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15863666", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15807875", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15279074", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11375792", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10650967", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9618167"
      ], 
      "type": "factoid", 
      "id": "53148a07dae131f847000002", 
      "snippets": [
        {
          "offsetInBeginSection": 154, 
          "offsetInEndSection": 363, 
          "text": "Loss or reduction of function mutations of SLC26A4 underlie Pendred syndrome, a disorder invariably leading to hearing loss with enlarged vestibular aqueducts and in some patients to hypothyroidism and goiter.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23235354", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 618, 
          "offsetInEndSection": 752, 
          "text": "Goiter development and hypothyroidism vary among affected individuals and seem to be partially dependent on nutritional iodide intake.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21511235", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 823, 
          "offsetInEndSection": 1063, 
          "text": "Elucidation of the molecular basis of Pendred syndrome and the function of pendrin has provided unexpected novel insights into the pathophysiology of the inner ear, thyroid hormone synthesis, and chloride/bicarbonate exchange in the kidney.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21511235", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 790, 
          "offsetInEndSection": 833, 
          "text": "Thyroid goiter was found in 46.5% of cases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20822748", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 144, 
          "text": "Biallelic mutations of SLC26A4 (encoding pendrin) cause Pendred syndrome (PS), an autosomal recessive genetic disorder with deafness and goiter.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20583162", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 468, 
          "offsetInEndSection": 620, 
          "text": "From age 15 years, her thyroid gland showed progressive enlargement accompanied by elevation of serum thyroglobulin reaching 10-fold the normal amount. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20583162", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1240, 
          "offsetInEndSection": 1457, 
          "text": "In summary, a molecularly confirmed PS patient showed goiter progression accompanied by elevated serum thyroglobulin and increased thyroidal iodine uptake, but normal serum TSH levels and normal iodine organification.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20583162", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 131, 
          "text": "A coherent organization of differentiation proteins is required to maintain an appropriate thyroid function in the Pendred thyroid.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20501687", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 141, 
          "text": "Pendred syndrome is an autosomal recessive disorder defined by sensorineural deafness, goiter and a partial organification defect of iodide. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22116361", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 333, 
          "offsetInEndSection": 611, 
          "text": "The clinical phenotype of patients with Pendred syndrome and the fact that pendrin can mediate iodide efflux in transfected cells suggest that this anion exchanger may be involved in mediating iodide efflux into the follicular lumen, a key step in thyroid hormone biosynthesis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22116361", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 602, 
          "offsetInEndSection": 813, 
          "text": "Results of immunoblot and immunofluorescence experiments reveal that TSH and forskolin rapidly increase pendrin abundance at the plasma membrane through the protein kinase A pathway in PCCL-3 rat thyroid cells. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22109890", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1166, 
          "offsetInEndSection": 1360, 
          "text": "These results demonstrate that pendrin translocates to the membrane in response to TSH and suggest that it may have a physiological role in apical iodide transport and thyroid hormone synthesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22109890", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 202, 
          "text": "Mutations in the SLC26A4 gene, coding for the anion transporter pendrin, are responsible for Pendred syndrome, characterized by congenital sensorineural deafness and dyshormonogenic goiter. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20834201", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 241, 
          "text": "Pendred syndrome is an autosomal recessive disorder characterized by sensorineural deafness, goiter and a partial defect in iodide organification. Goiter development and hypothyroidism vary and appear to depend on nutritional iodide intake. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20298745", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 370, 
          "offsetInEndSection": 570, 
          "text": "Pendrin is mainly expressed in the thyroid, the inner ear, and the kidney. In the thyroid, pendrin localizes to the apical membrane of thyrocytes, where it may be involved in mediating iodide efflux. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20298745", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 214, 
          "text": "Mutations of SLC26A4 cause an enlarged vestibular aqueduct, nonsyndromic deafness, and deafness as part of Pendred syndrome. SLC26A4 encodes pendrin, an anion exchanger located in the cochlea, thyroid, and kidney. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19692489", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 151, 
          "text": "Genetic causes of goiter and deafness: Pendred syndrome in a girl and cooccurrence of Pendred syndrome and resistance to thyroid hormone in her sister.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19318451", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 9, 
          "offsetInEndSection": 290, 
          "text": "Goiter and deafness can be associated in some genetic syndromes, e.g. Pendred syndrome (PS) and resistance to thyroid hormone (RTH). PS is an autosomal recessive disorder characterized by goiter and sensorineural hearing impairment with an enlarged vestibular aqueduct bilaterally.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19318451", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 754, 
          "offsetInEndSection": 1011, 
          "text": "The elder sister had an elevated TSH level at newborn screening followed by subclinical hypothyroidism, childhood-onset goiter, and bilateral progressive sensorineural hearing impairment with enlarged vestibular aqueducts, consistent with a diagnosis of PS.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19318451", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1611, 
          "offsetInEndSection": 1769, 
          "text": "This is the first report of the cooccurrence, in the same individual, of PS and RTH, two genetic syndromes both associated with goiter and hearing impairment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19318451", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 89, 
          "offsetInEndSection": 314, 
          "text": "Its diagnosis requires identification of the classical triad of symptoms, including hypoacusis, thyroid goitre and iodine organification defect in the thyroid, which may lead to thyroid functional disorders of hypothyroidism.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19205523", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1598, 
          "offsetInEndSection": 1741, 
          "text": "Endocrine examination showed hypothyroidism in 5, its subclinical form in 1, diffuse thyroid goitre in 4 and nodular thyroid goiter in 2 cases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19205523", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1115, 
          "offsetInEndSection": 1298, 
          "text": "Biallelic mutations in the SLC26A4 gene lead to Pendred syndrome, an autosomal recessive disorder characterized by sensorineural deafness, goiter, and impaired iodide organification. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19196800", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 145, 
          "text": "Thyroidectomy in a patient with multinodular dyshormonogenetic goitre--a case of Pendred syndrome confirmed by mutations in the PDS/SLC26A4 gene.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19189692", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 143, 
          "text": "We report a young woman with genetically confirmed Pendred syndrome and discuss the current therapeutic strategies of dyshormonogenetic goitre.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19189692", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 600, 
          "offsetInEndSection": 709, 
          "text": "Management of a patient with Pendred syndrome requires careful follow-up and regular imaging of the thyroid. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19189692", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 345, 
          "text": "Pendred syndrome is an autosomal recessive disorder characterized by sensorineural hearing impairment, presence of goiter, and a partial defect in iodide organification, which may be associated with insufficient thyroid hormone synthesis. Goiter development and development of hypothyroidism are variable and depend on nutritional iodide intake.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18692402", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 172, 
          "text": "Pendred syndrome (PS) is an autosomal recessive disease that is characterized by congenital sensorineural hearing loss, goiter, and a partial iodine organification defect. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17697873", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 568, 
          "offsetInEndSection": 803, 
          "text": "Levels of thyroid hormones were essentially normal in all patients: 2 patients had goiters and/or elevated serum thyroglobulin levels, whereas 2 other patients had positive thyroid antibodies and a positive perchlorate discharge test. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17697873", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 179, 
          "text": "Pendred syndrome, defined as the constellation of goiter, sensori-neural hearing loss, and positive perchlorate discharge test, is the most frequent cause of congenital deafness. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17365057", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 402, 
          "offsetInEndSection": 589, 
          "text": "Presuming the classic triad as the gold standard, we compared MRI findings in six such defined patients with six cases having goiter, hearing loss, and normal perchlorate discharge test. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17365057", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 177, 
          "text": "For over 100 years after the first description of the disorder, the molecular pathology underlying the deafness and thyroid pathology in Pendred syndrome (PS) remained unknown. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17120770", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 809, 
          "offsetInEndSection": 1143, 
          "text": "We review the literature to identify genetic defects involved in the iodination process of the thyroid hormone synthesis, particularly defects in iodide transport from circulation into the thyroid cell, defects in iodide transport from the thyroid cell to the follicular lumen (Pendred syndrome), and defects of iodide organification.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16263499", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 795, 
          "offsetInEndSection": 1024, 
          "text": "Among those causing dyshormonogenesis, the thyroid peroxidase and thyroglobulin genes were initially described, and more recently PDS (Pendred syndrome), NIS (sodium iodide symporter), and THOX2 (thyroid oxidase 2) gene defects. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15863666", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1692, 
          "offsetInEndSection": 1967, 
          "text": "Among permanent CH cases, those with a goitre (n = 27) had an iodine organification defect (n = 10), Pendred syndrome (n = 1), a defect of thyroglobulin synthesis (n = 8), or a defect of sodium iodine symporter (n = 1), and in seven patients no aetiology could be determined.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15807875", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 164, 
          "offsetInEndSection": 315, 
          "text": "Pendred syndrome consists in sensorineural deafness, goiter and impaired thyroid hormone synthesis while in EVA thyroid function seems to be preserved.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15279074", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1312, 
          "offsetInEndSection": 1465, 
          "text": "All patients harbouring mutations in the SLC26A4 gene had goiter and a positive perchlorate discharge test: 3 were slightly hypothyroid and 2 euthyroid. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15279074", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1763, 
          "offsetInEndSection": 1987, 
          "text": "Patients with mutations in the SLC26A4 gene had larger thyroid volume (p<0.002), higher serum thyroglobulin (Tg) levels (p<0.002) and greater radioiodine discharge after perchlorate (p=0.09) than patients without mutations. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15279074", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 148, 
          "text": "The autosomal recessive Pendred's syndrome is defined by congenital sensorineural deafness, goiter, and impaired iodide organification. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11375792", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 979, 
          "offsetInEndSection": 1041, 
          "text": "Two patients were hypothyroid, two individuals were euthyroid.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11375792", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 109, 
          "text": "Pendred syndrome is an autosomal recessive disorder characterized by congenital deafness and thyroid goiter. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10650967", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 215, 
          "text": "Pendred syndrome is an autosomal recessive disorder characterized by the association between sensorineural hearing loss and thyroid swelling or goitre and is likely to be the most common form of syndromic deafness. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9618167", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the role of brain natriuretic peptide in traumatic brain injury patients ?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23963125", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21808206", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19803787", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18325424", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17690842", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16774478", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16322908"
      ], 
      "type": "summary", 
      "id": "5314d05adae131f84700000d", 
      "snippets": [
        {
          "offsetInBeginSection": 1301, 
          "offsetInEndSection": 1613, 
          "text": "This study provides evidence that BNP plasma concentrations increase rapidly after TBI. Plasma BNP concentrations are correlated with hyponatremia in severe TBI patients but not in mild and moderate TBI patients. Furthermore, patients with elevated ICP have a higher serum BNP level in first 4 days after injury.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21808206", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 517, 
          "offsetInEndSection": 1288, 
          "text": "In average, the peak of BNP level was measured at 703.9 pg/mL\u00b1179.1 pg/mL on day 3 after injury, which was correlated to the severity of TBI. Among patients with severe TBI, plasma NT-proBNP concentrations in patients with hyponatremia were statistically higher than those without hyponatremia (p<0.05). In the hyponatremic group, the plasma NT-proBNP increased to a peak of 1001.16 pg/mL\u00b1131.52 pg/mL within 48 hours after injury and maintained at a high level for 3 days. In the normonatremic group, the plasma NT-proBNP reached a peak of 826.43 pg/mL\u00b1337.43 pg/mL on day 5 and quickly decreased thereafter. In addition, we found plasma NT-proBNP concentrations in patients with ICP>15 mm Hg were significantly higher than those in patients with ICP\u226415 mm Hg (p<0.01). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21808206", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 214, 
          "text": "There is emerging evidence to suggest that brain natriuretic peptide (BNP) is elevated after acute brain injury, and that it may play an adaptive role in recovery through augmentation of cerebral blood flow (CBF). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19803787", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1522, 
          "offsetInEndSection": 1750, 
          "text": "hBNP improves neurological function in murine models of TBI and ICH, and was associated with enhanced CBF and downregulation of neuroinflammatory responses. hBNP may represent a novel therapeutic strategy after acute CNS injury.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19803787", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 434, 
          "offsetInEndSection": 508, 
          "text": "Here, we describe 2 cases of CSW in TBI patients with elevated BNP levels.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18325424", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 934, 
          "offsetInEndSection": 1058, 
          "text": "These patients with TBI had findings consistent with CSW with elevated BNP levels in the setting of normal cardiac function.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18325424", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 559, 
          "offsetInEndSection": 842, 
          "text": "We measured NT-proBNP levels in cerebrospinal fluid (CSF) and serum of 14 patients suffering from severe TBI (GCS15 mm Hg (n=6), the serum (800+/-150 pg/mL) and CSF levels (55+/-9 pg/mL) of NT-proBNP were significantly increased after 24 h, as compared to patients with ICP15 mm Hg. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16774478", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1425, 
          "offsetInEndSection": 1645, 
          "text": "BNP plasma concentrations are elevated shortly after head injury and are continuously elevated during the acute phase in patients with more extensive SAH and in those with elevated ICP, and correlate with poor outcomes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16322908", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are the applications of a Dermaroller ?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23960389", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20808602", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20300368"
      ], 
      "type": "summary", 
      "id": "5325a1a69b2d7acc7e000025", 
      "snippets": [
        {
          "offsetInBeginSection": 1819, 
          "offsetInEndSection": 2148, 
          "text": "Dermaroller along with Minoxidil treated group was statistically superior to Minoxidil treated group in promoting hair growth in men with AGA for all 3 primary efficacy measures of hair growth. Microneedling is a safe and a promising tool in hair stimulation and also is useful to treat hair loss refractory to Minoxidil therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23960389", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 261, 
          "text": "Microneedling with dermaroller is a new treatment modality for the treatment of scars, especially acne scars, stretch marks, wrinkles, and for facial rejuvenation. It is a simple and relatively cheap modality that also can be used for transdermal drug delivery.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20808602", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1514, 
          "offsetInEndSection": 1632, 
          "text": "Microneedling therapy seems to be a simple and effective treatment option for the management of atrophic facial scars.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20300368", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What imaging modalities have been listed as method of choice  to diagnose CSF leak?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/8519147", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11109603", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19723768", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19242563", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11331153"
      ], 
      "type": "list", 
      "id": "5326300fd6d3ac6a34000005", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "CT cisternography in the investigation of cerebrospinal fluid rhinorrhoea.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8519147", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 775, 
          "offsetInEndSection": 903, 
          "text": "CTC is an accurate, well-tolerated procedure and should be regarded as the method of choice for investigation of this condition.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8519147", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 88, 
          "offsetInEndSection": 204, 
          "text": "Currently the method of choice for cerebrospinal fluid detection is qualitative determination of beta-2-transferrin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11109603", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 432, 
          "offsetInEndSection": 527, 
          "text": "surgery the use of intrathecal sodium-fluorescein improves visualisation of the site of leakage", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11109603", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 135, 
          "text": "The contribution of 3D-CISS and contrast-enhanced MR cisternography in detecting cerebrospinal fluid leak in patients with rhinorrhoea.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19723768", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1265, 
          "offsetInEndSection": 1390, 
          "text": " In conclusion, 3D-CISS is a non-invasive and reliable technique, and should be the first-choice method to localise CSF leak.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19723768", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 63, 
          "offsetInEndSection": 287, 
          "text": "unenhanced (three-dimensional constructive interference in steady state (3D-CISS)) and contrast-enhanced MR cisternography (CE-MRC) in detecting the localisation of cerebrospinal fluid (CSF) leak in patients with rhinorrhoea", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19723768", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 252, 
          "offsetInEndSection": 461, 
          "text": "The diagnostic work-up included lumbar tapping and measurement of CSF opening pressure, radioisotope cisternography, brain and spinal magnetic resonance imaging (MRI), and computed tomography (CT) myelography.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19242563", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 97, 
          "offsetInEndSection": 362, 
          "text": "A Tc-99m diethyltriaminepentacetic acid radionuclide cisternography (RNC) showed the accumulation of radioactivity in the area of the subarachnoid space, the poor migration of the isotope over the convexities, and the early appearance of kidney and bladder activity", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11331153", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is being measured with an accelerometer in back pain patients", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23865908", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23560880", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21872993", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21195646", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20921030", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20457489", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19945891", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19945334", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19895697", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19402888", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18752975", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16437292", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16426878", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15271728", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11387574"
      ], 
      "type": "list", 
      "id": "533f9df0c45e133714000016", 
      "snippets": [
        {
          "offsetInBeginSection": 373, 
          "offsetInEndSection": 511, 
          "text": "accelerometer assessment measuring overall physical activity (PAL), constant strain postures (CSP), standing time (ST) and lying time (LT)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23865908", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 690, 
          "offsetInEndSection": 790, 
          "text": "Physical activity was measured for 7 days at both baseline and at 3 months with an RT3 accelerometer", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23560880", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 534, 
          "offsetInEndSection": 600, 
          "text": "wearing an accelerometer to assess physical activity in daily life", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21872993", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 590, 
          "offsetInEndSection": 659, 
          "text": "An accelerometer was used to objectively assess their activity level ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21195646", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 68, 
          "offsetInEndSection": 581, 
          "text": "objective activity data to determine whether patients with chronic lower back pain report their activity levels as accurately as controls do. DESIGN: A cross-sectional study was performed in patients and controls. SETTING: The study was carried out in the daily environment of the subjects. SUBJECTS: Thirty-two chronic lower back pain patients with symptoms more than three months and 20 healthy controls from the Netherlands, aged 18-65 years. MAIN MEASURES: A tri-axial accelerometer was worn for five weekdays", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20921030", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 556, 
          "offsetInEndSection": 666, 
          "text": "During 14days physical activity in daily life was measured, with both an electronic diary and an accelerometer", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20457489", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 854, 
          "offsetInEndSection": 920, 
          "text": "physical activity in daily life was measured with an accelerometer", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19945891", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 127, 
          "offsetInEndSection": 539, 
          "text": "physical activity (PA) in individuals with chronic low back pain (CLBP). Thirty-eight participants with non-specific CLBP (29=distressed; 9=non-distressed) were recruited. PA levels were measured using an accelerometer (activPAL activity monitor) over a one week period. The following parameters of physical activity were recorded: time upright (standing or walking), time standing, time walking, and step count.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19945334", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 781, 
          "offsetInEndSection": 866, 
          "text": "Physical activity levels will be measured by self report, RT3 triaxial accelerometer,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19895697", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 322, 
          "offsetInEndSection": 452, 
          "text": "to study the time spent in different static trunk postures which was recorded by a biaxial accelerometer attached to the T12 level", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19402888", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 450, 
          "offsetInEndSection": 538, 
          "text": "Daily activities were assessed by measuring body movement with a tri-axial accelerometer", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18752975", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 118, 
          "offsetInEndSection": 556, 
          "text": "nighttime activity data from 18 patients diagnosed with chronic back pain. The patients were followed for 6 days and 5 nights. Pain levels were collected every 90 min between 0800 hours and 2,200 hours using a computerized electronic diary. Activity levels were collected using a wrist accelerometer (Actiwatch AW-64). The Actiwatch sampled activity counts every 1 min. Patients were asked to wear the Actiwatch on their non-dominant arm.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16437292", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 770, 
          "offsetInEndSection": 884, 
          "text": " 8-h accelerometer assessment in their daily life (physical activity level (PAL), number of constant postures (CP)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426878", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 214, 
          "offsetInEndSection": 321, 
          "text": "The activity levels were collected automatically using a wrist accelerometer and were sampled every minute.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15271728", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 572, 
          "offsetInEndSection": 691, 
          "text": "Physical activity in daily life, expressed as whole-body acceleration measured with a triaxial accelerometer (Tracmor),", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11387574", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "How could U1 small nuclear RNA be used in therapeutics?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22968481", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22454067", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22454066", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21520335", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21326217", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20869034"
      ], 
      "type": "summary", 
      "id": "5357a514f1005d6b58000003", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 133, 
          "text": "Exon 45 skipping through U1-snRNA antisense molecules recovers the Dys-nNOS pathway and muscle differentiation in human DMD myoblasts", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22968481", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 200, 
          "offsetInEndSection": 382, 
          "text": "Here, we show the selection of U1 snRNA-antisense constructs able to confer effective rescue of dystrophin synthesis in a \u039444 Duchenne genetic background, through skipping of exon 45", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22968481", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 457, 
          "offsetInEndSection": 521, 
          "text": "U1 small nuclear RNA have been used to carry antisense sequences", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22454067", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 769, 
          "offsetInEndSection": 955, 
          "text": "we showed that bifunctional U7 snRNAs harboring silencer motifs induce complete skipping of exon 51, and thus restore dystrophin expression in DMD patients cells to near wild-type levels", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22454067", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 957, 
          "offsetInEndSection": 1161, 
          "text": "These new constructs are very promising for the optimization of therapeutic exon skipping for DMD, but also offer powerful and versatile tools to modulate pre-mRNA splicing in a wide range of applications", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22454067", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 124, 
          "text": "U1 snRNA as an effective vector for stable expression of antisense molecules and for the inhibition of the splicing reaction", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22454066", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 152, 
          "text": "We report the use of the U1 snRNA as a vector for the stable expression of antisense molecules against the splice junctions of specific dystrophin exons", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22454066", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 344, 
          "offsetInEndSection": 470, 
          "text": "Effective exon skipping has been obtained for different dystrophin exons by antisense sequences against 5' and 3' splice sites", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22454066", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1036, 
          "offsetInEndSection": 1254, 
          "text": "the U1-antisense molecules, delivered to mice via systemic injection of recombinant AAV viruses, displayed body wide transduction, long-term expression, dystrophin rescue as well as morphological and functional benefit", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22454066", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 108, 
          "text": "U1 snRNA-mediated gene therapeutic correction of splice defects caused by an exceptionally mild BBS mutation", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21520335", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 860, 
          "offsetInEndSection": 1132, 
          "text": "For a gene therapeutic approach, we have adapted the sequence of U1 to increase its complementarity to the mutated SD. Lentiviral treatment of patient-derived fibroblasts with the adapted U1 partially corrected aberrant splicing of endogenously expressed BBS1 transcripts.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21520335", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1177, 
          "offsetInEndSection": 1328, 
          "text": "Our results show that the adaptation of U1 can correct pathogenic effects of splice donor site mutations and suggest a high potential for gene therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21520335", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "Gene therapeutic approach using mutation-adapted U1 snRNA to correct a RPGR splice defect in patient-derived cells.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21326217", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 504, 
          "offsetInEndSection": 623, 
          "text": "To correct the splice defect, we developed a gene therapeutic approach using mutation-adapted U1 small nuclear RNA (U1)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21326217", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1010, 
          "offsetInEndSection": 1251, 
          "text": "Full complementarity of U1 corrects the splice defect partially and increases recognition of the mutant SDS. The therapeutic effect is U1-concentration dependent as we show for endogenously expressed RPGR transcripts in patient-derived cells", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21326217", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1253, 
          "offsetInEndSection": 1391, 
          "text": "U1-based gene therapeutic approaches constitute promising technologies to treat SDS mutations in inherited diseases including X-linked RP.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21326217", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 160, 
          "text": "Correct mRNA processing at a mutant TT splice donor in FANCC ameliorates the clinical phenotype in patients and is enhanced by delivery of suppressor U1 snRNAs.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20869034", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1138, 
          "offsetInEndSection": 1487, 
          "text": "use of lentiviral vectors as a delivery system to introduce expression cassettes for TT-adapted U1 snRNAs into primary FANCC patient fibroblasts allowed the correction of the DNA-damage-induced G2 cell-cycle arrest in these cells, thus representing an alternative transcript-targeting approach for genetic therapy of inherited splice-site mutations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20869034", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the branch site consensus sequence in U12-dependent introns?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18824513"
      ], 
      "type": "factoid", 
      "id": "5357a6d0f1005d6b58000004", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 403, 
          "text": "Highly conserved sequences at the 5' splice site and branch site of U12-dependent introns are important determinants for splicing by U12-dependent spliceosomes. This study investigates the in vivo splicing phenotypes of mutations in the branch site consensus sequence of the U12-dependent intron F from a human NOL1 (P120) minigene. Intron F contains a fully consensus branch site sequence (UUCCUUAAC). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18824513", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the main CHEK2 genetic variant, thought to be involved in familial breast cancer?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17721994", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16998506", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12610780", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19763819"
      ], 
      "type": "factoid", 
      "id": "5357b36cf1005d6b58000006", 
      "snippets": [
        {
          "offsetInBeginSection": 560, 
          "offsetInEndSection": 654, 
          "text": "the two most studied breast cancer-predisposing variants of the CHEK2 gene, 1100delC and I157T", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16998506", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "The CHEK2-1100delC mutation is recurrent in the population and is a moderate risk factor for breast cancer", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17721994", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 675, 
          "offsetInEndSection": 904, 
          "text": "The germline CHEK2-1100delC mutation was present among 8/1,646 (0.5%) sporadic, 2/400 (0.5%) early-onset and 3/302 (1%) familial breast cancer cases, but undetectable amongst 2,105 multiethnic controls, including 633 from the US.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17721994", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 986, 
          "offsetInEndSection": 1145, 
          "text": "1100delC appears to be the only recurrent CHEK2 mutation associated with a potentially significant contribution to breast cancer risk in the general population", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17721994", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1559, 
          "offsetInEndSection": 1830, 
          "text": "Our findings highlight the notion that clinical testing for rare missense mutations within CHEK2 may have limited value in predicting breast cancer risk, but that testing for the 1100delC variant may be valuable in phenotypically- and geographically-selected populations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17721994", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 103, 
          "text": "Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12610780", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 202, 
          "text": "We recently reported that a sequence variant in the cell-cycle-checkpoint kinase CHEK2 (CHEK2 1100delC) is a low-penetrance breast cancer-susceptibility allele in noncarriers of BRCA1 or BRCA2 mutations", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12610780", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 994, 
          "offsetInEndSection": 1131, 
          "text": "These results indicate that 1100delC may be the only CHEK2 allele that makes an appreciable contribution to breast cancer susceptibility.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12610780", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 685, 
          "offsetInEndSection": 781, 
          "text": "CHEK2_1100delC was found in 5/903 (0.5%) breast cancer cases compared to 1/1016 (0.1%) controls.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19763819", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is PER3 required for CHK2 activation in human cells?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21070773"
      ], 
      "type": "yesno", 
      "id": "5357b5ecf1005d6b58000007", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 71, 
          "text": "Per3, a circadian gene, is required for Chk2 activation in human cells.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21070773", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 96, 
          "offsetInEndSection": 233, 
          "text": "Depletion of Per3 by siRNA almost completely abolished activation of checkpoint kinase 2 (Chk2) after inducing DNA damage in human cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21070773", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 293, 
          "offsetInEndSection": 376, 
          "text": "Per3 overexpression induced Chk2 activation in the absence of exogenous DNA damage,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21070773", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 414, 
          "offsetInEndSection": 508, 
          "text": "Per3 overexpression also led to the inhibition of cell proliferation and apoptotic cell death.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21070773", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 509, 
          "offsetInEndSection": 660, 
          "text": "These combined results suggest that Per3 is a checkpoint protein that plays important roles in checkpoint activation, cell proliferation and apoptosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21070773", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which are the major intramolecular phosphorylation sites of human Chk2 involved in cell cycle control?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18812180"
      ], 
      "type": "list", 
      "id": "5357b9bcf1005d6b58000008", 
      "snippets": [
        {
          "offsetInBeginSection": 697, 
          "offsetInEndSection": 889, 
          "text": "Transfection of HEK293 cells with Chk2 wildtype and Chk2 mutants in the absence or presence of DNA damage showed significant T68 phosphorylation already in the absence of DNA damaging reagents", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18812180", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 891, 
          "offsetInEndSection": 975, 
          "text": "Upon DNA damage, phosphorylation of additional Chk2 sites was observed (S19, S33/35)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18812180", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the effect of Chk2 splice variants on wild-type Chk2 kinase activity?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20080130"
      ], 
      "type": "summary", 
      "id": "5357bd56f1005d6b58000009", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 93, 
          "text": "Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20080130", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 661, 
          "offsetInEndSection": 1130, 
          "text": "Here we evaluated the function of four Chk2 splice proteins for which mRNA splice variants were identified in human breast carcinomas. These splice variants were stably expressed as nuclear proteins. Two splice forms (Chk2Delta4 and Chk2del(2-3)) expressed kinase activity while variants Chk2Delta11 and Chk2isoI were essentially kinase inactive. Independent of intrinsic kinase activity, each splice variant impaired wild-type Chk2 activity through heterodimerization.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20080130", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1154, 
          "offsetInEndSection": 1262, 
          "text": "we suggest alternative splicing as a possible novel mechanism for repression of the Chk2 wild-type function.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20080130", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are long non coding RNAs spliced?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22955988", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22955974", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22707570", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21622663", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24285305", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24106460"
      ], 
      "type": "yesno", 
      "id": "535d292a9a4572de6f000003", 
      "snippets": [
        {
          "offsetInBeginSection": 546, 
          "offsetInEndSection": 739, 
          "text": "Our analyses indicate that lncRNAs are generated through pathways similar to that of protein-coding genes, with similar histone-modification profiles, splicing signals, and exon/intron lengths.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22955988", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1602, 
          "offsetInEndSection": 1732, 
          "text": "For alternative exons and long noncoding RNAs, splicing tends to occur later, and the latter might remain unspliced in some cases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22955974", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 249, 
          "offsetInEndSection": 557, 
          "text": "bosome-mapping data to identify lncRNAs of Caenorhabditis elegans. We found 170 long intervening ncRNAs (lincRNAs), which had single- or multiexonic structures that did not overlap protein-coding transcripts, and about sixty antisense lncRNAs (ancRNAs), which were complementary to protein-coding transcripts", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22707570", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 275, 
          "offsetInEndSection": 401, 
          "text": "We introduce an approach to predict spliced lncRNAs in vertebrate genomes combining comparative genomics and machine learning.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21622663", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 711, 
          "offsetInEndSection": 856, 
          "text": "Owing to similar alternative splicing pattern to mRNAs, the concept of lncRNA genes was put forward to help systematic understanding of lncRNAs. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24285305", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 561, 
          "offsetInEndSection": 746, 
          "text": "Our synthesis of recent studies suggests that neither size, presence of a poly-A tail, splicing, direction of transcription, nor strand specificity are of importance to lncRNA function.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24106460", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is SCENAR therapy used for?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20396722", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20879466", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16924799", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8779182"
      ], 
      "type": "list", 
      "id": "535d69177d100faa09000003", 
      "snippets": [
        {
          "offsetInBeginSection": 48, 
          "offsetInEndSection": 141, 
          "text": "SCENAR therapy to patients with localized suppurative peritonitis in the postoperative period", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20396722", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 94, 
          "offsetInEndSection": 157, 
          "text": "post-herpetic neuralgia using a bioelectronical device (SCENAR)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20879466", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 397, 
          "offsetInEndSection": 474, 
          "text": "All patients experienced substantial relief of pain from the first treatment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20879466", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 715, 
          "offsetInEndSection": 831, 
          "text": "An electronic biofeedback device (SCENAR) may be successfully utilized in the management of post-herpetic neuralgia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20879466", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 148, 
          "text": "A new technique of low-frequency modulated electric current therapy, SCENAR therapy, was used in treatment of 103 patients with duodenal ulcer (DU).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16924799", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 433, 
          "offsetInEndSection": 648, 
          "text": "Addition of SCENAR therapy to the complex conventional pharmacotherapy fastened ulcer healing, increased the effectiveness of Helicobacter pylori eradication, and improved the condition of the gastroduodenal mucosa.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16924799", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 68, 
          "offsetInEndSection": 184, 
          "text": "SCENAR) as effective in the treatment of neurogenic dysfunction of the bladder in children with nocturnal enuresis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8779182", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is known about the role of mHealth in the prevention of disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24294329", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24246427", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24133558", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24050486", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23992038", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23624056", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23549699", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23330022", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22920991", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22548607", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22548595"
      ], 
      "type": "summary", 
      "id": "535d7c247d100faa09000006", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 46, 
          "text": "mHealth approaches to child obesity prevention", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24294329", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 78, 
          "text": "Daily text messaging for weight control among racial and ethnic minority women", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24246427", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 301, 
          "offsetInEndSection": 378, 
          "text": "text messaging intervention for weight loss among predominantly black women. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24246427", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1660, 
          "offsetInEndSection": 1843, 
          "text": "Given the increasing penetration of mobile devices, text messaging may be a useful self-monitoring tool for weight control, particularly among populations most in need of intervention", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24246427", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 798, 
          "offsetInEndSection": 1151, 
          "text": "The review revealed evidence that mHealth tools support HIV programmatic priorities, including: linkage to care, retention in care, and adherence to antiretroviral treatment. In terms of technical features, mHealth tools facilitate alerts and reminders, data collection, direct voice communication, educational messaging, information on demand, and more", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24133558", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 55, 
          "text": "Mobile health messages help sustain recent weight loss.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24050486", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1076, 
          "offsetInEndSection": 1272, 
          "text": " A clinically significant decrease in mean weight, higher rate of sustained weight loss, and medium-to-large effects on sustained weight loss occurred in the promotion and prevention interventions", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24050486", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 70, 
          "text": "A mobile health intervention for weight management among young adults:", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23992038", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 270, 
          "text": "HIV prevalence in Uganda has leveled off, however trends indicate that incidence is on the rise and disproportionately affects certain vulnerable groups, such as women. There is growing support for using mobile health (mHealth) programs to reach vulnerable populations. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23549699", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1763, 
          "offsetInEndSection": 1915, 
          "text": "We successully designed and implemented a mobile phone SMS-based system to track pregnancy and maternal and child outcomes in limited resources setting.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23330022", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 482, 
          "offsetInEndSection": 841, 
          "text": "The purpose of the study, Project ACTION (Adult smoking Cessation Treatment through Innovative Outreach to Neighborhoods), is to utilize a mobile clinic model, a network of community sites (i.e., community centers and churches) and an interactive mobile messaging system to reach and deliver smoking cessation treatment to underserved, low-income communities.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22920991", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1465, 
          "offsetInEndSection": 1749, 
          "text": "Participants were randomized to usual prenatal care plus text messaging or usual care alone. The evaluation has a theoretical model of behavior change and measures mediators as well as behavioral outcomes. Results will inform how behavioral theory works within mobile health programs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22548595", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the relation between sweating and anaerobic threshold?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12937031", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9694410", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7588694"
      ], 
      "type": "factoid", 
      "id": "536787467d100faa09000010", 
      "snippets": [
        {
          "offsetInBeginSection": 1353, 
          "offsetInEndSection": 1560, 
          "text": "It is concluded that the sweating response during upright recovery is significantly modified by exercise intensity and may likely be influenced by the nonthermal baroreceptor reflex adjustments postexercise.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12937031", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 257, 
          "offsetInEndSection": 429, 
          "text": " The purpose of this paper is to delineate the effects of training status, heat acclimation, environmental conditions and host factors on the sweating response to exercise.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9694410", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1183, 
          "offsetInEndSection": 1399, 
          "text": "These results would suggest that at a given exercise intensity in subjects with a higher aerobic capacity body temperature is maintained with a lower sweating rate than that in subjects with a lower aerobic capacity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7588694", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the gene most commonly mutated in Tay-Sachs disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/14648242", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9401008", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7858168", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8411703", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8490625", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3375249", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3362213", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2967444"
      ], 
      "type": "factoid", 
      "id": "536e46f27d100faa09000012", 
      "snippets": [
        {
          "offsetInBeginSection": 9, 
          "offsetInEndSection": 81, 
          "text": "mutations in the HEXA gene among Iraqi Jewish Tay-Sachs disease carriers", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14648242", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 4, 
          "offsetInEndSection": 81, 
          "text": "mutated HEXA alleles in a Druze patient with late-infantile Tay-Sachs disease", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9401008", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 4, 
          "offsetInEndSection": 101, 
          "text": "affected HEXA alleles were found in an Israeli Druze Tay-Sachs child born to first-cousin parents", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9401008", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 4, 
          "offsetInEndSection": 141, 
          "text": "abnormalities in the gene coding for the beta-hexosaminidase alpha subunit were analysed from fibroblast's RNAs of 42 Tay-Sachs patients ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7858168", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 667, 
          "offsetInEndSection": 804, 
          "text": "In the severest phenotype of Tay-Sachs disease (infantile form), mRNA of beta-hexosaminidase alpha subunit is not produced or is unstable", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8411703", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 4, 
          "offsetInEndSection": 69, 
          "text": "novel mutations in the HEXA gene in non-Jewish Tay-Sachs patients", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8490625", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 140, 
          "text": "ay-Sachs disease is an inherited disorder in which the alpha chain of the lysosomal enzyme beta-N-acetylhexosaminidase A bears the mutation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3375249", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 183, 
          "text": "ay-Sachs disease is an autosomal recessive genetic disorder resulting from mutation of the HEXA gene encoding the alpha-subunit of the lysosomal enzyme, beta-N-acetylhexosaminidase A", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3362213", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 203, 
          "offsetInEndSection": 370, 
          "text": "Tay-Sachs disease lack detectable alpha-chain message when analyzed by Northern blotting with complementary DNA encoding the alpha-chain of human beta-hexosaminidase A", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2967444", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can siRNA affect response to afatinib treatment?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23555954", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23266614", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22436374"
      ], 
      "type": "yesno", 
      "id": "54297ed2289fd6cb07000001", 
      "snippets": [
        {
          "offsetInBeginSection": 619, 
          "offsetInEndSection": 812, 
          "text": "On the other hand, miR-146a enhanced the inhibition of cell proliferation by drugs targeting EGFR, including both TKIs (gefitinib, erlotinib, and afatinib) and a monoclonal antibody (cetuximab)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23555954", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 814, 
          "offsetInEndSection": 1002, 
          "text": "These effects were independent of the EGFR mutation status (wild type, sensitizing mutation or resistance mutation), but were less potent compared to the effects of siRNA targeting of EGFR", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23555954", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1147, 
          "offsetInEndSection": 1280, 
          "text": "Among the anti-EGFR agents tested, the strongest biological effect was observed when afatinib was combined with T790M-specific-siRNAs", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23266614", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1527, 
          "offsetInEndSection": 1752, 
          "text": "The combination of a potent, irreversible kinase inhibitor such as afatinib, with T790M-specific-siRNAs should be further investigated as a new strategy in the treatment of lung cancer containing the resistant T790M mutation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23266614", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2418, 
          "offsetInEndSection": 2517, 
          "text": "The strongest biological effect was observed when afatinib was combined with an EGFR-specific siRNA", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22436374", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2175, 
          "offsetInEndSection": 2417, 
          "text": "The addition of EGFR siRNA to either TKIs or cetuximab additively enhanced growth inhibition and induction of apoptosis in all five cell lines, independent of the EGFR mutation status (wild-type or sensitizing mutation or resistant mutation).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22436374", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Mutations of which genes have been associated with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25480325", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24370574", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23908839", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23595086", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22589293", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22422768", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20301466"
      ], 
      "type": "list", 
      "id": "54c225bcf693c3b16b000002", 
      "snippets": [
        {
          "offsetInBeginSection": 1703, 
          "offsetInEndSection": 1921, 
          "text": "Mutation in four genes \u2013 RYR2, CASQ2, TRDN, and CALM1 \u2013 is known to cause CPVT or related phenotypes of adrenergically induced life-threatening arrhythmias. The presence of other as-yet unidentified loci is postulated ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20301466", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 239, 
          "offsetInEndSection": 384, 
          "text": "some KCNJ2 mutation carriers lack the ATS triad and sometimes share the phenotype of catecholaminergic polymorphic ventricular tachycardia (CPVT)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22589293", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 246, 
          "offsetInEndSection": 513, 
          "text": "In 50 Japanese probands from unrelated families who satisfied clinical criteria for CPVT, genetic testing was conducted in all exons on 3 CPVT-related genes: cardiac ryanodine receptor 2 (RYR2), calsequestrin 2 (CASQ2) and inward rectifier potassium channel 2 (KCNJ2)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23595086", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 621, 
          "offsetInEndSection": 947, 
          "text": "point mutations in RYR2, the gene encoding for the cardiac isoform of the RyR (RyR2), are associated with catecholaminergic polymorphic ventricular tachycardia (CPVT), an arrhythmogenic syndrome characterized by the development of adrenergically-mediated ventricular tachycardia in individuals with an apparently normal heart.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25480325", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 464, 
          "offsetInEndSection": 528, 
          "text": "Recessive CPVT variants are due to mutations in the CASQ2 gene. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24370574", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 367, 
          "offsetInEndSection": 507, 
          "text": "Recent studies have shown that CPVT is caused by mutations in the cardiac ryanodine receptor type 2 (RyR2) or calsequestrin 2 (CASQ2) genes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23908839", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 689, 
          "offsetInEndSection": 817, 
          "text": "We identified three mutations in triadin which cosegregated with the disease on a recessive mode of transmission in two families", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22422768", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is Calcium homeostasis important in cardiac physiology and pathophysiology?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24657282", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23595672", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22673935", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22137362", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21750914", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21614516", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20875630", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23554644", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20347784", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19920172", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19678847", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18172603", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17517353", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17509680", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17353151"
      ], 
      "type": "yesno", 
      "id": "54c26e29f693c3b16b000003", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 124, 
          "text": "Maintenance of cellular calcium homeostasis is critical to regulating mitochondrial ATP production and cardiac contraction. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24657282", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1520, 
          "offsetInEndSection": 1753, 
          "text": "the Ca(2+) signal regulates the most important activities of the cell, from the expression of genes, to heart and muscle contraction and other motility processes, to diverse metabolic pathways involved in the generation of cell fuels", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23595672", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 160, 
          "text": "Pharmacologic modification of cellular calcium handling recently moved into focus as an alternative for prevention and treatment of ventricular tachyarrhythmias", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22673935", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1128, 
          "offsetInEndSection": 1472, 
          "text": "diabetic rats displayed abnormal cardiac structure and systolic and diastolic dysfunction, and spermine (CaSR agonist) could prevent or slow its progression. These results indicate that the CaSR expression of myocardium is reduced in the progress of DCM, and its potential mechanism is related to the impaired intracellular calcium homeostasis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22137362", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 37, 
          "offsetInEndSection": 68, 
          "text": "calcium-sensing receptor (CaSR)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22137362", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "Na(+)/Ca(2+) exchanger (NCX) plays important roles in cardiac electrical activity and calcium homeostasis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21750914", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 107, 
          "offsetInEndSection": 321, 
          "text": "NCX current (I(NCX)) shows transmural gradient across left ventricle in many species. Previous studies demonstrated that NCX expression was increased and transmural gradient of I(NCX) was disrupted in failing heart", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21750914", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 219, 
          "offsetInEndSection": 298, 
          "text": "calcium homeostasis, the key process underlying excitation-contraction coupling", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21614516", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2057, 
          "offsetInEndSection": 2186, 
          "text": "The results indicate the calcium handling properties of hiPSC-derived cardiomyocytes are relatively immature to hESC counterparts", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21614516", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 495, 
          "text": "Our understanding of the molecular processes which regulate cardiac function has grown immeasurably in recent years. Even with the advent of \u03b2-blockers, angiotensin inhibitors and calcium modulating agents, heart failure (HF) still remains a seriously debilitating and life-threatening condition. Here, we review the molecular changes which occur in the heart in response to increased load and the pathways which control cardiac hypertrophy, calcium homeostasis, and immune activation during HF.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20875630", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 238, 
          "text": "Calcium-sensing receptors (CaSRs) are G-protein coupled receptors which maintain systemic calcium homeostasis and participate in hormone secretion, activation of ion channels, cell apoptosis, proliferation, and differentiation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23554644", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1389, 
          "offsetInEndSection": 1540, 
          "text": "CaSRs are associated with I/R injury and apoptosis in neonatal rat ventricular cardiomyocytes via suppressing Bcl-2 and promoting caspase-3 expression.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23554644", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 533, 
          "text": "Important insights into the molecular basis of hypertrophic cardiomyopathy and related diseases have been gained by studying families with inherited cardiac hypertrophy. Integrated clinical and genetic investigations have demonstrated that different genetic defects can give rise to the common phenotype of cardiac hypertrophy. Diverse pathways have been identified, implicating perturbations in force generation, force transmission, intracellular calcium homeostasis, myocardial energetics, and cardiac metabolism in causing disease", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20347784", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 150, 
          "offsetInEndSection": 407, 
          "text": "HAX-1 as a regulator of contractility and calcium cycling in the heart. HAX-1 overexpression reduced sarcoplasmic reticulum Ca-ATPase (SERCA2) pump activity in isolated cardiomyocytes and in vivo, leading to depressed myocyte calcium kinetics and mechanics.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19920172", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 917, 
          "offsetInEndSection": 1104, 
          "text": "Thus, HAX-1 represents a regulatory mechanism in cardiac calcium cycling and its responses to sympathetic stimulation, implicating its importance in calcium homeostasis and cell survival.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19920172", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 268, 
          "text": "Calcium ions are the most ubiquitous and versatile signaling molecules in eukaryotic cells. Calcium homeostasis and signaling systems are crucial for both the normal growth of the budding yeast Saccharomyces cerevisiae and the intricate working of the mammalian heart.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19678847", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1110, 
          "offsetInEndSection": 1233, 
          "text": "this knowledge can be used to help treat relevant human diseases such as pathological cardiac hypertrophy and heart failure", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19678847", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 373, 
          "text": "With aging, the heart develops myocyte hypertrophy associated with impaired relaxation indices. To define the cellular basis of this adaptation, we examined the physiological changes that arise in calcium handling in the aging heart and contrasted the adaptations that occur following the imposition of a stimulus that alters calcium homeostasis in a young and an old heart", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18172603", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1306, 
          "offsetInEndSection": 1489, 
          "text": "alterations in the calcium-handling machinery of the cardiocyte differ in the context of age and as such may predispose the older heart to the development of a hypertrophic phenotype.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18172603", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 142, 
          "text": "The cardiac sodium-calcium exchanger (NCX1) is a key sarcolemmal protein for the maintenance of calcium homeostasis in the heart. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17517353", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1302, 
          "offsetInEndSection": 1435, 
          "text": "Thus exchanger overexpression in mice leads to abnormal calcium handling and a decompensatory transition to heart failure with stress", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17517353", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 472, 
          "text": "Central to controlling intracellular calcium concentration ([Ca(2+)](i)) are a number of Ca(2+) transporters and channels with the L-type Ca(2+) channel, Na(+)-Ca(2+) exchanger and sarcoplasmic reticulum Ca(2+)-ATPase (SERCA) being of particular note in the heart. This review concentrates on the regulation of [Ca(2+)](i) in cardiac muscle and the homeostatic mechanisms employed to ensure that the heart can operate under steady-state conditions on a beat by beat basis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17509680", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1121, 
          "offsetInEndSection": 1480, 
          "text": "the tight regulation of SR Ca(2+) content is also required to prevent the abnormal, spontaneous or diastolic release of Ca(2+) from the SR. Such diastolic events are a major factor contributing to the genesis of cardiac arrhythmias in disease situations and in recently identified familial mutations in the SR Ca(2+) release channel (ryanodine receptor, RyR).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17509680", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 56, 
          "offsetInEndSection": 570, 
          "text": "Calcium channels have a unique functional role, because not only do they participate in this activity, they form the means by which electrical signals are converted to responses within the cell. Calcium channels play an integral role in excitation in the heart and shaping the cardiac action potential. In addition, calcium influx through calcium channels is responsible for initiating contraction. Abnormalities in calcium homeostasis underlie cardiac arrhythmia, contractile dysfunction and cardiac remodelling. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17353151", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which genes have been proposed as potential candidates for gene therapy of heart failure?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25327883", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25023328", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24833660", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24622121", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24403316", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22558250", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22383712", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21775667"
      ], 
      "type": "list", 
      "id": "54c90dabf693c3b16b000004", 
      "snippets": [
        {
          "offsetInBeginSection": 535, 
          "offsetInEndSection": 658, 
          "text": "The molecular abnormalities underlying HF are discussed along with potential targets for gene therapy, focusing on SERCA2a.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25327883", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 243, 
          "offsetInEndSection": 370, 
          "text": "The aim of this study was to improve cardiac function in chronic HF by overexpressing constitutively active inhibitor-1 (I-1c) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25023328", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1323, 
          "offsetInEndSection": 1440, 
          "text": "In summary, I-1c overexpression using BNP116 improves cardiac function in a clinically relevant model of ischemic HF.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25023328", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1313, 
          "offsetInEndSection": 1462, 
          "text": "therapeutic activation of YAP or its downstream targets, potentially through AAV-mediated gene therapy, may be a strategy to improve outcome after MI", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24833660", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1904, 
          "offsetInEndSection": 2024, 
          "text": "calcium up-regulation by AAV1/SERCA2a gene therapy is safe and of potential benefit in advanced heart failure patients. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24622121", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1487, 
          "offsetInEndSection": 1596, 
          "text": "Survivin gene therapy can attenuate the progression of LV systolic dysfunction in doxorubicin cardiomyopathy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24403316", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1959, 
          "offsetInEndSection": 2075, 
          "text": "Heart failure-inducible molecular targeting of PP1\u03b2 has potential as a novel therapeutic strategy for heart failure.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22558250", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 742, 
          "offsetInEndSection": 991, 
          "text": "The recent successful and safe completion of a phase 2 trial targeting the sarcoplasmic reticulum calcium ATPase pump (SERCA2a), along with the start of more recent phase 1 trials, opens a new era for gene therapy for the treatment of heart failure.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22383712", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1746, 
          "offsetInEndSection": 1939, 
          "text": "Our results present a strong rationale for a clinical trial of S100A1 gene therapy for human heart failure that could potentially complement current strategies to treat end-stage heart failure.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21775667", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 215, 
          "offsetInEndSection": 558, 
          "text": "S100A1, a positive inotropic regulator of myocardial contractility, becomes depleted in failing cardiomyocytes in humans and animals, and myocardial-targeted S100A1 gene transfer rescues cardiac contractile function by restoring sarcoplasmic reticulum calcium (Ca(2+)) handling in acutely and chronically failing hearts in small animal models.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21775667", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the main regulatory molecule of SERCA2A function in the cardiac muscle?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25451386", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23710633", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21266500", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18971376", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15598648", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11371203", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10555147", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19948724", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19112098", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18508637"
      ], 
      "type": "factoid", 
      "id": "54cb9c94f693c3b16b000005", 
      "snippets": [
        {
          "offsetInBeginSection": 406, 
          "offsetInEndSection": 705, 
          "text": "SR Ca-transport is mediated by the SR Ca-ATPase (SERCA2a) and its regulatory phosphoprotein, phospholamban (PLN). Dephosphorylated PLN is an inhibitor of SERCA2a and phosphorylation by protein kinase A (PKA) or calcium-calmodulin-dependent protein kinases (CAMKII) relieves these inhibitory effects.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451386", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 874, 
          "offsetInEndSection": 976, 
          "text": "SERCA2a activity can be regulated at multiple levels of a signaling cascade comprised of phospholamban", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23710633", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 193, 
          "text": "Phospholamban (PLN), the reversible inhibitor of the sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA2a), is a key regulator of myocyte Ca(2+) cycling with a significant role in heart failure.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21266500", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 97, 
          "offsetInEndSection": 271, 
          "text": "The sarco(endo)plasmic reticulum (SR) Ca(2+) transport ATPase (SERCA2a) and its inhibitor phospholamban (PLN) control the uptake of Ca(2+) by SR membranes during relaxation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18971376", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 687, 
          "offsetInEndSection": 762, 
          "text": "phospholamban (PLN), a muscle-specific SR Ca(2+)-ATPase (SERCA2a) inhibitor", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15598648", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 156, 
          "text": "Phospholamban (PLB) is a major target of the beta-adrenergic cascade in the heart, and functions as an endogenous inhibitor of Ca-ATPase transport activity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11371203", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 376, 
          "offsetInEndSection": 461, 
          "text": "muscle-specific sarcoplasmic reticulum Ca2+ ATPase (SERCA2a) inhibitor, phospholamban", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10555147", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 168, 
          "text": "Phospholamban (PLB) inhibits the activity of SERCA2a, the Ca(2+)-ATPase in cardiac sarcoplasmic reticulum, by decreasing the apparent affinity of the enzyme for Ca(2+).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19948724", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 214, 
          "text": "Phospholamban has been suggested to be a key regulator of cardiac sarcoplasmic reticulum (SR) Ca cycling and contractility and a potential therapeutic target in restoring the depressed Ca cycling in failing hearts.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19112098", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1269, 
          "offsetInEndSection": 1304, 
          "text": "phospholamban regulation of SERCA2a", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19112098", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 181, 
          "offsetInEndSection": 530, 
          "text": "SERCA2a activity is regulated by phosphorylation of another SR protein: Phospholamban (PLN). Dephosphorylated PLN inhibits SERCA2a. Phosphorylation of PLN by either cAMP or cGMP-dependent protein kinase at Ser16 or the Ca2+-calmodulin-dependent protein kinase (CaMKII), at Thr17, relieves this inhibition, increasing SR Ca2+ uptake and SR Ca2+ load.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18508637", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Describe armoured brain syndrome.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24403965", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23421586", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21319032", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19902386", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1580196"
      ], 
      "type": "summary", 
      "id": "54cf42bdf693c3b16b000007", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 83, 
          "text": "Armoured brain is a rare condition where dense calcification occurs over the brain.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24403965", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": -1, 
          "offsetInEndSection": 83, 
          "text": "Armoured brain due to chronic subdural collections masking underlying hydrocephalus.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23421586", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "Calcified chronic subdural collection (armoured brain) is a known long-standing complication of shunt overdrainage. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23421586", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 234, 
          "text": "The optimal surgical procedure for patients with calcified and organized chronic subdural haematoma (CSDH), or \"armoured brain\", has not been established because it is difficult to obtain good re-expansion of the brain after surgery. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21319032", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 436, 
          "offsetInEndSection": 647, 
          "text": "RESULTS: A patient with a bilateral symptomatic calcified chronic subdural hematoma, or so-called \"armoured brain\", was admitted to our intensive care unit with clinical signs of increased intracranial pressure.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19902386", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": -1, 
          "offsetInEndSection": 110, 
          "text": "High-field magnetic resonance image of a huge calcified chronic subdural haematoma, so-called \"armoured brain\".", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1580196", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "Calcification of chronic subdural haematoma is called \"armoured brain\" when it covers most of the cortical surface. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1580196", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Synostosis of which cranial structures are characteristic to the Mercedes Benz syndrome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20048621", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19396832", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9780908"
      ], 
      "type": "list", 
      "id": "54cf43abf693c3b16b000008", 
      "snippets": [
        {
          "offsetInBeginSection": 172, 
          "offsetInEndSection": 295, 
          "text": "Among these are a trisutural fusion, dubbed the \"Mercedes Benz pattern,\" involving the sagittal and both lambdoid sutures. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20048621", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1449, 
          "offsetInEndSection": 1615, 
          "text": "CONCLUSIONS: Despite fusion of the sagittal suture, the surgical treatment for Mercedes Benz pattern craniosynostosis should include skull lengthening, not reduction.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20048621", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 414, 
          "text": "Multisutural craniosynostosis that includes bilateral lambdoid and sagittal synostosis (BLSS) results in a very characteristic head shape with frontal bossing, turribrachycephaly, biparietal narrowing, occipital concavity, and inferior displacement of the ears. This entity has been reported both in the genetics literature as craniofacial dyssynostosis and in the surgical literature as \"Mercedes Benz\" syndrome. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19396832", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": -1, 
          "offsetInEndSection": 72, 
          "text": "Bilambdoid and posterior sagittal synostosis: the Mercedes Benz syndrome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9780908", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 281, 
          "text": "A consistent pattern of craniosynostosis in the sagittal and bilateral lambdoid sutures is described in three patients. The external cranial ridging associated with fusion of these sutures produces a characteristic triradiate, or \"Mercedes Benz,\" appearance to the posterior skull.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9780908", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is it possible to visualize subtahalamic nucleus by using transcranial ultrasound?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22941961", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21683505", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20846894", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20692508", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15639532", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14745222"
      ], 
      "type": "yesno", 
      "id": "54cf449cf693c3b16b000009", 
      "snippets": [
        {
          "offsetInBeginSection": 305, 
          "offsetInEndSection": 810, 
          "text": "After measuring thermal effects of TCS and imaging artefact sizes of DBS lead using a skull phantom, we prospectively enrolled 34 patients with DBS of globus pallidus internus, ventro-intermediate thalamic or subthalamic nucleus. TCS had no influence on lead temperature, electrical parameters of DBS device or clinical state of patients. TCS measures of lead coordinates agreed with MRI measures in anterior-posterior and medial-lateral axis. Lead dislocation requiring reinsertion was reliably detected.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21683505", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1012, 
          "offsetInEndSection": 1086, 
          "text": "TCS may therefore become a first-choice modality to monitor lead location.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21683505", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 149, 
          "offsetInEndSection": 473, 
          "text": "Two pilot studies have demonstrated that the intraoperative visualization with TCS and the TCS-assisted insertion of deep-brain stimulation (DBS) electrodes into the subthalamic nucleus and the globus pallidus interna are feasible and safe provided there is exact knowledge on the extent of electrode TCS imaging artifacts. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20692508", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": -1, 
          "offsetInEndSection": 148, 
          "text": "Peroperative transcranial sonography for electrode placement into the targeted subthalamic nucleus of patients with Parkinson disease: technical note", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15639532", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 680, 
          "offsetInEndSection": 873, 
          "text": "The correct anatomic position of the electrode tip could be indirectly assessed thanks to the topographic relationship of the STN with the hyperechogenic substantia nigra and the nucleus ruber.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15639532", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1151, 
          "offsetInEndSection": 1487, 
          "text": "CONCLUSIONS: Transcranial sonography is easily feasible during stereotactic surgery. In combination with the clinical effects of electrostimulation on the symptoms of Parkinson's disease and with stereotactic x-ray images, it enables the assessment and the documentation of the correct position of implanted STN electrodes in real time.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15639532", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the main calcium binding protein of the sarcoplasmic reticulum?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16571864", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14715535", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11058082", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1860177", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24025332", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16477617"
      ], 
      "type": "factoid", 
      "id": "54cf45e7f693c3b16b00000a", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 164, 
          "text": "Calsequestrin (CS) is the low-affinity, high-capacity calcium binding protein segregated to the lumen of terminal cisternae (TC) of the sarcoplasmic reticulum (SR).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16571864", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 13, 
          "offsetInEndSection": 133, 
          "text": "human cardiac calsequestrin (CASQ2), a high-capacity calcium-binding protein located in the sarcoplasmic reticulum (SR),", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14715535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 169, 
          "text": "Calsequestrin is the major calcium-binding protein of cardiac and skeletal muscles whose function is to sequester Ca(2+ )in the lumen of the sarcoplasmic reticulum (SR).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11058082", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 152, 
          "text": "Calsequestrin is a calcium-binding protein known to sequester calcium accumulated in the sarcoplasmic reticulum (SR) of muscle cells during relaxation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1860177", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 261, 
          "text": "Calsequestrin (CASQ) is the major component of the sarcoplasmic reticulum (SR) lumen in skeletal and cardiac muscles. This calcium-binding protein localizes to the junctional SR (jSR) cisternae, where it is responsible for the storage of large amounts of Ca(2+)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025332", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 234, 
          "offsetInEndSection": 317, 
          "text": "SR calcium-regulatory proteins: (1) luminal calcium-binding proteins (calsequestrin", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16477617", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is progesterone effective for treatment of patients with traumatic brain injury based on clinical trial data?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25493978", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25493974", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24241345", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24205899", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23871679", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22033509", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22668124", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23076947", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23326789", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21249708", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20486864", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19660659", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19394357", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19318112", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18447940", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18522765", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17933428", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17588708", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17418038", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17011666"
      ], 
      "type": "yesno", 
      "id": "54cf48acf693c3b16b00000b", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 196, 
          "text": "BACKGROUND: Progesterone has been associated with robust positive effects in animal models of traumatic brain injury (TBI) and with clinical benefits in two phase 2 randomized, controlled trials. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25493978", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1000, 
          "offsetInEndSection": 1583, 
          "text": "The proportion of patients with a favorable outcome on the Glasgow Outcome Scale (good recovery or moderate disability) was 50.4% with progesterone, as compared with 50.5% with placebo. Mortality was similar in the two groups. No relevant safety differences were noted between progesterone and placebo. CONCLUSIONS: Primary and secondary efficacy analyses showed no clinical benefit of progesterone in patients with severe TBI. These data stand in contrast to the robust preclinical data and results of early single-center trials that provided the impetus to initiate phase 3 trials.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25493978", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 239, 
          "text": "BACKGROUND: Traumatic brain injury (TBI) is a major cause of death and disability worldwide. Progesterone has been shown to improve neurologic outcome in multiple experimental models and two early-phase trials involving patients with TBI. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25493974", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1490, 
          "offsetInEndSection": 1869, 
          "text": "There was no significant difference between the progesterone group and the placebo group in the proportion of patients with a favorable outcome (relative benefit of progesterone, 0.95; 95% confidence interval [CI], 0.85 to 1.06; P=0.35). Phlebitis or thrombophlebitis was more frequent in the progesterone group than in the placebo group (relative risk, 3.03; CI, 1.96 to 4.66). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25493974", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1950, 
          "offsetInEndSection": 2094, 
          "text": "CONCLUSIONS: This clinical trial did not show a benefit of progesterone over placebo in the improvement of outcomes in patients with acute TBI. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25493974", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 544, 
          "offsetInEndSection": 693, 
          "text": "Numerous studies, however, show that progesterone has substantial pleiotropic properties as a neuroprotective agent in both animal models and humans.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24241345", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 478, 
          "offsetInEndSection": 1190, 
          "text": "RESULTS: There was a better recovery rate and GOS score for the patients who were given progesterone than for those in the control group in a 3-months follow-up period (50% vs. 21%); subgroup analysis showed a significant difference in the percentage of favorable outcome between the two groups with GCS of 5-8 (p=0.03). CONCLUSION: The use of progesterone may significantly improve neurologic outcome of patients suffering severe TBI up to 3 months after injury, especially those with 5\u2264GCS\u22648, providing a potential benefit to the treatment of acute severe TBI patients. Considering this drug had no significant side effects, so progesterone could be used in patients with severe TBI as a neuro-protective drug.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23871679", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1127, 
          "offsetInEndSection": 1283, 
          "text": "While progesterone and ciclosporin have shown promise in phase II studies, success in larger phase III, randomized, multicentre, clinical trials is pending.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22668124", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1458, 
          "offsetInEndSection": 1793, 
          "text": " All three studies reported the effects of progesterone on mortality. The pooled risk ratio (RR) for mortality at end of follow-up was 0.61, 95% confidence interval (CI) 0.40 to 0.93. Three studies measured disability and found the RR of death or severe disability in patients treated with progesterone to be 0.77, 95% CI 0.62 to 0.96.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23076947", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2161, 
          "offsetInEndSection": 2418, 
          "text": "AUTHORS' CONCLUSIONS: Current clinical evidence from three small RCTs indicates progesterone may improve the neurologic outcome of patients suffering TBI. This evidence is still insufficient and further multicentre randomised controlled trials are required.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23076947", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1438, 
          "offsetInEndSection": 1976, 
          "text": "GOS was classified to 2 main categories of favorable and unfavorable recovery, of which, favorable recovery in placebo, progesterone, and progesterone-vitamin D was 25%, 45%, and 60%, respectively which showed a statistical significant difference among the groups (P-value = 0.03). CONCLUSION: The results showed that recovery rate in patients with severe brain trauma in the group receiving progesterone and vitamin D together was significantly higher than that of progesterone group, which was in turn higher than that of placebo group.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23326789", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1287, 
          "offsetInEndSection": 1575, 
          "text": " The pooled relative risk (RR) for mortality at end of follow-up is 0.61, 95% confidence interval (CI) 0.40 to 0.93. Three studies measured disability and found the RR of death or severe disability in patients treated with progesterone was 0.77, 95% confidence interval (CI) 0.62 to 0.96.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21249708", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1774, 
          "offsetInEndSection": 2031, 
          "text": "AUTHORS' CONCLUSIONS: Current clinical evidence from three small RCTs indicates progesterone may improve the neurologic outcome of patients suffering TBI. This evidence is still insufficient and further multicentre randomised controlled trials are required.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21249708", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 463, 
          "offsetInEndSection": 633, 
          "text": "Clinical trials have shown that short-and long-term progesterone treatment induces a significant improvement in the level of disability among patients with brain injury. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19318112", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": -1, 
          "offsetInEndSection": 142, 
          "text": "Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18447940", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 701, 
          "offsetInEndSection": 998, 
          "text": "CONCLUSION: Our data suggest that acute severe TBI patients with administration of progesterone hold improved neurologic outcomes for up to 6 months. These results provide information important for further large and multicenter clinical trials on progesterone as a promising neuroprotective drug. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18447940", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1496, 
          "offsetInEndSection": 1814, 
          "text": "The modified Functional Independence Measure scores in the progesterone group were higher than those in the placebo group at both 3-month and 6-month follow-up (P < 0.05 and P < 0.01). The mortality rate of the progesterone group was significantly lower than that of the placebo group at 6-month follow-up (P < 0.05). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18447940", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2139, 
          "offsetInEndSection": 2436, 
          "text": "CONCLUSION: Our data suggest that acute severe TBI patients with administration of progesterone hold improved neurologic outcomes for up to 6 months. These results provide information important for further large and multicenter clinical trials on progesterone as a promising neuroprotective drug. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18447940", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 376, 
          "offsetInEndSection": 632, 
          "text": "These data, combined with the results of the previously published ProTECT trial, show progesterone to be safe and potentially efficacious in the treatment of TBI. Larger phase III trials will be necessary to verify results prior to clinical implementation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18522765", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1388, 
          "offsetInEndSection": 1649, 
          "text": "CONCLUSION: It indicated that successive early application of PG will benefit the patients with acute severe head injury by improving the recovery and reducing the disability, which may be related to its alleviating inflammatory and lipid peroxidation response.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17418038", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1286, 
          "offsetInEndSection": 1508, 
          "text": "Adverse and serious adverse event rates were similar in both groups, except that patients randomized to progesterone had a lower 30-day mortality rate than controls (rate ratio 0.43; 95% confidence interval 0.18 to 0.99). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17011666", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1690, 
          "offsetInEndSection": 1963, 
          "text": "However, moderate traumatic brain injury survivors who received progesterone were more likely to have a moderate to good outcome than those randomized to placebo. CONCLUSION: In this small study, progesterone caused no discernible harm and showed possible signs of benefit.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17011666", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is pregabalin effective for treatment of patients with restless leg syndrome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24899755", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24521108", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24363103", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24119681", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23859128", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23771546", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23746768", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23703310", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23524988", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23385700", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23304742", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22937989", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22851801", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22570552", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20466589", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20427750", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18656214"
      ], 
      "type": "yesno", 
      "id": "54cf4a0ef693c3b16b00000c", 
      "snippets": [
        {
          "offsetInBeginSection": 1504, 
          "offsetInEndSection": 1784, 
          "text": "CONCLUSIONS: This study demonstrated improvements in objective and subjective measures of sleep maintenance and sleep architecture with pregabalin compared with placebo and pramipexole. Effects of pregabalin on periodic limb movement arousal index were comparable to pramipexole. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24899755", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2175, 
          "offsetInEndSection": 2372, 
          "text": "CONCLUSIONS: Pregabalin provided significantly improved treatment outcomes as compared with placebo, and augmentation rates were significantly lower with pregabalin than with 0.5 mg of pramipexole.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24521108", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1095, 
          "offsetInEndSection": 1318, 
          "text": "The alpha-2-delta ligands, including gabapentin, gabapentin enacarbil, and pregabalin, are effective for RLS without known occurrence of augmentation or impulse control disorders, although sedation and dizziness can occur. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24363103", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 803, 
          "offsetInEndSection": 905, 
          "text": "Pregabalin has been established as effective for up to 1 year in treating RLS/WED (Level A evidence). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23859128", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2827, 
          "offsetInEndSection": 2982, 
          "text": "In the group of anticonvulsants, only the trials performed with \u03b1\u2082\u03b4 ligands such as gabapentin, gabapentin enacarbil, and pregabalin showed good efficacy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23746768", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1395, 
          "offsetInEndSection": 1619, 
          "text": "Alternative or additional pharmacologic treatment with a lower level of overall quality of evidence includes opioids (codeine, tramadol, and oxycodone) and anticonvulsants (gabapentin, gabapentin enacarbil, and pregabalin). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23703310", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 779, 
          "offsetInEndSection": 1116, 
          "text": "There is sufficient evidence to conclude that dopamine agonists such as rotigotine transdermal patch, pramipexole, ropinirole, gabapentin enacarbil, pregabalin and gabapentin are effective in the short-term treatment of RLS and rotigotine, followed by gabapentin enacarbil, ropinirole, pramipexole and gabapentin for long-term treatment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23524988", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 577, 
          "offsetInEndSection": 818, 
          "text": "Calcium channel alpha-2-delta ligands (gabapentin, gabapentin enacarbil, and pregabalin) provide alternative therapies for RLS especially in patients with augmentation, impulse control disorders, or hypersomnia induced by dopamine agonists. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23385700", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2129, 
          "offsetInEndSection": 2381, 
          "text": "Alpha-2-delta ligands (gabapentin enacarbil, gabapentin, and pregabalin) increased the number of IRLS responders (RR=1.66; [95% CI: 1.33 to 2.09], k=3, high strength of evidence) and mean change in IRLS symptom scores (k=3, high strength of evidence). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23304742", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1193, 
          "offsetInEndSection": 1408, 
          "text": "RECOMMENDATIONS: Level A recommendations can be made for rotigotine, ropinirole, pramipexole, gabapentin enacarbil, gabapentin and pregabalin, which are all considered effective for the short-term treatment for RLS.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22937989", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 639, 
          "offsetInEndSection": 810, 
          "text": "Therapies with an OPTION level of recommendation include carbamazepine, gabapentin, pregabalin, clonidine, and for patients with low ferritin levels, iron supplementation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22851801", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1439, 
          "offsetInEndSection": 1565, 
          "text": "CONCLUSIONS: In this 6-week phase 2b study, pregabalin reduced RLS symptoms in patients with moderate-to-severe idiopathic RLS", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20466589", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1974, 
          "offsetInEndSection": 2206, 
          "text": "CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that pregabalin is effective for the treatment of restless legs syndrome and improves sleep architecture and periodic limb movements in placebo-unresponsive patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20427750", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2493, 
          "offsetInEndSection": 2634, 
          "text": "In severe, refractory or neuropathy-associated RLS, antiepileptic (gabapentin, pregabalin) or opioid (oxycodone, tramadol) drugs can be used.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18656214", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is there an association between serum interleukin-6 concentrations and outcomes of stroke patients?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25295149", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19901973", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18685925", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18048088", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17337911", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14730251"
      ], 
      "type": "yesno", 
      "id": "54cf4bc3f693c3b16b00000d", 
      "snippets": [
        {
          "offsetInBeginSection": 1418, 
          "offsetInEndSection": 1496, 
          "text": " In addition, IL-6 concentrations affect clinical outcomes in ischemic stroke.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25295149", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 968, 
          "offsetInEndSection": 1363, 
          "text": "After appropriate adjustment, the odds ratios for the association of markers and poor outcome (comparing the upper and the lower third) were interleukin-6, 3.1 (95% CI: 1.9-5.0); C-reactive protein, 1.9 (95% CI: 1.2-3.1); fibrinogen, 1.5 (95% CI: 1.0-2.36); white cell count, 2.1 (95% CI: 1.3-3.4); and glucose 1.3 (95% CI: 0.8-2.1). The results for interleukin-6 were similar to other studies. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19901973", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1745, 
          "offsetInEndSection": 1992, 
          "text": "-6 and IL-10 levels were higher in patients with poor outcome. On logistic regression analysis, higher values of IL-6 were significantly associated with clinical outcome at 1 month (odds ratio [OR], 1.25; 95% confidence interval [CI], 1.02-1.54). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18685925", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2116, 
          "offsetInEndSection": 2216, 
          "text": "In hemorrhagic stroke, high levels of IL-6 in the early phase indicated a poor neurological outcome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18685925", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 903, 
          "offsetInEndSection": 1551, 
          "text": "Initially elevated levels of hs-IL-6 at presentation further correlated with unfavorable clinical outcomes (by NIHSS and mRs) at both time points. Analysis of variance in the different quartiles identified an hs-IL-6 gradient-dependent correlation at both time points, such that the higher the initial hs-IL-6 concentration, the higher the elevation in inflammatory biomarkers and the poorer the neurological state at both time points (p<0.001 for NIHSS and p=0.001 for mRs, for trend across quartiles). CONCLUSIONS: This study demonstrates the potential of employing hs-IL-6 as an early stage biomarker for the prognosis of acute ischemic stroke. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18048088", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1234, 
          "offsetInEndSection": 1325, 
          "text": "Another negative correlation was found between IL-6 and CNS scores (r = -0.451, p = 0.000).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17337911", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1816, 
          "offsetInEndSection": 1950, 
          "text": "In addition, increased levels of IL-6 and reduced levels of protein C and protein S may play a role in acute ischemic stroke severity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17337911", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 271, 
          "offsetInEndSection": 490, 
          "text": "Variables that are predictors of adverse stroke outcome include erythrocyte sedimentation rate, and levels of C-reactive protein (CRP), interleukin-6, tumour necrosis factor-alpha and intercellular adhesion molecule-1. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14730251", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which drugs acting via bradykinin system are effective for treatment of ACE-inhibitor-induced angioedema?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24565614", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20922352"
      ], 
      "type": "list", 
      "id": "54cf6d40f693c3b16b00000e", 
      "snippets": [
        {
          "offsetInBeginSection": 983, 
          "offsetInEndSection": 1206, 
          "text": "Medications recently developed, primarily icatibant and ecallantide, to control hereditary angioedema, a disorder also associated with kallikrein-kinin activation, have been used to treat ACEI angioedema with some success. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24565614", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 359, 
          "offsetInEndSection": 539, 
          "text": "A patient with acute ACE inhibitor-induced angioedema was treated with icatibant, a specific bradykinin B2 receptor antagonist approved for the treatment of hereditary angioedema. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20922352", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Treatment of which disease was investigated in the MR CLEAN study?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25517348", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25432979", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25179366", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24330796"
      ], 
      "type": "factoid", 
      "id": "54cf7051f693c3b16b000013", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 303, 
          "text": "INTRODUCTION: A recent randomized controlled trial (RCT), the Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands (MR CLEAN), demonstrated better outcomes with endovascular treatment compared with medical therapy for acute ischemic stroke (AIS). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25432979", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 302, 
          "text": "INTRODUCTION: A recent randomized controlled trial (RCT), the Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands (MR CLEAN), demonstrated better outcomes with endovascular treatment compared with medical therapy for acute ischemic stroke (AIS).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25432979", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1845, 
          "offsetInEndSection": 2223, 
          "text": "CONCLUSIONS: In patients with acute ischemic stroke caused by a proximal intracranial occlusion of the anterior circulation, intraarterial treatment administered within 6 hours after stroke onset was effective and safe. (Funded by the Dutch Heart Foundation and others; MR CLEAN Netherlands Trial Registry number, NTR1804, and Current Controlled Trials number, ISRCTN10888758.).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25517348", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 171, 
          "text": "MR CLEAN, a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands: study protocol for a randomized controlled trial.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25179366", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 480, 
          "offsetInEndSection": 744, 
          "text": " In our view, a rational and ethical approach would now be to treat quickly with IV rtPA and when possible, refer and include in new randomized clinical trials that compare intra-arterial treatment with standard care, such as MR CLEAN or BASICS in the Netherlands.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24330796", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List receptors of the drug Cilengitide", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25486381", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24595274", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24433287", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24328341", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23948974", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23728220", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23229276", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23152080", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23060541", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22582818", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22517378", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21914576", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21827415", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21512659", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21049281", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20820929", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20648558", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20029421", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19929817", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18981465", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18838556", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18779539", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17896915", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17693653", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16729916", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12706360", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12154028"
      ], 
      "type": "list", 
      "id": "54cf705ff693c3b16b000014", 
      "snippets": [
        {
          "offsetInBeginSection": -1, 
          "offsetInEndSection": 130, 
          "text": "Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins \u03b1v\u03b23 and \u03b1v\u03b25.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24595274", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1501, 
          "offsetInEndSection": 1764, 
          "text": "Also, this dimer bound 3650-fold stronger and inhibited tumor cell migration and proliferation compared with cilengitide, an integrin-targeting peptidomimetic that performed poorly in recent clinical trials, suggesting promise for further therapeutic development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25486381", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 480, 
          "offsetInEndSection": 727, 
          "text": "As there is evidence for expression of the integrins \u03b1v\u03b23 and \u03b1v\u03b25 in MPM, there is a rationale for investigating the effects on MPM of cilengitide, a synthetic peptide inhibitor of integrin \u03b1v heterodimer with high specificity for \u03b1v\u03b23 and \u03b1v\u03b25. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24595274", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1057, 
          "offsetInEndSection": 1186, 
          "text": "Gene knockdown experiments indicated that these effects of cilengitide were, at least partly, due to antagonism of \u03b1v\u03b23 and \u03b1v\u03b25.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24595274", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 148, 
          "text": "Abstract The RGD cyclic pentapetide, cilengitide, is a selective inhibitor of \u03b1v\u03b23 and \u03b1v\u03b25 integrins and was developed for antiangiogenic therapy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24433287", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 162, 
          "text": "Cilengitide is an RGD-peptide of sequence cyclo[RGDfNMeV] that was was developed as a highly active and selective ligand for the \u03b1v\u03b23 and \u03b1v\u03b25 integrin receptors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328341", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 529, 
          "offsetInEndSection": 793, 
          "text": "RESULTS: \u03b1v\u03b25 was the predominantly expressed integrin heterodimer in meningiomas, whereas \u03b1v\u03b23 was mainly detected in tumor blood vessels. Application of up to 100 \u03bcg/mL cilengitide resulted in only mildly reduced proliferation/survival of meningioma cell lines. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23948974", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 914, 
          "offsetInEndSection": 1066, 
          "text": "UW479 cells expressed only \u03b1v\u03b25 integrin and were not sensitive to cilengitide, suggesting that cilengitide's action largely depends on \u03b1v\u03b23 inhibition.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23728220", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1503, 
          "offsetInEndSection": 1629, 
          "text": "Cilengitide's action on glioma and neuroblastoma cells appears to be dependent on \u03b1v\u03b23 expression and sensitivity to anoikis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23728220", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 236, 
          "offsetInEndSection": 542, 
          "text": "METHODS: For this purpose, nude rats bearing bone metastases were treated with cilengitide, a small molecule inhibitor of \u03b1v\u03b23 and \u03b1v\u03b25 integrins, from day 30 to 55 after tumor cell inoculation of MDA-MB-231 breast cancer cells (25 mg/kg, 5 days per week; n = 8 rats) and compared to control rats (n = 8). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229276", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": -1, 
          "offsetInEndSection": 124, 
          "text": "The \u03b1V\u03b23/\u03b1V\u03b25 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23152080", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1122, 
          "offsetInEndSection": 1385, 
          "text": "Cilengitide, a cyclized Arg-Gly-Glu(RGD)-containing pentapeptide that selectively blocks activation of the \u03b1v\u03b23 and \u03b1v\u03b25 integrins has shown encouraging activity in patients with glioblastoma as single agent, and in association with standard RT and temozolomide. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23060541", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 573, 
          "offsetInEndSection": 871, 
          "text": " Aza-amino acid scanning was performed on the cyclic RGD-peptide Cilengitide, cyclo[R-G-D-f-N(Me)V] 1, and its parent peptide cyclo(R-G-D-f-V) 2, potent antagonists of the \u03b1v\u03b23, \u03b1v\u03b25, and \u03b15\u03b21 integrin receptors, which play important roles in human tumor metastasis and tumor-induced angiogenesis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22582818", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 90, 
          "offsetInEndSection": 244, 
          "text": "Cilengitide (EMD121974; Merck KGaA, Darmstadt, Germany) is a new drug targeting \u03b1v\u03b23 and \u03b1v\u03b25 integrins thanks to a specific peptide called RGD sequence. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21914576", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 548, 
          "offsetInEndSection": 669, 
          "text": "Cilengitide, a cyclic RGD-mimetic peptide of \u03b1v\u03b23 and \u03b1v\u03b25 integrins is in advanced clinical development in glioblastoma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21827415", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 330, 
          "text": "The purpose of this study was the assessment of the feasibility of dynamic positron emission tomography (PET) studies with fluorine-18 fluorodeoxyglucose ((18)F-FDG) to quantify effects of the cyclic Arg-Gly-Asp peptide cilengitide, which targets the \u03b1\u03bd\u03b2 3 and \u03b1\u03bd\u03b2 5 integrin receptors in rats with breast cancer bone metastases. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21512659", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 92, 
          "offsetInEndSection": 269, 
          "text": "We conducted a phase II study of cilengitide, a selective antagonist of \u03b1(v)\u03b2(3) and \u03b1(v)\u03b2(5) integrins, in non-metastatic castration resistant prostate cancer with rising PSA. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21049281", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 104, 
          "offsetInEndSection": 346, 
          "text": "AlphaVbeta3 and alphaVbeta5 integrins are overexpressed on both glioma cells and tumor vasculature. Cilengitide, the most advanced specific integrin inhibitor in oncology, has shown antitumor activity against glioma in early clinical trials. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20820929", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 468, 
          "text": "The aim of this study was to investigate the effect of inhibiting \u03b1v\u03b2(3)/\u03b1(v) \u03b2(5) integrins by cilengitide in experimentally induced breast cancer bone metastases using noninvasive imaging techniques. For this purpose, nude rats bearing established breast cancer bone metastases were treated with cilengitide, a small molecule inhibitor of \u03b1v\u03b2(3) and \u03b1v\u03b2(5) integrins (75 mg/kg, five days per week; n = 12 rats) and compared to vehicle-treated control rats (n = 12). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20648558", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1237, 
          "offsetInEndSection": 1488, 
          "text": " In conclusion, treatment of experimental breast cancer bone metastases with cilengitide resulted in pronounced antiresorptive and antitumor effects, suggesting that \u03b1v\u03b2(3)/\u03b1v\u03b2(5) inhibition may be a promising therapeutic approach for bone metastases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20648558", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 302, 
          "offsetInEndSection": 543, 
          "text": "Integrin antagonists, including the alphavbeta3 and alphavbeta5 inhibitor cilengitide, have shown encouraging activity in Phase II clinical trials and cilengitide is currently being tested in a Phase III trial in patients with glioblastoma. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20029421", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 983, 
          "offsetInEndSection": 1108, 
          "text": "Cilengitide (cyclic peptidic alphavbeta3 and alphavbeta5 antagonist) is currently in clinical trials for anti cancer therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19929817", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 260, 
          "text": "PURPOSE: Cilengitide, an inhibitor of alphavbeta3 and alphavbeta5 integrin receptors, demonstrated minimal toxicity and durable activity across a wide range of doses administered to adults with recurrent glioblastoma multiforme (GBM) in a prior phase I study. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18981465", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 413, 
          "offsetInEndSection": 865, 
          "text": "In line with this concept, peptide ligands containing the Arginine-Glycine-Aspartate (RGD) triad, which display a strong affinity and selectivity to the alpha(V)beta(3) integrin, have been developed to target the tumor-associated cells expressing the alpha (V)beta (3) receptors. Among the validated ligands, the leader compound is the cyclic pentapeptide c[-RGDf(NMe)V-] (Cilengitide) developed by kessler et al. (J. Med. Chem., 1999, 42, 3033-3040). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17896915", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": -1, 
          "offsetInEndSection": 192, 
          "text": "Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17693653", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 247, 
          "text": "BACKGROUND: Cilengitide, an antiangiogenic agent that inhibits the binding of integrins alpha(nu)beta(3) and alpha(nu)beta(5) to the extracellular matrix, was studied at two dose levels in cancer patients to determine the optimal biological dose. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17693653", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 289, 
          "offsetInEndSection": 397, 
          "text": "Cilengitide (EMD121974; NSC 707544), is a potent selective alphavbeta3 and alphavbeta5 integrin antagonist. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16729916", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": -1, 
          "offsetInEndSection": 219, 
          "text": "Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12706360", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 194, 
          "text": "A single-agent dose escalating phase I and pharmacokinetic study with Cilengitide, an inhibitor of the integrins alphavbeta3 and alphavbeta5, was performed to determine its safety and toxicity. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12706360", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 449, 
          "offsetInEndSection": 767, 
          "text": "This study was designed to determine whether, and how, the cyclic Arg-Gly-Asp peptide Cilengitide (EMD 121974), which targets the alpha(v)beta(3) integrin receptor expressed on neovasculature, could increase systemic RIT efficacy of therapy in a human breast cancer tumor model having mutant p53 and expressing bcl-2. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12154028", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Does magnesium sulfate improve outcomes of subarachnoid hemorrhage patients?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25201463", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23931043", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22966500", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22890635", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22633825", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22170177", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21748496", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21608279", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21489317", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21299874", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21125466", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20538692", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20378868", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20334471", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20228677", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19812935", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19828484", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19658274", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18705917", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18054611", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17636626", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17121134", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16723884", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16628069", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16463861", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16463831", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16427437", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16164489", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16159090", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15790946", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15753761", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12632115", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11883835", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11426093"
      ], 
      "type": "yesno", 
      "id": "54d62ede3706e89528000002", 
      "snippets": [
        {
          "offsetInBeginSection": 1687, 
          "offsetInEndSection": 1937, 
          "text": "CONCLUSION: Patients assigned a higher serum magnesium concentration had a reduced incidence of vasospasm as seen by angiography, but the difference was not statistically significant. Clinically significant outcomes were not different between groups.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23931043", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1605, 
          "offsetInEndSection": 2174, 
          "text": "158 patients (26\u00b72%) had poor outcome in the magnesium group compared with 151 (25\u00b73%) in the placebo group (risk ratio [RR] 1\u00b703, 95% CI 0\u00b785-1\u00b725). Our updated meta-analysis of seven randomised trials involving 2047 patients shows that magnesium is not superior to placebo for reduction of poor outcome after aneurysmal subarachnoid haemorrhage (RR 0\u00b796, 95% CI 0\u00b786-1\u00b708). INTERPRETATION: Intravenous magnesium sulphate does not improve clinical outcome after aneurysmal subarachnoid haemorrhage, therefore routine administration of magnesium cannot be recommended. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22633825", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1109, 
          "offsetInEndSection": 1177, 
          "text": "There is a tendency in the magnesium group to have better outcomes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22170177", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 592, 
          "offsetInEndSection": 865, 
          "text": "Due to inconsistently reported benefits and the occurrence of side effects, phase II data suggested that intravenous magnesium for SAH provided either no overall net benefit or uncertain trade-offs. Benefit was likewise not supported in the single phase III clinical trial.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21748496", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1923, 
          "offsetInEndSection": 2262, 
          "text": "tatistically significant clinical benefits could not be demonstrated for the other drugs (clazosentan, statins, and magnesium). CONCLUSIONS: Insufficient evidence is available to support the use of the triple-H therapy, clazosentan, statins, or magnesium sulfate for the prevention of cerebral vasospasm following subarachnoid hemorrhage. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21608279", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 448, 
          "offsetInEndSection": 679, 
          "text": "Magnesium sulfate decreased the rate of cerebral infarction, but not of DCI or poor functional outcome. Regarding outcome, a beneficial effect of magnesium sulfate on outcome can not be ruled out because of sample size limitations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21489317", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1497, 
          "offsetInEndSection": 1901, 
          "text": "CONCLUSIONS: The present findings do not lend support to a beneficial effect of magnesium sulphate infusion on delayed cerebral infarction. The reduction in DCI and improvement in the clinical outcomes of aneurysmal SAH patients following magnesium sulphate infusion observed in previous pilot studies are not confirmed, although a beneficial effect cannot be ruled out because of sample size limitation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21299874", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1145, 
          "offsetInEndSection": 1422, 
          "text": "Favorable outcome (Good recovery and moderate disability, as defined by Glasgow Outcome Scale) was achieved in 20 of 30 (67%) patients receiving magnesium sulfate infusion and 16 of 30 (53%) patients receiving placebo treatment, p = 0.292, odds ratio 1.750, 95% CI 0.616-4.974.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21125466", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1739, 
          "offsetInEndSection": 1851, 
          "text": "Similarly, the pooled odds ratio for favorable outcome is 1.598, 95% CI 1.074-2.377, statistically significant. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21125466", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 671, 
          "offsetInEndSection": 1156, 
          "text": "RESULTS: The worst clinical outcomes at 6 months were seen in MgSO(4) group patients, with mean plasma magnesium concentrations in the fourth quartile, and in placebo group patients, with mean such concentrations in the third and fourth quartiles. CONCLUSIONS: No evidence was found to suggest that a higher mean plasma magnesium concentration improves clinical outcomes. On the contrary, we found an association between high plasma magnesium concentration and worse clinical outcomes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20538692", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1009, 
          "offsetInEndSection": 1388, 
          "text": "The proportions of patients with a favorable outcome at 6 months (Extended Glasgow Outcome Scale 5 to 8) were similar, 64% in the magnesium sulfate group and 63% in the saline group (OR, 1.0; 95% CI, 0.7 to 1.6). Secondary outcome analyses (modified Rankin Scale, Barthel Index, Short Form 36, and clinical vasospasm) also showed no significant differences between the 2 groups. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20378868", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1726, 
          "offsetInEndSection": 1907, 
          "text": "CONCLUSIONS: The results do not support a clinical benefit of intravenous magnesium sulfate infusion over placebo infusion in patients with acute aneurysmal subarachnoid hemorrhage.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20378868", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 752, 
          "offsetInEndSection": 952, 
          "text": "Magnesium infusion reduced the risk of poor outcome and delayed cerebral ischemia (DCI): the relative risk was 0.62 (95% confidence interval (CI) 0.46-0.83) and 0.73 (95% CI 0.53-1.00), respectively. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20334471", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1153, 
          "offsetInEndSection": 1290, 
          "text": "CONCLUSION: The meta-analysis suggests that intravenous magnesium therapy reduces the risk of DCI and poor outcome after aneurysmal SAH. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20334471", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1361, 
          "offsetInEndSection": 1575, 
          "text": "The incidence of delayed ischemic infarction was significantly lower in magnesium-treated patients (22% vs. 51%; p = .002); 34 of 54 magnesium patients and 27 of 53 control patients reached good outcome (p = .209).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20228677", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 209, 
          "text": "BACKGROUND: A meta-analysis of current data suggests that magnesium sulfate infusion improves the outcome after aneurysmal subarachnoid hemorrhage through a reduction in delayed ischemic neurological deficit. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19812935", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1505, 
          "offsetInEndSection": 1701, 
          "text": "These data imply that intravenous magnesium therapy, besides a supposed beneficial effect on outcome, also provides pain relief for SAH patients, for whom it might also improve functional outcome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19828484", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 185, 
          "text": "Preliminary evidence has suggested that magnesium sulfate infusion reduces delayed ischemic neurological deficit and improves clinical outcome after aneurysmal subarachnoid hemorrhage. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19658274", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 238, 
          "offsetInEndSection": 373, 
          "text": "In a phase II randomized clinical trial of 283 patients, magnesium treatment reduced the risk of DCI by 34% and of poor outcome by 23%.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18705917", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 145, 
          "text": "BACKGROUND: Recent studies suggest that high-dose MgSO4 therapy is safe and reduces the incidence of DIND and subsequent poor outcome after SAH. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18054611", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 863, 
          "offsetInEndSection": 1008, 
          "text": "On-treatment analysis showed a significantly better outcome after 3 months (P = .017) and a trend toward better outcome after 1 year (P = .083). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18054611", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1316, 
          "offsetInEndSection": 1455, 
          "text": " CONCLUSIONS: High-dose MgSO4 therapy might be efficient as a prophylactic adjacent therapy after SAH to reduce the risk for poor outcome. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18054611", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1229, 
          "offsetInEndSection": 1652, 
          "text": "There was no significant difference in mortality rate at discharge (p = 0.328). A trend toward improved outcome as measured by the modifed Rankin Scale (p = 0.084), but not the Glasgow Outcome Scale (p = 1.0), was seen in the MgSO4 treated group. CONCLUSIONS: Analysis of the results suggests that MgSO4 infusion may have a role in cerebral vasospasm prophylaxis if therapy is initiated within 48 hours of aneurysm rupture.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17121134", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1040, 
          "offsetInEndSection": 1144, 
          "text": "There was, however, no difference between groups in functional recovery or Glasgow Outcome Scale score. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16628069", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1078, 
          "offsetInEndSection": 1204, 
          "text": "Patients receiving MgSO4 tended to have fewer neurological deficits, better functional recovery and an improved score in GOS. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16463861", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1419, 
          "offsetInEndSection": 1532, 
          "text": "CONCLUSIONS: MgSO4 infusion after aneurysmal SAH is well tolerated and may be useful in producing better outcome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16463861", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1488, 
          "offsetInEndSection": 1642, 
          "text": "CONCLUSION: Magnesium did not seem to interfere in vasospasm frequency but apparently acted favorably in decreasing morbidity and length of hospital stay.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16427437", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1862, 
          "offsetInEndSection": 2011, 
          "text": "None of the patients died; no CT evidence of ischemic infarction was present; and most had good outcomes (GOS 5 in 10 patients; GOS 4 in 8 patients).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16159090", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1110, 
          "offsetInEndSection": 1379, 
          "text": "At that time, 18 patients in the treatment group and 6 in the placebo group had an excellent outcome (risk ratio, 3.4; 95% CI, 1.3 to 8.9). CONCLUSIONS: This study suggests that magnesium reduces DCI and subsequent poor outcome, but the results are not yet definitive. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15790946", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2757, 
          "offsetInEndSection": 2944, 
          "text": "We observed a trend in which a higher percentage of patients obtained GOS scores of 4 or 5 in the group treated with MgSO4, but the trend did not reach a statistically significant level. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11883835", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can NXY-059 be used for treatment of acute ischemic stroke patients?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23109881", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23419732", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22709256", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21651461", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19631615", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19167593", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19074479", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18673209", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18416999", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18369171", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17975102", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17687131", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17579658", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17478741", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17420989", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17408618", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17244778", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17068304", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16467546"
      ], 
      "type": "yesno", 
      "id": "54d62faf3706e89528000003", 
      "snippets": [
        {
          "offsetInBeginSection": 402, 
          "offsetInEndSection": 704, 
          "text": "Even when the international recommendations for preclinical stroke research, the Stroke Academic Industry Roundtable (STAIR) criteria, were followed, we have still seen limited success in the clinic, examples being NXY-059 and haematopoietic growth factors which fulfilled nearly all the STAIR criteria", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23109881", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 791, 
          "offsetInEndSection": 1035, 
          "text": "This occurred during 1993-2006, when the 2,4-disulfonylphenyl PBN derivative, called NXY-059 in the stroke studies, was shown to be safe in humans and was taken all the way through clinical phase 3 trials and then was deemed to be ineffective. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23419732", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 155, 
          "offsetInEndSection": 364, 
          "text": "The nitrone-based compound NXY-059, which is the first drug to reach clinical trials for the treatment of acute ischemic stroke, has provided promise for the development of more robust pharmacological agents. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22709256", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 459, 
          "offsetInEndSection": 739, 
          "text": "OKN-007 is a proprietary compound that has had extensive commercial development (designated as NXY-059) for another indication, acute ischemic stroke, and after extensive clinical studies was shown to lack efficacy for this indication but was shown to be very safe for human use. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21651461", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 244, 
          "text": "NXY-059, a polar compound with limited transport across the blood-brain barrier, has demonstrated neuroprotection in several animal models of acute ischemic stroke but failed to confirm clinical benefit in the second phase III trial (SAINT-II).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19631615", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 356, 
          "offsetInEndSection": 488, 
          "text": "NXY-059 is no longer in development following a lack of efficacy found in a Phase III trial in patients with acute ischemic stroke. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19167593", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 202, 
          "offsetInEndSection": 385, 
          "text": "We analyzed the quality and adequacy of animal studies supporting the efficacy of NXY-059 and other neuroprotective agents that are currently being investigated in phase II/III trials", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19074479", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 138, 
          "offsetInEndSection": 320, 
          "text": " In the aftermath of the failed stroke clinical trials with the nitrone spin trap/radical scavenger, NXY-059, a number of articles raised the question: are we doing the right thing? ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18673209", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 614, 
          "offsetInEndSection": 852, 
          "text": " In 2006, the first positive trial of neuroprotection was published: the SAINT I (Stroke-Acute Ischemic NXY Treatment) study. In February 2008, the SAINT II study was published, indicating that NXY-059 was not effective for AIS treatment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18416999", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1920, 
          "offsetInEndSection": 2010, 
          "text": "CONCLUSIONS: NXY-059 is ineffective for treatment of AIS within 6 hours of symptom onset. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18369171", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 247, 
          "text": "BACKGROUND AND PURPOSE: The SAINT I trial that showed a significant benefit of the neuroprotectant NXY-059 used a novel outcome for acute ischemic stroke trials: a shift toward good functional outcome on the 7-category modified Rankin scale (mRS).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17975102", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 224, 
          "text": "BACKGROUND: The free-radical-trapping agent NXY-059 showed promise as a neuroprotectant in the Stroke-Acute Ischemic NXY Treatment I (SAINT I) trial, reducing disability when given to patients who had acute ischemic stroke. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17687131", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1773, 
          "offsetInEndSection": 1895, 
          "text": "CONCLUSIONS: NXY-059 is ineffective for the treatment of acute ischemic stroke within 6 hours after the onset of symptoms.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17687131", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 187, 
          "text": "The continued failure in approving new drugs for treatment of acute stroke has been recently set back by the failure of the NXY-059 (Stroke-Acute Ischemic NXY Treatment (SAINT) II) trial.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17579658", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 176, 
          "text": "The SAINT II Trial, a large randomized multicenter clinical trial of the putative neuroprotectant, NXY-059, failed to demonstrate a treatment benefit in acute ischemic stroke. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17478741", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 509, 
          "offsetInEndSection": 844, 
          "text": "The positive results from the first Stroke-Acute-Ischaemic-NXY-Treatment (SAINT-I) trial of the free-radical spin-trap drug, NXY-059, which followed many of the STAIR guidelines, reinvigorated enthusiasm in neuroprotection, but the SAINT-II trial did not replicate the positive effect on the same primary prespecified outcome measure. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17420989", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 302, 
          "offsetInEndSection": 613, 
          "text": "NXY-059, a free radical spin trap agent, was felt by many to have followed these criteria and it was recently shown to improve outcome in AIS patients in the SAINT I trial. However, the repeat, SAINT II trial was a neutral study, the results of which cast doubt on neuroprotection as a viable strategy for AIS. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17408618", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 307, 
          "text": "NXY-059 is a novel free radical-trapping neuroprotectant that reduces infarct size and preserves brain function in animal models of acute ischemic stroke. It is the first neuroprotectant to demonstrate a reduction in global disability in a phase III clinical trial, as measured by the modified Rankin Scale.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17244778", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 130, 
          "text": "BACKGROUND AND PURPOSE: NXY-059 is a free radical-trapping neuroprotectant demonstrated to reduce disability from ischemic stroke.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17068304", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1432, 
          "offsetInEndSection": 1527, 
          "text": "CONCLUSIONS: NXY-059 within 6 hours of acute ischemic stroke significantly reduced disability. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17068304", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1701, 
          "offsetInEndSection": 2095, 
          "text": "CONCLUSIONS: The administration of NXY-059 within six hours after the onset of acute ischemic stroke significantly improved the primary outcome (reduced disability at 90 days), but it did not significantly improve other outcome measures, including neurologic functioning as measured by the NIHSS score. Additional research is needed to confirm whether NXY-059 is beneficial in ischemic stroke. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467546", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Do carmustine wafers improve survival of glioblastoma patients?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25054300", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22715955", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21330749", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21300471", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20706757", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20511192", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19123896", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19046047", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18636295", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18366283", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18035958", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17350791", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16482400", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15937647", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15015668", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12672279", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12074689", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20155992", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19514083", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23662801", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23535992", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21756557", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21479583", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21390826", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10414561", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25269031", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24246204", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23118709"
      ], 
      "type": "yesno", 
      "id": "54d630283706e89528000004", 
      "snippets": [
        {
          "offsetInBeginSection": 338, 
          "offsetInEndSection": 472, 
          "text": "At recurrence, treatment options include repeat surgery (with or without Gliadel wafer placement), reirradiation or systemic therapy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25054300", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1563, 
          "offsetInEndSection": 1909, 
          "text": "DISCUSSION: Carmustine wafers for primary HGG surgery in accordance with the NICE TA121 were associated with a median survival of 15.3 months; this is improved compared with previously reported randomised trials. Multimodal treatment with carmustine wafers, radical radiotherapy and concomitant temozolomide was associated with improved survival.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22715955", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 642, 
          "offsetInEndSection": 886, 
          "text": "Gliadel wafer is a new approach to the treatment of glioblastoma, which involves controlled release delivery of carmustine from biodegradable polymer wafers. It has shown promising results and provides a silver lining for glioblastoma patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21330749", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 613, 
          "offsetInEndSection": 745, 
          "text": "For patient with and without Gliadel, median and 1-year RFS were 12.9 months and 52% vs. 14 months and 42%, respectively (p = 0.89).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21300471", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1276, 
          "offsetInEndSection": 1371, 
          "text": "According to pathology, Gliadel did not influence OS of patients with Grade III or glioblastoma", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21300471", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1821, 
          "offsetInEndSection": 1945, 
          "text": "CONCLUSION: In patients with high-grade gliomas, adding Gliadel before performing a Stupp protocol did not improve survival.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21300471", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 219, 
          "text": "Randomized phase III trials have shown significant improvement of survival 1, 2, and 3 years after implantation of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) wafers for patients with newly diagnosed malignant glioma. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20706757", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2138, 
          "offsetInEndSection": 2438, 
          "text": "CONCLUSIONS: The combination of aggressive resection, Gliadel wafer implantation, and GKS in addition to standard fractionated RT in selected patients resulted in increased local control and increased survival compared with a historical control group treated with surgery and involved-field RT alone.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19123896", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 230, 
          "text": "OBJECT: Gliadel (BCNU) wafer and concomitant temozolomide (TMZ) therapy, when used individually as adjuvant therapies, extend survival from that achieved by resection and radiation therapy (XRT) for glioblastoma multiforme (GBM). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19046047", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 193, 
          "text": "BACKGROUND: Gliadel (polifeprosan 20 with carmustine [BCNU] implant) is commonly used for local delivery of BCNU to high-grade gliomas after resection and is associated with increased survival.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18636295", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 546, 
          "offsetInEndSection": 719, 
          "text": "Temozolomide administered according to this protocol produced a median survival benefit of 2 months in glioblastomas, and carmustine a similar benefit in high-grade gliomas.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350791", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 283, 
          "offsetInEndSection": 455, 
          "text": "Analysis of a large trial by Westphal and colleagues (n = 240) showed a 29% risk reduction (P = 0.03) in the BCNU wafer-treated group over the course of the 30-month trial.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16482400", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1032, 
          "offsetInEndSection": 1360, 
          "text": "Median survival of patients treated with BCNU wafers was 13.8 months vs 11.6 months in placebo-treated patients (P = 0.017) with a hazard ratio of 0.73 (P = 0.018), representing a 27% significant risk reduction. This survival advantage was maintained at 1, 2, and 3 years and was statistically significant (P = 0.01) at 3 years.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16482400", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1474, 
          "offsetInEndSection": 1689, 
          "text": "CONCLUSION: Malignant glioma patients treated with BCNU wafers at the time of initial surgery in combination with radiation therapy demonstrated a survival advantage at 2 and 3 years follow-up compared with placebo.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16482400", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 210, 
          "text": "OBJECTIVE: Recently a randomized placebo-controlled phase III trial of biodegradable polymers containing carmustine has demonstrated a significant survival benefit for patients treated with local chemotherapy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15015668", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1810, 
          "offsetInEndSection": 2051, 
          "text": "CONCLUSION: In this subgroup analysis of a phase III trial population both the clinical progression and radiological progression were significantly delayed in patients treated with local chemotherapy, resulting in an increased survival time.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15015668", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 399, 
          "text": "A previous placebo-controlled trial has shown that biodegradable 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) wafers (Gliadel wafers) prolong survival in patients with recurrent glioblastoma multiforme. A previously completed phase 3 trial, also placebo controlled, in 32 patients with newly diagnosed malignant glioma also demonstrated a survival benefit in those patients treated with BCNU wafers.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12672279", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 815, 
          "offsetInEndSection": 1198, 
          "text": "Median survival in the intent-to-treat group was 13.9 months for the BCNU wafer-treated group and 11.6 months for the placebo-treated group (log-rank P -value stratified by country = 0.03), with a 29% reduction in the risk of death in the treatment group. When adjusted for factors affecting survival, the treatment effect remained positive with a risk reduction of 28% ( P = 0.03). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12672279", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 253, 
          "text": "Controlled release delivery of carmustine from biodegradable polymer wafers was approved as an adjunct to surgical resection in the treatment of recurrent glioblastoma multiforme after it was shown in clinical trials to be well tolerated and effective. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12074689", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 349, 
          "offsetInEndSection": 513, 
          "text": "Clinical trials have demonstrated significant improvements in survival and quality of life for patients after complete tumour resection and BCNU wafer implantation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20155992", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1553, 
          "offsetInEndSection": 1767, 
          "text": "BCNU wafers are an effective means of increasing survival and quality of life in patients diagnosed with malignant glioma, and are a valuable addition to the overall multimodal treatment strategy for these tumours.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20155992", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1520, 
          "offsetInEndSection": 1717, 
          "text": "CONCLUSIONS: Carmustine wafer with concurrent TMZ and radiation followed by rotational chemotherapy is a well tolerated, effective therapy, and has a survival benefit compared with radiation alone.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19514083", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1297, 
          "offsetInEndSection": 1518, 
          "text": "Median overall survival in 14 studies of newly-diagnosed patients suggested a modest improvement versus resection followed by Stupp protocol or resection with BCNU wafers, with an acceptable and manageable safety profile.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23535992", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 103, 
          "text": "The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21756557", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1607, 
          "offsetInEndSection": 1826, 
          "text": "DISCUSSION: Older patients with GBM may benefit from carmustine wafers. The survival for older patients who received carmustine wafers is significantly longer than matched patients who did not receive carmustine wafers.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21756557", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 668, 
          "offsetInEndSection": 958, 
          "text": "For glioblastoma patients who received \u226590% resection in the BCNU wafer study, median survival increased for BCNU wafer versus placebo (14.5 versus 12.4\u00a0months, respectively; P\u2009=\u20090.02), but no survival increase was found for <90% resection (11.7 versus 10.6\u00a0months, respectively; P\u2009=\u20090.98).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21479583", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1923, 
          "offsetInEndSection": 2144, 
          "text": "A wafer impregnated with carmustine, for use as an implant after surgical removal of recurrent GBM showed a prolongation in the median survival time of only 2 mo, from 20 to 28 wk in a study with a total of 222 patients. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21390826", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1620, 
          "offsetInEndSection": 1696, 
          "text": "No clear survival benefit associated with wafer implantation was identified.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10414561", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 710, 
          "offsetInEndSection": 866, 
          "text": "In three of the trials, patients with GBM who received carmustine wafers had significantly longer median survival than patients who did not receive wafers. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25269031", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1142, 
          "offsetInEndSection": 1298, 
          "text": "TMZ and carmustine (BCNU) biodegradable wafer (Gliadel) are the only adjuvant chemotherapies that have improved survival in randomised GB clinical trials . ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24246204", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 297, 
          "offsetInEndSection": 519, 
          "text": "The carmustine implant wafer was demonstrated to improve survival in blinded placebo-controlled trials in selected patients with newly diagnosed or recurrent malignant glioma, with little increased risk of adverse events. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23118709", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1365, 
          "offsetInEndSection": 1644, 
          "text": "For patients undergoing repeat resection for malignant glioma, a randomized, blinded, placebo-controlled trial demonstrated a median survival for 110 patients who received carmustine polymers of 31 weeks compared with 23 weeks for 122 patients who only received placebo polymers.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23118709", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1977, 
          "offsetInEndSection": 2261, 
          "text": "Median survival was improved from 11.6 to 13.9 months (P = 0.03), with a 29% reduction in the risk of death. When patients with glioblastoma multiforme alone were analyzed, the median survival improved from 11.4 to 13.5 months, but this improvement was not statistically significant. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23118709", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is there any association of the chromosomal region harboring the gene ITIH3 with schizophrenia?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25414627", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22614287", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21926974", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21926972", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25136889", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24618187", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24461634", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24373612"
      ], 
      "type": "yesno", 
      "id": "54d63d873706e89528000006", 
      "snippets": [
        {
          "offsetInBeginSection": 807, 
          "offsetInEndSection": 1000, 
          "text": "The most widely shared subset of genes-common to five of six disorders-included ANK3, AS3MT, CACNA1C, CACNB2, CNNM2, CSMD1, DPCR1, ITIH3, NT5C2, PPP1R11, SYNE1, TCF4, TENM4, TRIM26, and ZNRD1. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25414627", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 163, 
          "text": "Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCCAG8, and extensive replication of associations reported by the Schizophrenia PGC.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22614287", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 852, 
          "offsetInEndSection": 1053, 
          "text": "After combining the new schizophrenia data with those of the PGC, variants at three loci (ITIH3/4, CACNA1C and SDCCAG8) that had not previously been GWS in schizophrenia attained that level of support.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22614287", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 916, 
          "offsetInEndSection": 1195, 
          "text": "In a joint analysis with a bipolar disorder sample (16,374 affected individuals and 14,044 controls), three loci reached genome-wide significance: CACNA1C (rs4765905, P = 7.0 \u00d7 10(-9)), ANK3 (rs10994359, P = 2.5 \u00d7 10(-8)) and the ITIH3-ITIH4 region (rs2239547, P = 7.8 \u00d7 10(-9)).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21926974", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 728, 
          "offsetInEndSection": 901, 
          "text": "Finally, a combined GWAS analysis of schizophrenia and bipolar disorder yielded strong association evidence for SNPs in CACNA1C and in the region of NEK4-ITIH1-ITIH3-ITIH4. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21926972", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 191, 
          "text": "A recent genome-wide analysis indicated that a polymorphism (rs2535629) of ITIH3 showed the strongest association signal with susceptibility to psychiatric disorders in Caucasian populations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24373612", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1170, 
          "offsetInEndSection": 1336, 
          "text": "We detected a novel association between suicide attempt and the ITIH3/4-region in a combined group of patients with BD, SCZ and related psychosis spectrum disorders. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24461634", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 908, 
          "offsetInEndSection": 1221, 
          "text": "These include variations in chromosomal structure at 16p11.2, rare de novo point mutations at the gene SCN2A, and common single nucleotide polymorphisms (SNPs) mapping near loci encoding the genes ITIH3, AS3MT, CACNA1C and CACNB2. These selected examples point to the challenges to current diagnostic approaches. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24618187", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1073, 
          "offsetInEndSection": 1271, 
          "text": "STAB1 is located in close proximity to PBMR1 and the NEK4-ITIH1-ITIH3-ITIH4 region, which are the top findings from GWAS meta-analyses of mood disorder, and a combined BD and schizophrenia data set.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25136889", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1364, 
          "offsetInEndSection": 1499, 
          "text": "Our findings suggest that rs2535629 influences the susceptibility to psychiatric disorders by affecting the expression level of GLT8D1.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24373612", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the enzymatic activity of the myotubularin family of proteins?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23857703", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23818870", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23114011", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21372139", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21510942", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22578719", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22647598", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23086420", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21175430", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20736309", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20188094", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19325702", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17346927", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16914545", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16828287", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16787938", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16410353", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16289848", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16262718", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15998640", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14690594", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12925573", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12829232", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12788949", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12646134", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12554688", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12118066", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12045210", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12018406", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11846405", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11733541", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11275328"
      ], 
      "type": "factoid", 
      "id": "54d6562c3706e8952800000b", 
      "snippets": [
        {
          "offsetInBeginSection": 518, 
          "offsetInEndSection": 554, 
          "text": "myotubularin family of phosphatases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23857703", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 114, 
          "offsetInEndSection": 282, 
          "text": "Myotubularin belongs to a large family of conserved lipid phosphatases that include both catalytically active and inactive myotubularin-related proteins (i.e., \"MTMRs\")", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23818870", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 432, 
          "offsetInEndSection": 463, 
          "text": "myotubalarin family phosphatase", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23114011", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 77, 
          "text": "MTMR2 is a member of the myotubularin family of inositol lipid phosphatases, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21372139", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 118, 
          "text": "Myotubularin related protein 2 (MTMR2) is a member of the myotubularin family of phosphoinositide lipid phosphatases. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21510942", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 91, 
          "text": "Myotubularin phosphoinositide phosphatases: cellular functions and disease pathophysiology.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22578719", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 481, 
          "offsetInEndSection": 795, 
          "text": "Although myotubularin was thought to be a dual-specificity protein phosphatase, recent results indicate that it is primarily a lipid phosphatase, acting on phosphatidylinositol 3-monophosphate, and might be involved in the regulation of phosphatidylinositol 3-kinase (PI 3-kinase) pathway and membrane trafficking.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11275328", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 105, 
          "text": "Myotubularin is the archetype of a family of highly conserved protein-tyrosine phosphatase-like enzymes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11733541", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 245, 
          "offsetInEndSection": 364, 
          "text": "we and others have characterized myotubularin as a potent and specific phosphatidylinositol 3-phosphate 3-phosphatase. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11846405", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 292, 
          "offsetInEndSection": 544, 
          "text": "MTMR2 encodes a member of the myotubularin family of phosphoinositide-3-phosphatases, which dephosphorylate phosphatidylinositol 3-phosphate (PI(3)P) and bisphosphate PI(3,5)P2. MTMR13 encodes a large, uncharacterized member of the myotubularin family.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15998640", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 147, 
          "text": "Myotubularin-related proteins are a large subfamily of protein tyrosine phosphatases (PTPs) that dephosphorylate D3-phosphorylated inositol lipids.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14690594", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 289, 
          "offsetInEndSection": 409, 
          "text": "Myotubularin, the gene mutated in myotubular myopathy, functions as a lipid phosphatase with specificity for PtdIns(3)P.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12018406", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 59, 
          "text": "The myotubularin family: novel phosphoinositide regulators.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12018406", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 82, 
          "text": "The myotubularins are a large family of inositol polyphosphate 3-phosphatases that", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22647598", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 172, 
          "offsetInEndSection": 422, 
          "text": "The myotubularin family consists of 16 different proteins, 9 members of which possess catalytic activity, dephosphorylating phosphatidylinositol 3-phosphate [PtdIns(3)P] and phosphatidylinositol 3,5-bisphosphate [PtdIns(3,5)P(2)] at the D-3 position.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22647598", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 61, 
          "text": "Myotubularin phosphoinositide phosphatases in human diseases.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23086420", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 153, 
          "text": "The MTM (myotubularin)/MTMR (myotubularin-related) protein family is comprised of 15 lipid phosphatases, of which nine members are catalytically active. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21175430", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 46, 
          "text": "The myotubularin family of lipid phosphatases ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21175430", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "When are itaconic acid levels elevated?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25209111", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25064235", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23610393"
      ], 
      "type": "factoid", 
      "id": "54d669003706e8952800000e", 
      "snippets": [
        {
          "offsetInBeginSection": 1138, 
          "offsetInEndSection": 1371, 
          "text": "taconic acid (P = 0.0003), with a false discovery rate of 0.012, was found to be significantly more abundant in women who subsequently developed gestational diabetes mellitus, when compared to controls with uncomplicated pregnancies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25064235", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 360, 
          "offsetInEndSection": 585, 
          "text": "Using a gain-and-loss-of-function approach in both mouse and human immune cells, we found Irg1 expression levels correlating with the amounts of itaconic acid, a metabolite previously proposed to have an antimicrobial effect.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23610393", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 869, 
          "offsetInEndSection": 1021, 
          "text": "Here we show that itaconic acid inhibits the growth of bacteria expressing isocitrate lyase, such as Salmonella enterica and Mycobacterium tuberculosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23610393", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1306, 
          "offsetInEndSection": 1322, 
          "text": " immune defense ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23610393", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List Genes associated with adolescent idiopathic scoliosis", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25504735", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25401082", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25283277", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25005481", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24603539", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24038971", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23812140", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23724359", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22278929", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22183150", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22095884", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21983728", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21740577", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21216876", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20733416", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20627007", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19726741", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19212754", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19192405", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19139660", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18386809", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17632395", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17414906", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17108395", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15832907", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15717203", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15457701", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15457700", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15303021", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15088139", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12973153", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12384783", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11343318", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11136708", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10494097", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10466862", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10399127", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10096591", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9408396", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8982144", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8180508", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1345899", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2605936", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2932368", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19080622", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18985072", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18794762", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18021699", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18007247", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18001530", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17932119", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17785083", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25410117", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25408124", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25313366", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24833718", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24551838", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24469715", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24023777", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23591653", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23467837", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23453657", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23364988", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23259508", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23096252", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23038618", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22992817", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22744455", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22615788", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22193623", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22158057", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22002330", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21691901", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21520258", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21308753", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21228746", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21228692", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21192222", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21146321", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20543391", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20436380", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22009847", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19634821", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19340878", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19337134", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17534191", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17156628", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17108457", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17108412", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17108398", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17023856", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16540873"
      ], 
      "type": "list", 
      "id": "54d670163706e8952800000f", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 95, 
          "text": "Exome Sequencing Identifies a Rare HSPG2 Variant Associated with Familial Idiopathic Scoliosis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25504735", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1184, 
          "offsetInEndSection": 1329, 
          "text": "Overall, these findings demonstrate a novel role for kif6 in spinal development and identify a new candidate gene for human idiopathic scoliosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25283277", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 933, 
          "offsetInEndSection": 1299, 
          "text": "HL1 is of interest, as it encodes an axon guidance protein related to Robo3. Mutations in the Robo3 protein cause horizontal gaze palsy with progressive scoliosis (HGPPS), a rare disease marked by severe scoliosis. Other top associations in our GWAS were with SNPs in the DSCAM gene encoding an axon guidance protein in the same structural class with Chl1 and Robo3.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21216876", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the generic name of Gliolan?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25248327", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24468659", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23870657", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18389144", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22849976"
      ], 
      "type": "factoid", 
      "id": "54d73e223706e89528000010", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 152, 
          "text": "BACKGROUND: Five-aminolevulinic acid (Gliolan, medac, Wedel, Germany, 5-ALA) is approved for fluorescence-guided resections of adult malignant gliomas. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25248327", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 202, 
          "text": "OBJECTIVE: This study evaluates the cost-effectiveness of 5-aminolevulinic acid (5-ALA, Gliolan\u00ae) in patients undergoing surgery for malignant glioma, in standard clinical practice conditions in Spain. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24468659", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 256, 
          "text": "OBJECTIVE: To assess effectiveness of 5-aminolevulinic acid (5-ALA, Gliolan(\u00ae)) in patients treated for malignant glioma under typical daily practice conditions in Spain, using complete resection rate (CR) and progression free survival at 6 months (PFS6). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23870657", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 355, 
          "offsetInEndSection": 585, 
          "text": "Today, ALA is approved as Levulan for actinic keratoses, the ALA-methyl ester Metvix for actinic keratoses and basal cell carcinoma, the ALA-hexyl ester Hexvix for the diagnosis of bladder cancer and Gliolan for malignant glioma. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18389144", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 655, 
          "offsetInEndSection": 850, 
          "text": "MATERIAL AND METHODS: All patients who had undergone 5-ALA fluorescence-guided surgery due to suspected malignant glioma were included. Patients received a standard preoperative dose of Gliolan. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22849976", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can cognitive behavioral therapy improve fatigue in cancer patients?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25299140", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25233905", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25150812", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25083010", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24971014", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24650832", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24458595", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24419112", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23707383", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23557323", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20890148", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20656618", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20651011", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19900778", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19450037", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18246853", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21538678"
      ], 
      "type": "yesno", 
      "id": "54d762653706e89528000014", 
      "snippets": [
        {
          "offsetInBeginSection": 536, 
          "offsetInEndSection": 697, 
          "text": "Physical activity, educational interventions, and cognitive-behavioral therapy have the most supportive data and can be recommended to patients with confidence. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25299140", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1201, 
          "offsetInEndSection": 1327, 
          "text": "For women undergoing radiotherapy (3 RCTs), hypnosis combined with cognitive-behavioral therapy improved distress and fatigue.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25233905", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1327, 
          "offsetInEndSection": 1452, 
          "text": "Patients in the CBT group reported a significantly larger decrease in fatigue scores than patients in the waiting list group.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25150812", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1128, 
          "offsetInEndSection": 1327, 
          "text": "However, relative to VCBT-I, PCBT-I was associated with significantly greater improvements of insomnia severity, early morning awakenings, depression, fatigue, and dysfunctional beliefs about sleep. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25083010", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1204, 
          "offsetInEndSection": 1458, 
          "text": "CBT-I may also improve mood, fatigue, and overall quality of life, and can be successfully delivered through a variety of treatment modalities, making it possible to reach a broader range of patients who may not have access to more traditional programs. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24971014", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1296, 
          "offsetInEndSection": 1378, 
          "text": "No group differences in improvement were noted relative to QOL, fatigue, or mood. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24650832", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1715, 
          "offsetInEndSection": 1806, 
          "text": "In case of persistent fatigue, personalized cognitive behavioral therapy can be considered.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24458595", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1423, 
          "offsetInEndSection": 1567, 
          "text": "ONCLUSION: The results support CBTH as an evidence-based intervention to control fatigue in patients undergoing radiotherapy for breast cancer. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24419112", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 156, 
          "offsetInEndSection": 331, 
          "text": "Severe fatigue after cancer treatment can be treated effectively with cognitive behavioral therapy (CBT), but it is unclear whether CBT has an effect on cognitive functioning.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23707383", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1590, 
          "offsetInEndSection": 1681, 
          "text": "CONCLUSION: CBT for post-cancer fatigue has already been shown to be an effective therapy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23707383", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 309, 
          "offsetInEndSection": 549, 
          "text": "Frequently reported side effects include cancer-related fatigue, peripheral neuropathy, and psychological distress. Exercise and cognitive behavioral therapy interventions have counteracted such adverse effects in other cancer populations. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23557323", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 783, 
          "offsetInEndSection": 1142, 
          "text": "There is evidence from methodologically rigorous controlled trials that exercise, psycho-educational interventions, and cognitive-behavioral therapy for insomnia are effective in the treatment of CRF, and a wide range of pharmacologic and nonpharmacologic interventions has shown initial promise in single-arm pilot studies with small, heterogeneous samples. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20656618", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2060, 
          "offsetInEndSection": 2535, 
          "text": "CONCLUSIONS: Physical training combined with cognitive-behavioral therapy and physical training alone had significant and beneficial effects on fatigue compared with no intervention. Physical training was equally effective as or more effective than physical training combined with cognitive-behavioral therapy in reducing cancer-related fatigue, suggesting that cognitive-behavioral therapy did not have additional beneficial effects beyond the benefits of physical training.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20651011", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1092, 
          "offsetInEndSection": 1262, 
          "text": "RESULTS: Imagery/hypnosis and CBT/CST interventions have produced improvement in all the three cancer-related symptoms individually: pain, fatigue, and sleep disturbance.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19900778", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 805, 
          "offsetInEndSection": 1139, 
          "text": "RESULTS: Multilevel modeling indicated that for weekly FACIT fatigue data, there was a significant effect of the CBTH intervention on the rate of change in fatigue (p < .05), such that on average, CBTH participants' fatigue did not increase over the course of treatment, whereas control group participants' fatigue increased linearly.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19450037", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1194, 
          "offsetInEndSection": 1347, 
          "text": "ONCLUSION: The results suggest that CBTH is an effective means for controlling and potentially preventing fatigue in breast cancer radiotherapy patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19450037", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 467, 
          "offsetInEndSection": 596, 
          "text": "Results were consistent with the view that CBTH was effective in managing fatigue and skin discomfort, and increasing relaxation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18246853", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 867, 
          "offsetInEndSection": 1314, 
          "text": "RESULTS: Participants in the Internet group showed significant improvements at post-assessment compared with those in the control group in overall insomnia severity (F(1,26) = 22.8; p<0.001), sleep efficiency (F(1,24) = 11.45; P = 0.002), sleep onset latency (F(1,24) = 5.18; P = 0.03), soundness of sleep (F(1,24) = 9.34; P = 0.005), restored feeling upon awakening (F(1,24) = 11.95; P = 0.002), and general fatigue (F(1,26) = 13.88; P = 0.001). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21538678", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is there any data to suggest that TRH (thyrotropin releasing hormone) administration can improve symptom severity of amyotrophic lateral sclerosis patients?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22017410", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9444487", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8899662", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7925318", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1469425", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1579228", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1596403", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1792854", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1906441", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1904337", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2127925", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2126554", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2233870", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2125610", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2132051", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2514091", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2518665", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2513155", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2475830", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2563937", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2497685", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2497684", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3147318", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3146705", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3136230", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3148186", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3148185", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3068777", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11681403", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3104820", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3104751", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3104750", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3091628", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3097367", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3080695", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3080694", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3080693", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3088700", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2982071", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3923160", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6134961"
      ], 
      "type": "yesno", 
      "id": "54d76ac63706e89528000016", 
      "snippets": [
        {
          "offsetInBeginSection": 212, 
          "offsetInEndSection": 514, 
          "text": "These central nervous system (CNS)-mediated effects provide the rationale for use of TRH and its analogs in the treatment of brain and spinal injury, and CNS disorders like schizophrenia, Alzheimer's disease, epilepsy, amyotrophic lateral sclerosis, Parkinson's disease, depression, shock and ischemia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22017410", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 558, 
          "offsetInEndSection": 733, 
          "text": "The Effect of TRH to correct the abnormal F responses in SSP might be consistent with effects of TRH to reduce spasticity in amyotrophic lateral sclerosis described previously", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9444487", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1087, 
          "offsetInEndSection": 1221, 
          "text": "Agents undergoing therapeutic trials at present include CNTF, IGF1 glutamate antagonists, branched-chain amino acids and TRH analogue.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7925318", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 207, 
          "text": "Evidence that thyrotropin-releasing hormone (TRH) has prominent trophic effects on the motor system led to several negative therapeutic trials in amyotrophic lateral sclerosis, a disease of the motor system.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1579228", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 859, 
          "offsetInEndSection": 1131, 
          "text": "The results of the clinical evaluation at the beginning and end of the treatment as well as after patient follow up demonstrated that beneficial effects do not occur equally in all patients but rather are transitory and do not improve the natural evolution of the disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1596403", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 436, 
          "offsetInEndSection": 538, 
          "text": "The neurological evaluation after acute TRH-T treatment showed an objective improvement in 3 of the 8.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1792854", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 286, 
          "offsetInEndSection": 568, 
          "text": "The outcome of the study, in agreement with some and at variance with other studies, was that TRH induced a statistically significant neurological improvement in 17 of the 23 ALS patients but little or none in the other ALS patients and in patients with other neurological diseases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1906441", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 137, 
          "text": "[A case of amyotrophic lateral sclerosis with disturbance of vertical ocular movement responding to thyrotropin releasing hormone (TRH)].", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1904337", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 629, 
          "offsetInEndSection": 763, 
          "text": "TRH injections resulted in improvement of disturbance of vertical ocular movement, but no effect was seen on the weakness of the limb.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1904337", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 132, 
          "text": "13 patients with amyotrophic lateral sclerosis (ALS) were treated with intravenous infusion of thyrotropin-releasing hormone (TRH). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2127925", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 182, 
          "offsetInEndSection": 347, 
          "text": "Similar improvements in speech, swallowing and in tongue and jaw movements were seen after iv and oral administration in nine, five and eight patients respectively. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2126554", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 182, 
          "offsetInEndSection": 220, 
          "text": "No clinical improvement was detected. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2125610", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 246, 
          "text": "A trial of Thyrotropin Releasing Hormone (TRH) 5.0 mg/kg body weight subcutaneously every other day for two weeks produced transient increased tone in muscles, along with other (side-) effects in patients with Amyotrophic Lateral Sclerosis (ALS).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2514091", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1561, 
          "offsetInEndSection": 1705, 
          "text": "Although the mechanism is not known, several reports of the effectiveness of thyrotropin releasing hormone (TRH) in ALS were recently published.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2513155", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 208, 
          "text": "Protirelin (thyrotropin-releasing hormone) appears to be a neuromodulator in the extrahypothalamic nervous system and has been suggested as an adjunct in the treatment of amyotrophic lateral sclerosis (ALS). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2563937", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1129, 
          "offsetInEndSection": 1437, 
          "text": "Clinical studies have shown that response to TRH is state dependent, that is, it depends on whether the patient has bulbar or nonbulbar signs and is male or female. Future studies must take into consideration this state dependence as a specific feature of the pharmacological action of TRH and its analogues.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2497685", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 315, 
          "offsetInEndSection": 617, 
          "text": "Three of the studies showed a transient, statistically significant effect in at least some muscles. The two studies that demonstrated no such effect both used TRH in very small doses. It therefore seems reasonable to conclude that the effect of TRH in ALS is a definite, acute, and transient response. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2497684", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 373, 
          "offsetInEndSection": 642, 
          "text": "It was found that in only 3 out of 14 patients with moderately progressed disease no improvement was achieved, while in 11 cases the improvement was from 10 to 20%. However, the improvement was transient, and TRH treatment failed to stop the progression of the disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3146705", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 124, 
          "offsetInEndSection": 181, 
          "text": "Only 3 patients noted subjective improvement of strength.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3148186", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 140, 
          "offsetInEndSection": 348, 
          "text": "In 6 of the 9, TRH induced a significant increase in vibratory inhibition. This suggests that the TRH-induced reduction of spasticity might be due to an increase in presynaptic inhibition acting on Ia fibres.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3148185", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 299, 
          "offsetInEndSection": 446, 
          "text": "However, 2 mg DN-1417, IM twice a day for 1 month in an open-label trial, produced no objective improvement of strength in nine patients with ALS. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3104820", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 501, 
          "offsetInEndSection": 623, 
          "text": "Our experience suggests that this approach is safe, has high patient acceptance, and is worthy of more careful evaluation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3104751", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 504, 
          "text": "Focal, small-to-moderate and transient improvement occurred in the muscle strength and function of patients with ALS who received TRH in dose-response and screening studies. In a small pilot study of 12 patients, 3 months administration of TRH at 10 mg per kg on alternate days resulted in localized increased strength of jaw muscles as well as significant improvement in lower extremity function. Aerobic exercise capacity was particularly improved in patients with ALS following administration of TRH. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3104750", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 346, 
          "offsetInEndSection": 412, 
          "text": "Mild to moderate improvement was found in 9 (56%) of 16 patients. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3097367", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 588, 
          "offsetInEndSection": 653, 
          "text": "We thought such action of TRH to be useful to the therapy of ALS.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3097367", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 725, 
          "offsetInEndSection": 1011, 
          "text": "With daily TRH, 10 patients noted subjective improvement without objective evidence, and 10 patients complained of worsening of the disease with objective decline after TRH was stopped. Statistical analysis, however, showed no beneficial effects from either acute or chronic TRH trials.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3080695", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 317, 
          "offsetInEndSection": 576, 
          "text": "A temporary increase in the strength of some muscles was detected following the administration of TRH, but no change in functional performance was noted. Neither the patients nor the investigators believed the effects were of any marked clinical significance.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3080694", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 511, 
          "offsetInEndSection": 910, 
          "text": "Nevertheless, statistically significant improvement was seen only in dynametric strength 1 hour after subcutaneous injection (p less than 0.05). Significant improvement occurred, in one patient only, on subjective speech testing during IV infusion of TRH. In none of six other ratings was there a significant difference between TRH and placebo. Subjective improvement was noted by 11 of 12 patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3080693", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 398, 
          "offsetInEndSection": 607, 
          "text": "Significant improvement, as shown by statistical analysis, was noted in muscle strength in the 9 patients by 5 infusions over a 4-week period and a sub-group of 5 patients treated by 8 infusions over 10 weeks.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3088700", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 168, 
          "offsetInEndSection": 291, 
          "text": "The progressive course of this disease, manifested by increasing atrophy, paralysis and disability score, was not altered. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3923160", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 479, 
          "text": "Very high intravenous doses (2-19 mg/min) of thyrotropin-releasing hormone (TRH, L-pyroglutamyl-L-histidyl-L-prolinamide) given to 12 patients with amyotrophic lateral sclerosis (ALS) produced a moderate to marked improvement of functions caused by deficiency of lower motor neurons (weakness) and upper motor neurons (spasticity). The improvement was sustained throughout the infusion and for about 1 h thereafter; sometimes a slight improvement was evident 20 h after infusion.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6134961", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What was the aim of the HAMLET clinical trial?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23943217", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23868265", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17400593", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16965617", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14723030"
      ], 
      "type": "summary", 
      "id": "54d776453706e89528000018", 
      "snippets": [
        {
          "offsetInBeginSection": 212, 
          "offsetInEndSection": 531, 
          "text": "METHODS: We assessed clinical outcomes, costs, and cost-effectiveness for the first 3 years in patients who were randomized to surgical decompression or best medical treatment within 48 hours after symptom onset in the Hemicraniectomy After Middle Cerebral Artery Infarction With Life-Threatening Edema Trial (HAMLET). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23943217", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "Surgical decompression for space-occupying cerebral infarction: outcomes at 3 years in the randomized HAMLET trial.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23868265", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 172, 
          "offsetInEndSection": 413, 
          "text": "METHODS: Patients with space-occupying hemispheric infarction, who were enrolled in the Hemicraniectomy After Middle cerebral artery infarction with Life-threatening Edema Trial within 4 days after stroke onset, were followed up at 3 years. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23868265", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 263, 
          "offsetInEndSection": 622, 
          "text": "We studied differences in recall of information and in appreciation of the informed consent procedure between representatives included in the Hemicraniectomy After Middle cerebral artery infarction with Life-threatening Edema Trial (HAMLET) and representatives of patients participating in the randomised trial of Paracetamol (Acetaminophen) In Stroke (PAIS).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17400593", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 99, 
          "text": "Hemicraniectomy after middle cerebral artery infarction with life-threatening Edema trial (HAMLET).", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16965617", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 381, 
          "offsetInEndSection": 577, 
          "text": "This study is designed to compare the efficacy of decompressive surgery to improve functional outcome with that of conservative treatment in patients with space-occupying supratentorial infarction", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16965617", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 375, 
          "offsetInEndSection": 717, 
          "text": "The 'Hemicraniectomy after middle cerebral artery infarction with life-threatening edema trial' (HAMLET) is a newly-conceived randomised multi-centre clinical trial that compares the efficacy of decompressive surgery to improve functional outcome with that of conservative treatment in patients with space-occupying supratentorial infarction.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14723030", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List chromosomes that have been linked to Arnold Chiari syndrome in the literature.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24359474", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23942271", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23620759", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23476832", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20101707", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17190989", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17103432", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15742475", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11754060", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2130777", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2798270", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6548367", 
        "http://www.ncbi.nlm.nih.gov/pubmed/324229", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20571508"
      ], 
      "type": "list", 
      "id": "54d77bdf3706e89528000019", 
      "snippets": [
        {
          "offsetInBeginSection": 920, 
          "offsetInEndSection": 1247, 
          "text": "Consistent with a genetic hypothesis for CMI, much of the PF morphology was found to be heritable and multiple genomic regions were strongly implicated from OSA, including regions on Chromosomes 1 (LOD = 3.07, p = 3 \u00d7 10(-3) ) and 22 (LOD = 3.45, p = 6 \u00d7 10(-5) ) containing several candidates warranting further investigation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24359474", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2057, 
          "offsetInEndSection": 2206, 
          "text": "Furthermore, we report the first case of documented Arnold-Chiari malformation type I and increased factor XIII activity associated with 6p trisomy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23942271", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1237, 
          "offsetInEndSection": 1506, 
          "text": "Of particular interest were two regions (Chr8, Max LOD\u200a=\u200a3.04; Chr12, Max LOD\u200a=\u200a2.09) identified within the subset of \"CTD-negative\" families, both of which harbor growth differentiation factors (GDF6, GDF3) implicated in the development of Klippel-Feil syndrome (KFS).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23620759", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 671, 
          "offsetInEndSection": 766, 
          "text": "Moreover, the performed DNA analysis showed interstitial duplication in chromosome 5 (5q35.1). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23476832", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 662, 
          "offsetInEndSection": 774, 
          "text": "CGH microarray showed a approximately 520.7 kb microdeletion on 16p13.3 involving CREBBP, ADCY9, and SRL genes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20101707", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 84, 
          "text": "Pentasomy 49,XXXXY associated with a Chiari type 1 malformation and cervical syrinx.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17190989", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 312, 
          "offsetInEndSection": 431, 
          "text": "A 13-year-old with pentasomy 49,XXXXY and a Chiari type 1 malformation with an associated cervical syrinx is presented.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17190989", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 170, 
          "text": "Phenotypic definition of Chiari type I malformation coupled with high-density SNP genome screen shows significant evidence for linkage to regions on chromosomes 9 and 15.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17103432", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 949, 
          "offsetInEndSection": 1101, 
          "text": "Two-point LOD scores on chromosome 15 reached 3.3 and multipoint scores in this region identified a 13 cM region with LOD scores over 1 (15q21.1-22.3). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17103432", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1317, 
          "offsetInEndSection": 1516, 
          "text": "Multipoint LOD scores on chromosome 9 maximized at 3.05, identifying a 40 cM region with LOD scores over 1 (9q21.33-33.1) and a tighter region with multipoint LOD scores over 2 that was only 8.5 cM. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17103432", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 809, 
          "offsetInEndSection": 1032, 
          "text": "In addition, this child had an Arnold-Chiari type I malformation that required surgical decompression. FISH studies using BAC clones spanning the 5q15 to 5q22 region revealed that these were all present in both homologues. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15742475", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 401, 
          "offsetInEndSection": 448, 
          "text": "The karyotype showed 46, XY, del(1)(q23q31.2). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11754060", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1038, 
          "offsetInEndSection": 1091, 
          "text": "Karyotype analysis showed inversion of Y chromosome. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2130777", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 557, 
          "text": "The clinical features and morphological findings in 31 Japanese infants with trisomy 18 are presented. The majority were small-for-date infants. There was no sex predominance in our series, as opposed to male:female ratios of 1:3 reported in the literature. The average age at death was greater in females than in males. Cardiovascular anomalies were consistently present; ventricular septar defect and patent ductus arteriosus being the most common malformations. Various other internal malformations including the Arnold-Chiari malformation were observed.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2798270", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 185, 
          "text": "An unusual heterotopia of striated skeletal muscle and glial tissue occurred in the pontine meninges of a stillborn male showing feature of trisomy 13 and an Arnold-Chiari malformation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6548367", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 67, 
          "text": "Type II Arnold-Chiari malformation with normal spine in trisomy 18.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/324229", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 315, 
          "text": "A variety of anomalies of the central nervous system are observed in trisomy 18. The present case describes an infant having a type II Arnold-Chiari malformation without spina bifida. One previous case of an Arnold-Chiari malformation was reported in trisomy 18 but that infant also had a lumbar meningomyelocoele. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/324229", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 443, 
          "offsetInEndSection": 806, 
          "text": "Recently, a child was reported who presented with a 3p13-14.1 deletion of four genes, including FOXP1, and a constellation of deficits that included speech delay. In this study, we report the case of a patient with a single deletion of FOXP1. This patient presented with speech and motor developmental delays, a Chiari I malformation, and epileptiform discharges.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20571508", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is cytisine superior to nicotine replacement therapy for smoking cessation?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21328282", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21385905", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22104038", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22513936", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25517706", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24831822", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24574554", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23978314", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23834141", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23728690", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23404838", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21154363", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20040957", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18646137", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18076335", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17825502", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17253581", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17220536", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17130378"
      ], 
      "type": "yesno", 
      "id": "54d77f0e3706e8952800001b", 
      "snippets": [
        {
          "offsetInBeginSection": 1245, 
          "offsetInEndSection": 1541, 
          "text": "The effectiveness of cytisine for continuous abstinence was superior to that of nicotine-replacement therapy at 1 week, 2 months, and 6 months. In a prespecified subgroup analysis of the primary outcome, cytisine was superior to nicotine-replacement therapy among women and noninferior among men.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25517706", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1833, 
          "offsetInEndSection": 2068, 
          "text": "CONCLUSIONS: When combined with brief behavioral support, cytisine was found to be superior to nicotine-replacement therapy in helping smokers quit smoking, but it was associated with a higher frequency of self-reported adverse events.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25517706", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Has protein citrullination been implicated in rheumatoid arthritis?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25520183", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25515746", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25475141", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25355199", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25182207", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25116951", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24823363", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24782594", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24763532", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24724574", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24498912", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24497204"
      ], 
      "type": "yesno", 
      "id": "54d796f93706e8952800001e", 
      "snippets": [
        {
          "offsetInBeginSection": 30, 
          "offsetInEndSection": 193, 
          "text": ": Citrullination has become a hot topic within recent years due to its involvement in diseases such as rheumatoid arthritis (RA), multiple sclerosis and fibrosis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25520183", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 802, 
          "offsetInEndSection": 933, 
          "text": "Current literature suggests that increased levels of citrullinated proteins are found in several if not all inflammatory diseases. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25520183", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 234, 
          "offsetInEndSection": 377, 
          "text": "Antibodies directed against citrullinated proteins and peptides (ACPAs) are the most specific serological markers available for diagnosing RA. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25515746", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 152, 
          "offsetInEndSection": 306, 
          "text": "Citrullination of proteins is well described in rheumatoid arthritis (RA), and hypercitrullination of proteins may be related to inflammation in general. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25475141", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 982, 
          "offsetInEndSection": 1180, 
          "text": "Some ACPA are remarkably effective as diagnostics in autoimmune disorders, most notably rheumatoid arthritis (RA). Several ACPA can be observed before other clinical RA manifestations are apparent. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25355199", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 177, 
          "text": "Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by the presence of rheumatoid factor (RF) and anti-citrullinated protein/peptide autoantibodies (ACPAs). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25182207", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 91, 
          "text": "Anti-citrullinated peptides as autoantigens in rheumatoid arthritis-relevance to treatment.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25182207", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1248, 
          "offsetInEndSection": 1467, 
          "text": "The implications of citrullination affecting integrin binding in disease open up a new area of study and might have implications for the pathogenesis of inflammatory diseases like rheumatoid arthritis and periodontitis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25116951", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 636, 
          "offsetInEndSection": 777, 
          "text": "In this paper, we will review the three of the main classes of PTMs already associated with RA: citrullination, carbamylation, and oxidation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24782594", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 90, 
          "text": "Citrullinated collagen II (CII) is a well-known autoantigen in rheumatoid arthritis (RA). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24823363", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 355, 
          "offsetInEndSection": 501, 
          "text": "Among the RA-associated autoantibodies, especially anti-citrullinated protein antibodies (ACPAs) have been studied intensively in the last decade.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24763532", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 159, 
          "text": "Protein citrullination is a posttranslational modification that has attracted increased attention, especially for its involvement in rheumatoid arthritis (RA).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24724574", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 111, 
          "text": "Identification of citrullinated cellular fibronectin in synovial fluid from patients with rheumatoid arthritis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24498912", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 206, 
          "text": "Cellular fibronectin (cFn) has been implicated in the pathogenesis of rheumatoid arthritis (RA), and we previously demonstrated the presence of citrullinated cFn in rheumatoid synovial tissues. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24498912", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 122, 
          "offsetInEndSection": 313, 
          "text": ". In rheumatoid arthritis, PAD4 and protein citrullination are increased in inflamed joints, and anti-citrullinated protein antibodies (ACPAs) form against citrullinated antigens are formed. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24497204", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the subcellular localization of the protein angiogenin?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24603325", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23843625", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22438557", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22384259", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21528671", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18246300", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11443914", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9299500", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7945327"
      ], 
      "type": "factoid", 
      "id": "54d7a1047035c08008000002", 
      "snippets": [
        {
          "offsetInBeginSection": 488, 
          "offsetInEndSection": 725, 
          "text": "Under growth conditions, ANG is located in nucleolus where it promotes ribosomal RNA (rRNA) transcription thereby stimulating cell growth. In adverse conditions, ANG is relocated to cytoplasm to promote damage repairs and cell survival. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24603325", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 52, 
          "offsetInEndSection": 184, 
          "text": "Under growth conditions, ANG undergoes nuclear translocation and accumulates in the nucleolus where it stimulates rRNA transcription", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23843625", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 583, 
          "offsetInEndSection": 638, 
          "text": "Under growth conditions, ANG is located in the nucleus ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23843625", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 860, 
          "offsetInEndSection": 957, 
          "text": "Under stress conditions, ANG is localized to the cytoplasm and is concentrated in stress granules", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23843625", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1367, 
          "offsetInEndSection": 1473, 
          "text": "Silencing ANG or inhibiting its nuclear translocation resulted in decreased nuclear LANA-1 and ANG levels,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22438557", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1863, 
          "offsetInEndSection": 1928, 
          "text": " results in loss of nuclear translocation activity in ANG mutants", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22384259", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 719, 
          "offsetInEndSection": 816, 
          "text": "Immunofluorescence staining was applied to investigate co-localization and nuclear translocation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21528671", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 554, 
          "offsetInEndSection": 713, 
          "text": "Recombinant angiogenin was found to mainly concentrate in the pars granulosa of the nucleus, where the protein accumulates to form ribonucleoprotein particles.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18246300", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 69, 
          "text": "Identification of the nucleolar targeting signal of human angiogenin.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7945327", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 123, 
          "text": "Angiogenin is endocytosed by subconfluent endothelial cells, translocated to the nucleus and accumulates in the nucleolus. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7945327", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 135, 
          "text": "Nuclear translocation of human angiogenin in cultured human umbilical artery endothelial cells is microtubule and lysosome independent.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9299500", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 149, 
          "text": "Exogenous angiogenin undergoes rapid nuclear translocation in cultured human umbilical artery endothelial cells at 37 degrees C but not at 4 degrees ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9299500", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 479, 
          "offsetInEndSection": 553, 
          "text": "the nuclear localization of angiogenin in proliferating endothelial cells ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11443914", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the molecular weight of the protein angiogenin?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/1723310", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2775757", 
        "http://www.ncbi.nlm.nih.gov/pubmed/4074709", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18055286", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10673358", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10486275", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10441122", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8574597", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7585697"
      ], 
      "type": "factoid", 
      "id": "54d7ae1fe19bba8909000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 134, 
          "text": "Angiogenin is a potent blood-vessel-inducing polypeptide with a molecular weight of 14,000 that has a unique ribonucleolytic activity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1723310", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 200, 
          "offsetInEndSection": 339, 
          "text": " Bovine angiogenin is a single-chain protein of 125 amino acids; it contains six cysteines and has a calculated molecular weight of 14,595.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2775757", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 714, 
          "offsetInEndSection": 875, 
          "text": "The amino acid composition of this basic (isoelectric point greater than 9.5), single-chain protein of molecular weight approximately 14 400 has been determined.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/4074709", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 376, 
          "offsetInEndSection": 536, 
          "text": "was found to have a molecular weight of 15 kDa on SDS-PAGE, and the sequence of the N-terminal 25 amino acid residues was identical to that of bovine angiogenin", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18055286", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 92, 
          "text": "Human angiogenin is a 14-kDa plasma protein with angiogenic and ribonucleolytic activities. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10673358", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 326, 
          "offsetInEndSection": 350, 
          "text": " angiogenin-1 (15 kDa). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10486275", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1059, 
          "offsetInEndSection": 1158, 
          "text": "This protein is 14 kD in molecular weight, and is identical to the angioplastic factor angiogenin. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8574597", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1128, 
          "offsetInEndSection": 1156, 
          "text": " angiogenin (M(r) = 14,120),", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7585697", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the \"Proteomic ruler\"?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25225357"
      ], 
      "type": "summary", 
      "id": "54d7b457e19bba8909000004", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "A \"proteomic ruler\" for protein copy number and concentration estimation without spike-in standards.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25225357", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 451, 
          "offsetInEndSection": 791, 
          "text": "We show that the MS signal of histones can be used as a \"proteomic ruler\" because it is proportional to the amount of DNA in the sample, which in turn depends on the number of cells. As a result, our proteomic ruler approach adds an absolute scale to the MS readout and allows estimation of the copy numbers of individual proteins per cell.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25225357", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are the hallmarks of congestive heart failure?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22707076", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19808348", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11930867", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9519348", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2936238", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17922627", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12691636", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7777669"
      ], 
      "type": "summary", 
      "id": "54d892ee014675820d000005", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 146, 
          "text": "Disturbed myocardial calcium (Ca(+)) handling is one of the pathophysiologic hallmarks of cardiovascular diseases such as congestive heart failure", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22707076", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 142, 
          "text": "Congestive heart failure (HF) is a clinical syndrome, with hallmarks of fatigue and dyspnea, that continues to be highly prevalent and morbid.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19808348", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 312, 
          "offsetInEndSection": 435, 
          "text": "Common pathophysiologic features of HF include changes in left ventricle structure, function, and neurohormonal activation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19808348", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 736, 
          "offsetInEndSection": 831, 
          "text": "the compensatory neurohormonal systems and ventricular remodeling that are the hallmarks of CHF", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11930867", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 168, 
          "offsetInEndSection": 361, 
          "text": "The most important processes to be activated in heart failure are the neurohormonal systems, which include the reninangiotensin system, the sympathetic nervous system and the endothelin system.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9519348", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 404, 
          "offsetInEndSection": 492, 
          "text": "the formation of reactive oxygen free radicals is increased in congestive heart failure.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9519348", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 493, 
          "offsetInEndSection": 775, 
          "text": "It has been proposed that the activation of neurohormonal pathways and the formation of oxygen free radicals ultimately lead to the activation of a family of transcription factors that are involved in cardiac and vascular remodelling which are hallmarks of congestive heart failure.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9519348", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 372, 
          "offsetInEndSection": 560, 
          "text": "Myocardial failure ultimately leads to exaggerated neurohumoral compensatory mechanisms and derangements of the peripheral circulation, which are the hallmarks of congestive heart failure.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2936238", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 80, 
          "offsetInEndSection": 183, 
          "text": "The two hallmarks of this syndrome, sodium and water retention, are frequently a therapeutic challenge.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17922627", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 163, 
          "text": "Accumulation of oxidized matrix between the endothelium and cardiac muscle, and endocardial endothelial dysfunction, are the hallmarks of congestive heart failure.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12691636", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 250, 
          "text": "One of the hallmarks of chronic congestive heart failure is an increase in sympathetic tone to the peripheral circulation and to the heart. A correlation between plasma norepinephrine and the severity of the heart failure state has been demonstrated.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7777669", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Do Parkinson's disease patients experience stridor?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21819188", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14703107", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16575624", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19010952", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19628429", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20205147", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12884831", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12023429", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10391085", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6622345", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8353712", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7785431", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7651445", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20003593"
      ], 
      "type": "yesno", 
      "id": "54d8d4d1014675820d000006", 
      "snippets": [
        {
          "offsetInBeginSection": 381, 
          "offsetInEndSection": 640, 
          "text": "The authors describe a patient experiencing stridor and dysphagia with confirmed pulmonary restriction and aspiration following subthalamic nucleus deep brain stimulator adjustment, with a resolution of symptoms and signs when the stimulator was switched off.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21819188", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 374, 
          "offsetInEndSection": 596, 
          "text": "Stridor was not noted during sleep at night. Endoscopic examination of the larynx revealed insufficient abduction of the bilateral vocal cords, although the glottis was not so small as to cause stridor during inspiration. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14703107", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1031, 
          "offsetInEndSection": 1064, 
          "text": "The stridor was specific to MSA. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16575624", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 172, 
          "offsetInEndSection": 705, 
          "text": "Patients with MSA can present other clinical features, such as inspiratory stridor and rapid eye movement (REM) sleep behaviour disorder (RBD). We report a patient with pathologically confirmed MSA who presented with a longstanding history of stridor, RBD and autonomic disturbances but did not develop overt parkinsonism or cerebellar signs. This case illustrates that MSA may present clinically without its cardinal motor symptoms, and that stridor and RBD may be clues to recognise the disease in a patient with autonomic failure.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19010952", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1116, 
          "offsetInEndSection": 1214, 
          "text": "Patients with PD did not display sleep hypoventilation, stridor and abnormal central sleep apnea. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19628429", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 303, 
          "offsetInEndSection": 678, 
          "text": "DEVELOPMENT: Autonomic disorders such as seborrhoeic dermatitis and disorders involving sweating, fatigue, weight loss or respiratory problems (dyspnea, inspiratory stridor) are highly prevalent and very disabling symptoms. In addition, they may be the main problem in a particular phase of PD (fatigue, stridor) and condition the quality of life of patients with Parkinson. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205147", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 146, 
          "offsetInEndSection": 294, 
          "text": ". Her dyspneic attacks consisting of inspiratory stridor and cyanosis occurred mainly during the wearing-off time and continued for less than 30 min", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12884831", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 609, 
          "offsetInEndSection": 873, 
          "text": "The most commonly reported sleep disorders were sleep fragmentation (52.5%), vocalisation (60%), REM sleep behaviour disorder (47.5%), and nocturnal stridor (19%). Except for sleep fragmentation, the incidence of these disorders was significantly higher than in PD", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12023429", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 535, 
          "offsetInEndSection": 644, 
          "text": "Six days after admission, dyspnea and inspiratory stridor were noted, and the respiratory distress worsened. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10391085", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 88, 
          "text": "A patient is described with idiopathic Parkinson's disease and severe laryngeal stridor.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6622345", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 279, 
          "offsetInEndSection": 392, 
          "text": "The laryngeal stridor responded to levodopa therapy, and we are not aware that this has been reported previously.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6622345", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 778, 
          "offsetInEndSection": 1032, 
          "text": "The subsequent clinical course of the former eight patients has been typical of idiopathic Parkinson's disease, whilst the ninth patient has developed postural hypotension, urinary incontinence and respiratory stridor typical of multiple system atrophy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8353712", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 674, 
          "offsetInEndSection": 907, 
          "text": "Although each of five autonomic domains was affected in variable numbers of IPD patients, AD in MSA generally involved more autonomic domains than in IPD, and to a more severe degree, in particular with regard to inspiratory stridor.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7785431", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1055, 
          "offsetInEndSection": 1187, 
          "text": "However, the presence of severe AD, of AD preceding parkinsonism, or of inspiratory stridor, are all individually suggestive of MSA.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7785431", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 375, 
          "offsetInEndSection": 995, 
          "text": "Apart from dysautonomia, the principal discriminant clinical features that distinguished SND from PD were the early appearance of the following symptoms and signs: (a) severe and atypical progressive parkinsonism characterized by bilateral bradykinesia and rigidity, slowness of gait, postural instability, and falls, and poor or absent response to adequate levodopa treatment; (b) increased tendon reflexes associated or not with frank pyramidal signs, severe dysarthria, and less consistently, dysphagia, stridor, antecollis, and stimulus-sensitive myoclonus, which, when present, are highly suggestive of the disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7651445", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 360, 
          "text": "OBJECTIVES: (1) To present a rare case of stridor secondary to prolonged laryngospasm in a patient with Parkinson's disease, and (2) to review the literature on stridor in Parkinson's disease. METHODS: We report a 73-year-old Parkinson's disease patient who developed acute stridor due to prolonged laryngospasm triggered by overspill of excessive secretions. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20003593", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 570, 
          "offsetInEndSection": 672, 
          "text": "RESULT: Only 12 previously reported cases of stridor in Parkinson's disease patients were identified. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20003593", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1189, 
          "offsetInEndSection": 1328, 
          "text": "This case emphasises the importance of recognising different causes of stridor in Parkinson's disease patients, as this affects management.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20003593", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List BRAF inhibitors that have been tested in clinical trials for treatment of melanoma patients", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25287827", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25265494", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25056920", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25040674", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25037139", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24958825", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24720932", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24616537", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24463460", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24408395", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24333389", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24295639", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24259661", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23833299", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23918947", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23795808", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23569304", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23326492", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23251089", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23020132", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22804352", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22594466", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22431777", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22382362", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22356324", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22332713", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21505227"
      ], 
      "type": "list", 
      "id": "54d8d60d014675820d000007", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 159, 
          "text": "Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25287827", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 482, 
          "offsetInEndSection": 732, 
          "text": " Here, we report patients treated with combination therapy after disease progression with BRAF inhibitor treatment administered before study enrollment (part B; n = 26) or after cross-over at progression with dabrafenib monotherapy (part C; n = 45). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25287827", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 210, 
          "offsetInEndSection": 335, 
          "text": "This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25265494", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 366, 
          "offsetInEndSection": 658, 
          "text": "METHODS: All patients treated with the BRAF inhibitors vemurafenib or dabrafenib or combination BRAF inhibitor and mitogen-activated protein kinase kinase (MEK) inhibitor therapy at Westmead Hospital, Sydney, Australia underwent regular dermatological assessments for the duration of therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25040674", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 228, 
          "offsetInEndSection": 394, 
          "text": "We assessed the safety and efficacy of combined BRAF inhibition with vemurafenib and MEK inhibition with cobimetinib in patients with advanced BRAF-mutated melanoma. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25037139", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 488, 
          "offsetInEndSection": 598, 
          "text": "We included individuals who had either recently progressed on vemurafenib or never received a BRAF inhibitor. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25037139", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 789, 
          "offsetInEndSection": 1181, 
          "text": "However, it is becoming evident that the effects of paradoxical mitogen-activated protein kinase pathway activation by BRAF inhibitors in non-BRAF-mutant cells needs to be taken into account, which may be implicated in the problems encountered in the first clinical trial testing a combination of the BRAF inhibitor vemurafenib with ipilimumab (anti-CTLA4), with significant liver toxicities.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24958825", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 526, 
          "offsetInEndSection": 641, 
          "text": "The BRAF inhibitor dabrafenib recently was approved for use in patients with BRAF V600-mutated metastatic melanoma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24720932", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 161, 
          "offsetInEndSection": 575, 
          "text": "His treatment course to date has included surgery, adjuvant radiotherapy, and interferon, metastasectomies, granulocyte-macrophage colony-stimulating factors, a clinical trial with the BRAF inhibitor vemurafenib (PLX-4032), clinical trial with combination BRAF plus MEK inhibition with vemurafenib plus GDC-0973, and combination targeted and immune therapy with vemurafenib plus the anti-CTLA4 antibody ipilimumab.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24616537", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 609, 
          "offsetInEndSection": 739, 
          "text": "Thirty-one patients commenced dabrafenib therapy including six individuals who had progressed on a prior BRAF-inhibitor treatment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24463460", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 133, 
          "text": "Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolites.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24408395", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 108, 
          "text": "Dabrafenib is a BRAF kinase inhibitor indicated for the treatment of BRAF V600E mutation-positive melanoma. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24408395", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 277, 
          "offsetInEndSection": 475, 
          "text": "This was a prospective study of melanoma patients harboring the BRAF V600 mutation and treated with iBRAF within a clinical trial (dabrafenib) or as part of an expanded access program (vemurafenib).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24333389", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 113, 
          "offsetInEndSection": 236, 
          "text": "We investigated the BRAF kinase inhibitor vemurafenib in patients with advanced melanoma with symptomatic brain metastases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24295639", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 803, 
          "offsetInEndSection": 900, 
          "text": "This discovery led to the development of BRAF kinase inhibitors like vemurafenib and dabrafenib. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259661", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1524, 
          "offsetInEndSection": 1718, 
          "text": "CONCLUSIONS: Dabrafenib joins vemurafenib to confirm the superior clinical outcome of the BRAF inhibitors when compared with dacarbazine in patients with BRAF(V600E)-positive advanced melanoma. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259661", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23833299", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 199, 
          "text": "PURPOSE: Dabrafenib is a selective inhibitor of V600-mutant BRAF kinase, which recently showed improved progression-free survival (PFS) as compared with dacarbazine, in metastatic melanoma patients. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23833299", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 108, 
          "text": "Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918947", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 78, 
          "text": "PURPOSE: Dabrafenib (GSK2118436) is a potent inhibitor of mutated BRAF kinase.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918947", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 264, 
          "text": "Cutaneous squamous cell carcinoma (cSCC) is a concerning toxicity with BRAF inhibitors in the treatment for melanoma. While the two drugs shown to improve survival, vemurafenib, and dabrafenib, have similar efficacy, the reported rates of cSCC are quite different.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23795808", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 289, 
          "text": "PURPOSE To assess pharmacodynamic effects and intrinsic and acquired resistance mechanisms of the BRAF inhibitor vemurafenib in BRAF(V600)-mutant melanoma, leading to an understanding of the mechanism of action of vemurafenib and ultimately to optimization of metastatic melanoma therapy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23569304", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 217, 
          "text": "BACKGROUND: The cobas 4800 BRAF V600 Mutation Test is a CE-marked and FDA-approved in vitro diagnostic assay used to select patients with metastatic melanoma for treatment with the selective BRAF inhibitor vemurafenib", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23326492", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 213, 
          "text": "The purpose of this study is to review the development of BRAF inhibitors, with emphasis on the trials conducted with dabrafenib (GSK2118436) and the evolving role of dabrafenib in treatment for melanoma patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23251089", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 365, 
          "offsetInEndSection": 477, 
          "text": "Dabrafenib inhibits the mutant BRAF (BRAF(mut)) protein in melanomas with BRAF(V600E) and BRAF(V600K) genotypes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23251089", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 150, 
          "offsetInEndSection": 333, 
          "text": "To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23020132", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 127, 
          "text": "Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22804352", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 197, 
          "offsetInEndSection": 392, 
          "text": "We conducted a systematic prospective dermatological review of all patients enrolled at a single institution in the phase I/II clinical trial of the mutant BRAF inhibitor dabrafenib (GSK2118436).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22804352", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1768, 
          "offsetInEndSection": 1959, 
          "text": "CONCLUSIONS: Administration of the mutant BRAF inhibitor dabrafenib is associated with induction of keratinocytic proliferation, which in some cases develops features of low-grade malignancy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22804352", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 123, 
          "text": "Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22594466", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 854, 
          "offsetInEndSection": 992, 
          "text": "For this reason, she was enrolled into another clinical trial with the GSK2118436 BRAF inhibitor, dabrafenib, as a second line of therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22594466", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 181, 
          "text": "BACKGROUND: The development of keratoacanthomas (KAs) and well-differentiated squamous cell carcinomas (SCCs) is a known adverse effect of novel BRAF inhibitors such as vemurafenib.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22431777", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 295, 
          "offsetInEndSection": 548, 
          "text": "OBSERVATIONS: We describe a patient with stage IV melanoma who received the BRAF inhibitor vemurafenib (recently approved by the US Food and Drug Administration) as part of a clinical trial and developed numerous diffuse, pathology-proven KAs and SCCs. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22431777", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 837, 
          "offsetInEndSection": 1046, 
          "text": "CONCLUSIONS: Given vemurafenib's recent approval by the US Food and Drug Administration, we provide a timely case report on the effective use of PDT in the treatment of BRAF inhibitor-associated KAs and SCCs. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22431777", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 199, 
          "offsetInEndSection": 374, 
          "text": "The BRAF inhibitor, vemurafenib, has shown up to 78% objective response rates in melanoma patients harboring the BRAF-V600E mutation but not in patients lacking the mutation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22382362", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 131, 
          "offsetInEndSection": 338, 
          "text": "The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600-mutant metastatic melanoma in a phase 1 trial and improved overall survival in a phase 3 trial. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22356324", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 269, 
          "text": "CONTEXT: A polymerase chain reaction-based companion diagnostic (cobas 4800 BRAF V600 Mutation Test) was recently approved by the US Food and Drug Administration to select patients with BRAF-mutant metastatic melanoma for treatment with the BRAF inhibitor vemurafenib. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22332713", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 200, 
          "offsetInEndSection": 397, 
          "text": "However, in the recent clinical trial of the BRAF inhibitor, vemurafenib (PLX4032), a significant percentage of BRAF V600E mutant melanoma patients did not meet the RECIST criteria for a response. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21505227", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are the main characteristics of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25440180", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25112803", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25092222", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24025405", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23908839", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22987135"
      ], 
      "type": "summary", 
      "id": "54d8e319014675820d000009", 
      "snippets": [
        {
          "offsetInBeginSection": 29, 
          "offsetInEndSection": 166, 
          "text": "Catecholaminergic polymorphic ventricular tachycardia is a malignant disease, due to mutations in proteins controlling Ca(2+) homeostasis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25440180", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 174, 
          "offsetInEndSection": 256, 
          "text": "the phenotype is characterized by polymorphic ventricular arrhythmias under stress", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25440180", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 251, 
          "text": "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited heart rhythm disorder characterized by the occurrence of potentially life-threatening polymorphic ventricular tachyarrhythmias in conditions of physical or emotional stress. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25112803", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 365, 
          "offsetInEndSection": 502, 
          "text": "CPVT is an inherited arrhythmia that is induced by physical or emotional stress and may lead to ventricular fibrillation syncope or SCD. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25092222", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 340, 
          "text": "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a lethal, rare hereditary disease with an estimated prevalence of 1:10\u2009000. The genetic variants that cause CPVT are usually highly penetrant. To date, about 189 variants in 5 genes (RYR2, CASQ2, CALM1, TRND, and KCNJ2) have been associated with CPVT pathogenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025405", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 242, 
          "text": "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmogenic cardiac disorder characterized by life-threatening arrhythmias induced by physical or emotional stress, in the absence structural heart abnormalities.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23908839", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 243, 
          "offsetInEndSection": 327, 
          "text": "The arrhythmias may cause syncope or degenerate into cardiac arrest and sudden death", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23908839", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 231, 
          "text": "Catecholaminergic polymorphic ventricular tachycardia (PCVT) is a rare, congenital ventricular tachyarrhythmia which occurs in the setting of adrenergic activation. It potentially leads to syncope and/or sudden cardiac death (SCD).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22987135", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the most prevalent form of arrhythmia worldwide?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25534665", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24828991", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23259476", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25432121", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24474959", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23541013", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25546992"
      ], 
      "type": "factoid", 
      "id": "54d8ea2c4b1fd0d33c000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 123, 
          "text": "Atrial fibrillation remains the most prevalent cardiac arrhythmia, and its incidence is increasing as the population ages. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24828991", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 29, 
          "offsetInEndSection": 93, 
          "text": "Atrial fibrillation is the most prevalent sustained arrhythmia. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534665", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 122, 
          "text": "Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia and has a significant impact on morbidity and mortality.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23259476", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 171, 
          "text": "Atrial fibrillation is the most common heart rhythm disorder in the world, with major public health impact especially due to increased risk of stroke and hospitalizations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25432121", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 75, 
          "text": "Atrial fibrillation is the most common arrhythmia affecting patients today.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24474959", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 239, 
          "text": "Atrial fibrillation (AF) is the most common arrhythmia worldwide, and it has a significant effect on morbidity and mortality. It is a significant risk factor for stroke and peripheral embolization, and it has an effect on cardiac function.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23541013", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 104, 
          "text": "Atrial fibrillation (AF) is the most common cardiac arrhythmia affecting up to 1-1.5% of the population.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25546992", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are the main characteristics/symptoms of the \"Brugada\" syndrome", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25448794", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25187091", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24932359", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24827804", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24405173", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24352520", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23905889", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23669108", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23612926"
      ], 
      "type": "summary", 
      "id": "54d8efb84b1fd0d33c000003", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 456, 
          "text": "In 1992, Brugada and Brugada first described a new entity, which became known as Brugada syndrome, that is associated with a high risk of ventricular arrhythmias and sudden cardiac death in patients without structural heart disease. This syndrome is characterized by a distinct electrocardiographic phenotype, type 1 Brugada pattern, consisting of a coved ST-segment elevation (\u22650.2 mV) followed by a negative T wave in more than one right precordial lead.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25448794", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 233, 
          "text": "Brugada syndrome predisposes individuals to ventricular arrhythmias and sudden cardiac death, in the absence of structural heart disease. The typical Brugada electrocardiogram (ECG) phenotype is often concealed in affected population", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25187091", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 176, 
          "text": "Brugada syndrome is a rare cardiac arrhythmia characterized by electrocardiographic right bundle branch block and persistent ST-segment elevation in the right precordial leads.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24932359", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 207, 
          "text": "Brugada syndrome is a genetically determined familial disease with autosomal dominant transmission and variable penetrance, conferring a predisposition to sudden cardiac death due to ventricular arrhythmias.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24827804", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 21, 
          "offsetInEndSection": 44, 
          "text": "Brugada syndrome (BrS) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24405173", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 104, 
          "offsetInEndSection": 298, 
          "text": "BrS is considered to be a primary inherited channelopathy often involving the inward sodium current and the diagnosis has traditionally required the exclusion of overt structural heart disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24405173", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 97, 
          "text": "Brugada syndrome (BrS) primarily associates with the loss of sodium channel function.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24352520", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1778, 
          "offsetInEndSection": 1854, 
          "text": "PKP2 mutations may be a molecular substrate leading to the diagnosis of BrS.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24352520", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 91, 
          "text": "Brugada syndrome is an inherited arrhythmia syndrome predisposing to sudden cardiac death. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23905889", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 153, 
          "offsetInEndSection": 239, 
          "text": "the first mutations in SCN5A encoding the cardiac sodium channel Nav1.5 were reported.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23905889", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 6, 
          "offsetInEndSection": 152, 
          "text": "Brugada syndrome is characterized by typical ECG features, ventricular arrhythmias and sudden cardiac death (SCD), more frequent during nighttime.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23669108", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 6, 
          "offsetInEndSection": 290, 
          "text": "Brugada syndrome (BrS) is an inherited cardiac disease characterized by ST segment elevation in V1-V3 ECG leads. Mutations SCN5A gene encoding for the cardiac voltage-gated Na(+) channel are found in some BrS patients, but also in family members with isolated conduction disturbances.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23612926", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is the HRC Ser96Ala variant associated with sudden cardiac death in patients with dilated cardiomyopathy?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18617481", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24805197", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24125847", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21742996", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20807542"
      ], 
      "type": "yesno", 
      "id": "54d8f37b4b1fd0d33c000004", 
      "snippets": [
        {
          "offsetInBeginSection": 1207, 
          "offsetInEndSection": 1423, 
          "text": "The Ser96Ala genetic variant of HRC is associated with life-threatening ventricular arrhythmias in idiopathic DCM and may serve as an independent predictor of susceptibility to arrhythmogenesis in the setting of DCM.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18617481", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 256, 
          "text": "The Ser96Ala (S96A) mutation within the histidine rich Ca(2+) binding protein (HRC) has recently been linked to cardiac arrhythmias in idiopathic dilated cardiomyopathy patients, potentially attributable to an increase in spontaneous Ca(2+) release events.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24805197", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 211, 
          "text": "A human genetic variant (Ser96Ala) in the sarcoplasmic reticulum (SR) histidine-rich Ca(2+)-binding (HRC) protein has been linked to ventricular arrhythmia and sudden death in dilated cardiomyopathy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24125847", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 214, 
          "text": "The histidine-rich calcium binding protein (HRC) Ser96Ala polymorphism was shown to correlate with ventricular arrhythmias and sudden death only in dilated cardiomyopathy patients but not in healthy human carriers.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21742996", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1200, 
          "offsetInEndSection": 1403, 
          "text": " HRC has been linked with familiar cardiac conduction disease and an HRC polymorphism was shown to associate with malignant ventricular arrhythmias in the background of idiopathic dilated cardiomyopathy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20807542", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Rindopepimut is an analog of which growth factor?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25186601", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23055947", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22309662", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21154166"
      ], 
      "type": "factoid", 
      "id": "54d8fd334b1fd0d33c000005", 
      "snippets": [
        {
          "offsetInBeginSection": 600, 
          "offsetInEndSection": 829, 
          "text": "Rindopepimut consists of a 14-mer peptide that spans the length of EGF receptor variant III, a mutant variant of EGF receptor found on approximately 30% of primary GBM, conjugated to the carrier protein keyhole limpet hemocyanin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25186601", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 540, 
          "offsetInEndSection": 645, 
          "text": "Rindopepimut is a peptide vaccine which elicits EGFRvIII-specific humoral and cellular immune responses. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23055947", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 529, 
          "offsetInEndSection": 731, 
          "text": "A peptide vaccine, rindopepimut (CDX-110, Celldex Therapeutics), is directed against the novel exon 1-8 junction produced by the EGFRvIII deletion, and it has shown high efficacy in preclinical models. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22309662", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 122, 
          "text": "Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21154166", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 157, 
          "offsetInEndSection": 365, 
          "text": "Rindopepimut specifically targets a novel junctional epitope of the EGFR deletion mutant EGFRvIII, which is a constitutively active receptor that is expressed in approximately 60 to 70% of patients with GBM. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21154166", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Does nimotuzumab improve survival of glioblastoma patients?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24571331", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24521695", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23782513", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23575267", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21575527", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21483304", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19293809", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18094616"
      ], 
      "type": "yesno", 
      "id": "54d901ec4b1fd0d33c000006", 
      "snippets": [
        {
          "offsetInBeginSection": 1369, 
          "offsetInEndSection": 1454, 
          "text": "The survival times were similar to those seen in historical data of standard therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24571331", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1182, 
          "offsetInEndSection": 1446, 
          "text": "The survival time of a matched population treated at the same hospital with irradiation alone was decreased (median 8.0 and 12.2 mo for GBM and AA patients, respectively) compared with that of the patients who received nimotuzumab and curative-intent radiotherapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24521695", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1571, 
          "offsetInEndSection": 1752, 
          "text": "This study, in a poor prognosis population, validates the previous data of survival gain after combining nimotuzumab and radiotherapy, in newly diagnosed high-grade glioma patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24521695", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1534, 
          "offsetInEndSection": 1827, 
          "text": "The mean and median survival time for subjects treated with nimotuzumab was 31.06 and 17.76 vs. 21.07 and 12.63 months for the control group. CONCLUSIONS: In this randomized trial, nimotuzumab showed an excellent safety profile and significant survival benefit in combination with irradiation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23782513", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 480, 
          "offsetInEndSection": 813, 
          "text": "Nimotuzumab was well-tolerated and treatment with the antibody yielded a survival benefit: median survival time was 32.66 mo and the 2-y survival rate was 54.2%. This study demonstrated the feasibility of prolonged administration of nimotuzumab and showed preliminary evidence of clinical benefit in HGG patients with poor prognosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23575267", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 115, 
          "offsetInEndSection": 223, 
          "text": " Recent clinical studies show that patients with malignant gliomas could benefit from nimotuzumab treatment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21575527", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1679, 
          "offsetInEndSection": 1872, 
          "text": "CONCLUSIONS: Nimotuzumab in combination with chemotherapy has moderate activity in patients with malignant gliomas and the toxicities are well tolerable, therefore, worth further investigation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21575527", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 138, 
          "offsetInEndSection": 322, 
          "text": "It has been evaluated in malignant brain tumors in adults and children, and shown to be therapeutically safe and effective in terms of increased survival and improved quality of life. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21483304", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2046, 
          "offsetInEndSection": 2329, 
          "text": "Conclusions As used in this study, nimotuzumab demonstrated a broad safety profile, making it acceptable for chronic use, and implied clinical benefits in terms of increased survival and improved functional status in these patients, compared to findings described in the literature. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21483304", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is DNA methylation an epigenetic modification of chromatin related to gene expression?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25531272", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25534027", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25437055", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25514241", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25512710"
      ], 
      "type": "yesno", 
      "id": "54d9f7894b1fd0d33c00000a", 
      "snippets": [
        {
          "offsetInBeginSection": 21, 
          "offsetInEndSection": 164, 
          "text": "DNA methylation is a chemical modification of DNA involved in the regulation of gene expression by controlling the access to the DNA sequence. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25531272", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 163, 
          "text": "Epigenetic marks such as DNA methylation play important biological roles in gene expression regulation and cellular differentiation during development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534027", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 196, 
          "text": "DNA methylation patterns are characterized by highly conserved developmental programs, but allow for divergent gene expression resulting from stochastic epigenetic drift or divergent environments.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25437055", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 76, 
          "text": "DNA methylation plays a critical role in the regulation of gene expression. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25514241", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 198, 
          "text": "Epigenetic changes such as DNA methylation and histone methylation and acetylation alter gene expression at the level of transcription by upregulating, downregulating, or silencing genes completely.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25512710", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 199, 
          "offsetInEndSection": 358, 
          "text": "Dysregulation of epigenetic events can be pathological, leading to cardiovascular disease, neurological disorders, metabolic disorders, and cancer development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25512710", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is phospholamban phosphorylated by Protein kinase A?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19191503", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16226237", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15909986", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15524173", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15362510", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15229104", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15049694", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14577598", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12962492", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11502581"
      ], 
      "type": "yesno", 
      "id": "54da0c524b1fd0d33c00000b", 
      "snippets": [
        {
          "offsetInBeginSection": 456, 
          "offsetInEndSection": 514, 
          "text": "cAMP-dependent protein kinase (PKA) phosphorylation of PLB", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19191503", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 197, 
          "offsetInEndSection": 246, 
          "text": "phosphorylation of PLN, at either Ser(16) by PKA ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16226237", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 222, 
          "text": "Activation of cardiac muscle sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) by beta1-agonists involves cAMP- and PKA-dependent phosphorylation of phospholamban (PLB), which relieves the inhibitory effects of PLB on SERCA2a. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15909986", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 101, 
          "text": "Phospholamban (PLB) is a sarcoplasmic reticulum (SR) protein that when phosphorylated at Ser16 by PKA", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15524173", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1044, 
          "offsetInEndSection": 1163, 
          "text": "phosphorylation of PLB by the Ca2+-calmodulin-dependent protein kinase (CaMK) and cAMP-dependent protein kinase (PKA). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15362510", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 897, 
          "offsetInEndSection": 990, 
          "text": "cAMP-dependent protein kinase (PKA)-mediated phospholamban (PLB) phosphorylation at serine-16", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15229104", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 404, 
          "text": "Phospholamban (PLB) is a major target of the beta-adrenergic cascade in the heart, functioning to modulate contractile force by altering the rate of calcium re-sequestration by the Ca-ATPase. Functionally, inhibition by PLB binding is manifested by shifts in the calcium dependence of Ca-ATPase activation toward higher calcium levels; phosphorylation of PLB by PKA reverses the inhibitory action of PLB.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15049694", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 134, 
          "offsetInEndSection": 213, 
          "text": "phosphorylation of both PLB residues (Ser16, PKA site, and Thr17, CaMKII site) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14577598", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1401, 
          "offsetInEndSection": 1434, 
          "text": "Phosphorylation of Ser(16) by PKA", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12962492", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2296, 
          "offsetInEndSection": 2370, 
          "text": "stabilization of the structure of PLB following phosphorylation of Ser(16)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12962492", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 173, 
          "text": "Phospholamban (PLB) inhibits the sarcoplasmic reticulum (SR) Ca(2+)-ATPase, and this inhibition is relieved by cAMP-dependent protein kinase (PKA)-mediated phosphorylation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11502581", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Describe what is the advantage of using a stain free protein gel in a Western Blot experiment?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24429481", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23712695", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23085117"
      ], 
      "type": "summary", 
      "id": "54da21bf4b1fd0d33c00000d", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "V3 stain-free workflow for a practical, convenient, and reliable total protein loading control in western blotting.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24429481", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1089, 
          "offsetInEndSection": 1199, 
          "text": "The V3 stain-free workflow makes the western blot process faster, transparent, more quantitative\u00a0and reliable.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24429481", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 251, 
          "offsetInEndSection": 430, 
          "text": "Direct Blue 71 (DB71) staining-a novel, sensitive, dye-binding staining method compatible with immunodetection-may offer advantages over these traditional loading control methods.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23712695", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 101, 
          "text": "Direct Blue 71 staining as a destaining-free alternative loading control method for Western blotting.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23712695", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 71, 
          "text": "Stain-Free technology as a normalization tool in Western blot analysis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23085117", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1080, 
          "offsetInEndSection": 1162, 
          "text": "Stain-Free technology appears to be more reliable, more robust, and more sensitive", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23085117", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1252, 
          "offsetInEndSection": 1442, 
          "text": "tain-Free technology offers the additional advantages of providing checkpoints throughout the Western blotting process by allowing rapid visualization of gel separation and protein transfer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23085117", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the main target of the anti-arrhythmic activity of flecainide?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24858181", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24510469", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25274603", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24917414", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24614665", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23558880", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23334259"
      ], 
      "type": "factoid", 
      "id": "54da32bc0f63c58e6e000001", 
      "snippets": [
        {
          "offsetInBeginSection": 728, 
          "offsetInEndSection": 764, 
          "text": "flecainide (sodium channel blocker) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24858181", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 226, 
          "offsetInEndSection": 326, 
          "text": "Flecainide is a sodium channel blocker with minimal effects expected on ventricular repolarization. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24510469", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 175, 
          "offsetInEndSection": 269, 
          "text": "Flecainide, a class I antiarrhythmic drug, inhibits Na(+) and RyR2 channels and prevents CPVT.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25274603", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 26, 
          "offsetInEndSection": 196, 
          "text": " flecainide, a Class I antiarrhythmic drug, improves left ventricular pressure gradient (LVPG) or symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24917414", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 181, 
          "text": "Flecainide is a class 1c antiarrhythmic that acts by blocking sodium channels to reduce intracardiac conduction and is used mainly in the treatment of supraventricular arrhythmias. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24614665", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 110, 
          "text": "Flecainide is a class 1C antiarrhythmic drug especially used for the management of supraventricular arrhythmia", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23558880", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1401, 
          "offsetInEndSection": 1619, 
          "text": "Flecainide reduces spark and wave frequency in the intact rat cardiomyocyte at therapeutically relevant concentrations but the mechanism involves I(Na) reduction rather than direct ryanodine receptor (RyR2) inhibition.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23334259", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is Alu hypomethylation associated with breast cancer?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24971511", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20682973"
      ], 
      "type": "yesno", 
      "id": "54db1d580f63c58e6e000005", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 88, 
          "text": "Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24971511", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1159, 
          "offsetInEndSection": 1241, 
          "text": "In IBC, Alu hypomethylation correlated with negative estrogen receptor (ER) status", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24971511", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1516, 
          "offsetInEndSection": 1637, 
          "text": "In survival analyses, low Alu methylation status tended to be associated with poor disease-free survival of the patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24971511", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1709, 
          "offsetInEndSection": 1786, 
          "text": "Alu hypomethylation is probably a late event during breast cancer progression", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24971511", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1792, 
          "offsetInEndSection": 1928, 
          "text": "prominent hypomethylation of Alu and LINE-1 in HER2 enriched subtype may be related to chromosomal instability of this specific subtype.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24971511", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 560, 
          "offsetInEndSection": 754, 
          "text": "DNA methylation for three repetitive elements (LINE1, Sat2 and Alu) were analyzed in invasive ductal carcinoma of the breast, paired adjacent normal tissue and WBC from 40 breast cancer patients", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20682973", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1132, 
          "offsetInEndSection": 1241, 
          "text": "DNA methylation for the three repetitive elements was lower in tumor compared to adjacent tissue and WBC DNA.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20682973", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the disorder in which mutations in U4atac snRNA are detected?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24865609", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21990275", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21815888", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21474760"
      ], 
      "type": "factoid", 
      "id": "54db5e24bcba1b1817000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 146, 
          "text": "Biallelic mutations of the human RNU4ATAC gene, which codes for the minor spliceosomal U4atac snRNA, cause the developmental disorder, MOPD I/TALS", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24865609", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 148, 
          "offsetInEndSection": 233, 
          "text": "To date, nine separate mutations in RNU4ATAC have been identified in MOPD I patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24865609", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 996, 
          "offsetInEndSection": 1306, 
          "text": "In this report, we establish a mechanistic basis for MOPD I disease and show that the inefficient splicing of genes containing U12-dependent introns in patient cells is due to defects in minor tri-snRNP formation, and the MOPD I-associated RNU4ATAC mutations can affect multiple facets of minor snRNA function.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24865609", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 150, 
          "text": "A homozygous mutation in RNU4ATAC as a cause of microcephalic osteodysplastic primordial dwarfism type I (MOPD I) with associated pigmentary disorder.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21990275", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 307, 
          "offsetInEndSection": 690, 
          "text": "We describe two brothers, born to healthy, consanguineous parents, with intrauterine and postnatal growth retardation, microcephaly with abnormal gyral pattern and partial agenesis of corpus callosum, and skeletal anomalies reminiscent of those described in MOPD type I. This was confirmed by the identification of the homozygous g.55G > A mutation of RNU4ATAC encoding U4atac snRNA.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21990275", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 103, 
          "text": "Microcephalic osteodysplastic primordial dwarfism type I with biallelic mutations in the RNU4ATAC gene.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21815888", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 338, 
          "offsetInEndSection": 502, 
          "text": "Recently, mutations in the RNU4ATAC gene, which encodes U4atac, a small nuclear RNA that is a crucial component of the minor spliceosome, were found to cause MOPD I", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21815888", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 592, 
          "offsetInEndSection": 761, 
          "text": "We describe here the clinical and molecular data for 17 cases of MOPD I, including 15 previously unreported cases, all carrying biallelic mutations in the RNU4ATAC gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21815888", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 102, 
          "text": "Mutations in U4atac snRNA, a component of the minor spliceosome, in the developmental disorder MOPD I.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21474760", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 77, 
          "offsetInEndSection": 446, 
          "text": "By means of homozygosity mapping and deep sequencing, we show that a gene encoding U4atac snRNA, a component of the minor U12-dependent spliceosome, is mutated in individuals with microcephalic osteodysplastic primordial dwarfism type I (MOPD I), a severe developmental disorder characterized by extreme intrauterine growth retardation and multiple organ abnormalities.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21474760", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 706, 
          "offsetInEndSection": 799, 
          "text": "The introduction of wild-type U4atac snRNA into MOPD I cells enhanced U12-dependent splicing.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21474760", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the main calcium pump of the sarcoplasmic reticulum?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25531267", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24807223", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24170972", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24164241", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22482463", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21674635", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17584678"
      ], 
      "type": "factoid", 
      "id": "54db62a3034aea571d000001", 
      "snippets": [
        {
          "offsetInBeginSection": 47, 
          "offsetInEndSection": 95, 
          "text": "sarcoplasmic reticulum (SR) calcium pump (SERCA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25531267", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 401, 
          "offsetInEndSection": 454, 
          "text": "the sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24807223", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 483, 
          "offsetInEndSection": 609, 
          "text": "SERCA, an endoplasmic reticulum (ER) calcium pump, is solely responsible for transporting cytosolic calcium into the ER lumen.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24807223", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 175, 
          "text": "Sarcoplasmic reticulum Ca(2+)-ATPase (SERCA) is the pump crucial for calcium homeostasis and its impairment results in pathologies such as myopathy, heart failure or diabetes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24170972", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 298, 
          "offsetInEndSection": 454, 
          "text": "Sarcoplasmic reticulum calcium ATPase (SERCA2a), the sarcoplasmic reticulum calcium pump, was found to be a key factor in the alteration of calcium cycling.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24164241", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 169, 
          "text": "The calcium pump SERCA2a (sarcoplasmic reticulum calcium ATPase 2a), which plays a central role in cardiac contraction, shows decreased expression in heart failure (HF).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22482463", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 207, 
          "offsetInEndSection": 341, 
          "text": "Calcium is actively accumulated in the endoplasmic reticulum by Sarco/Endoplasmic Reticulum Calcium transport ATPases (SERCA enzymes).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21674635", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 153, 
          "offsetInEndSection": 201, 
          "text": "sarcoendoplasmic reticulum calcium pump (SERCA1)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19863735", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 61, 
          "offsetInEndSection": 110, 
          "text": "sarco(endo)plasmic reticulum calcium pump (SERCA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17584678", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 151, 
          "offsetInEndSection": 301, 
          "text": "SERCA is a membrane protein that belongs to the family of P-type ion translocating ATPases and pumps free cytosolic calcium into intracellular stores.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17584678", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 478, 
          "offsetInEndSection": 614, 
          "text": "Three different SERCA genes were identified-SERCA1, SERCA2, and SERCA3. SERCA is mainly represented by the SERCA2a isoform in the heart.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17584678", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "How many and which are the different isoforms for the ryanodine receptor?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24521037", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20961976", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19503748", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18221109", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18005397", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17707769", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17526017"
      ], 
      "type": "list", 
      "id": "54db7217c4c6ce8e1d000003", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 89, 
          "text": "Skeletal (RyR1) and cardiac muscle (RyR2) isoforms of ryanodine receptor calcium channels", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24521037", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 335, 
          "text": "Ryanodine receptors (RyRs) are located in the sarcoplasmic/endoplasmic reticulum membrane and are responsible for the release of Ca(2+) from intracellular stores during excitation-contraction coupling in both cardiac and skeletal muscle. RyRs are the largest known ion channels (> 2MDa) and exist as three mammalian isoforms (RyR 1-3),", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20961976", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 168, 
          "offsetInEndSection": 446, 
          "text": "Ryanodine receptors (RyRs) are a family of intracellular calcium release channels that mediate calcium-induced calcium release from the endoplasmic reticulum. Among the three RyR isoforms, RyR3 is preferentially expressed in the brain especially in the hippocampus and striatum.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19503748", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 573, 
          "text": "In excitable cells such as skeletal and cardiac myocytes excitation-contraction coupling is an important intermediate step between initiation of the action potential and induction of contraction. This process is predominantly controlled by Ca(2+) release from the sarcoplasmic reticulum via the ryanodine receptor. This very large protein (MW 560 kDa) exists as a homotetramer (~2.2 MDa) and is expressed in three isoforms: RyR1, expressed in skeletal muscle; RyR2, expressed in cardiac muscle; and RyR3, expressed in various cells at lower levels than the other isoforms. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18221109", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 252, 
          "offsetInEndSection": 320, 
          "text": "Generally, three ryanodine receptor isoforms (RyR1-RyR3) are known; ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18005397", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "Ryanodine receptor (RyR) is a Ca(2+) channel that mediates Ca(2+) release from intracellular stores.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17707769", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 286, 
          "offsetInEndSection": 315, 
          "text": "There are three RyR isoforms,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17707769", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 240, 
          "text": "Ryanodine receptors (RyRs) are intracellular Ca(2+) channels that mediate the release of calcium from internal stores and therefore play an important role in Ca(2+) signaling and homeostasis. Three RyR isoforms have been described thus far,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17526017", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 547, 
          "offsetInEndSection": 560, 
          "text": "RyR1 and RyR2", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17526017", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 570, 
          "offsetInEndSection": 574, 
          "text": "RyR3", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17526017", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which protein kinases have been found to phosphorylate Phospholamban and affect its biological activity?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25451386", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22772476", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20349314", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20060004", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19696029", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22707725", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22463608"
      ], 
      "type": "list", 
      "id": "54db7c4ac0bb8dce23000001", 
      "snippets": [
        {
          "offsetInBeginSection": 520, 
          "offsetInEndSection": 706, 
          "text": "Dephosphorylated PLN is an inhibitor of SERCA2a and phosphorylation by protein kinase A (PKA) or calcium-calmodulin-dependent protein kinases (CAMKII) relieves these inhibitory effects. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451386", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 798, 
          "offsetInEndSection": 945, 
          "text": "We have found that phosphorylation of PLN by protein kinase A (PKA) leads to an increase in the rate of Ca(2+) leak from Ca(2+)-loaded SR vesicles.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22772476", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 611, 
          "offsetInEndSection": 724, 
          "text": "PKG activity of cardiac myocytes was assessed by phospholamban (PLB) phosphorylation determined by western blot. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20349314", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1210, 
          "offsetInEndSection": 1315, 
          "text": "PLB is not a unique reporter for PKG activity since it is also phosphorylated by protein kinase A (PKA), ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20349314", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 141, 
          "text": "Ca(2+)-calmodulin-dependent protein kinase II (CaMKII) plays an important role mediating apoptosis/necrosis during ischemia-reperfusion (IR).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20060004", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 345, 
          "offsetInEndSection": 516, 
          "text": "The onset of reperfusion increased the phosphorylation of Thr(17) site of phospholamban, without changes in total protein, consistent with an increase in CaMKII activity. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20060004", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1017, 
          "offsetInEndSection": 1308, 
          "text": "We found that when activated, Akt interacts with and phosphorylates PLN at Thr(17), the Ca(2+)-calmodulin-dependent kinase IIdelta site, whereas silencing Akt signaling, through the knock-out of phosphatidylinositol-dependent kinase-1, resulted in reduced phosphorylation of PLN at Thr(17). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19696029", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 482, 
          "offsetInEndSection": 642, 
          "text": "Deletion of Arg(14) disrupts the protein kinase A recognition motif, which abrogates phospholamban phosphorylation and results in constitutive SERCA inhibition.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22707725", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 111, 
          "offsetInEndSection": 345, 
          "text": "Dephosphorylated PLN tonically inhibits the SR Ca-ATPase (SERCA2a), while phosphorylation at Ser16 by PKA and Thr17 by Ca(2+) /calmodulin-dependent protein kinase (CaMKII) relieves the inhibition, and this increases SR Ca(2+) uptake. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22463608", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is known as Calcium Induced Calcium Release (CICR) and its role in cardiomyocyte contractility?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25377479", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21979103", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21718716", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18538346", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15194743", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10779321", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2726431"
      ], 
      "type": "summary", 
      "id": "54dc8ed6c0bb8dce23000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 286, 
          "text": "Cardiomyocyte contraction depends on rapid changes in intracellular Ca(2+). In mammals, Ca(2+) influx as L-type Ca(2+) current (ICa) triggers the release of Ca(2+) from sarcoplasmic reticulum (SR) and Ca(2+)-induced Ca(2+) release (CICR) is critical for excitation-contraction coupling.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25377479", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 9, 
          "offsetInEndSection": 291, 
          "text": "Release of calcium (Ca(2+)) from the sarcoplasmic reticulum (SR) induced by Ca(2+) influx through voltage-dependent sarcolemmal L-type Ca(2+) channels (CICR) in cardiac muscle cells has been implicated as a potential target contributing to anesthetic-induced myocardial depression. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21979103", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 240, 
          "text": "It is well known that calcium-induced calcium-release in cardiac myocytes takes place in spatially restricted regions known as dyads, where discrete patches of junctional sarcoplasmic reticulum tightly associate with the t-tubule membrane. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21718716", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 348, 
          "text": "Calcium (Ca(2+))-induced Ca(2+) release (CICR) is widely accepted as the principal mechanism linking electrical excitation and mechanical contraction in cardiac cells. The CICR mechanism has been understood mainly based on binding of cytosolic Ca(2+) with ryanodine receptors (RyRs) and inducing Ca(2+) release from the sarcoplasmic reticulum (SR).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18538346", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 137, 
          "text": "Waves of calcium-induced calcium release occur in a variety of cell types and have been implicated in the origin of cardiac arrhythmias. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15194743", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 329, 
          "text": "Calcium-induced calcium release (CICR) has been observed in cardiac myocytes as elementary calcium release events (calcium sparks) associated with the opening of L-type Ca(2+) channels. In heart cells, a tight coupling between the gating of single L-type Ca(2+) channels and ryanodine receptors (RYRs) underlies calcium release. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10779321", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 354, 
          "offsetInEndSection": 487, 
          "text": "L-type Ca(2+) channels activate RYRs to produce CICR in smooth muscle cells in the form of Ca(2+) sparks and propagated Ca(2+) waves.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10779321", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 498, 
          "offsetInEndSection": 587, 
          "text": " the importance of Ca-induced Ca release in excitation-contraction coupling in the heart.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2726431", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which pathological condition of the heart is known as hypertrophic cardiomyopathy (HCM)?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25328416", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25309450", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25228955", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25209314", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25191275", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25081404", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25044876"
      ], 
      "type": "summary", 
      "id": "54dcb29dc0bb8dce23000004", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 410, 
          "text": "Hypertrophic cardiomyopathy (HCM) is a primary disease of the cardiac muscle that occurs mainly due to mutations (>1,400 variants) in genes encoding for the cardiac sarcomere. HCM, the most common familial form of cardiomyopathy, affecting one in every 500 people in the general population, is typically inherited in an autosomal dominant pattern, and presents variable expressivity and age-related penetrance.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25328416", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 204, 
          "text": "Familial hypertrophic cardiomyopathy (HCM), due to point mutations in genes for sarcomere proteins such as myosin, occurs in 1/500 people and is the most common cause of sudden death in young individuals.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25309450", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 443, 
          "offsetInEndSection": 689, 
          "text": "n HCM, the modified protein function leads, over years to decades, to secondary remodeling with substantial morphological changes, such as hypertrophy, myofibrillar disarray, and extensive fibrosis associated with severe functional deterioration.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25309450", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 131, 
          "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (SCD) in the young, particularly among athletes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25228955", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 6, 
          "offsetInEndSection": 134, 
          "text": "Familial hypertrophic cardiomyopathy (HCM) is one the most common heart disorders, with gene mutations in the cardiac sarcomere.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25209314", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 522, 
          "text": "Hypertrophic cardiomyopathy (HCM) has been recently recognized as the most common inherited cardiovascular disorder, affecting 1 in 500 adults worldwide. HCM is characterized by myocyte hypertrophy resulting in thickening of the ventricular wall, myocyte disarray, interstitial and/or replacement fibrosis, decreased ventricular cavity volume and diastolic dysfunction. HCM is also the most common cause of sudden death in the young. A large proportion of patients diagnosed with HCM have mutations in sarcomeric proteins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25191275", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 240, 
          "text": "Hypertrophic cardiomyopathy (HCM) is a genetic cardiomyopathy. The prevalence of phenotypic expression, in the absence of another systemic or cardiac disease causing increased left ventricular (LV) wall thickness, is estimated to be 1:500. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25081404", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 562, 
          "offsetInEndSection": 819, 
          "text": "HCM is the most prevalent genetic disorder affecting the heart, it often goes undiagnosed until midlife after patients show symptoms of myocardial remodeling. Adults with cardiomyopathy suffer SCD or adverse events such as stroke and heart failure from HCM.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25044876", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are Alu elements transcribed?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17514354", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16682445", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15593371", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15342557", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21987713", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22716230"
      ], 
      "type": "yesno", 
      "id": "54dcd8f61388e8454a000001", 
      "snippets": [
        {
          "offsetInBeginSection": 15, 
          "offsetInEndSection": 50, 
          "text": "Alu RNAs in the human transcriptome", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17514354", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 179, 
          "offsetInEndSection": 264, 
          "text": "Alu elements can be transcribed in two different ways, by two independent polymerases", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17514354", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 266, 
          "offsetInEndSection": 332, 
          "text": "'Free Alu RNAs' are transcribed by Pol III from their own promoter", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17514354", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 340, 
          "offsetInEndSection": 433, 
          "text": "'embedded Alu RNAs' are transcribed by Pol II as part of protein- and non-protein-coding RNAs", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17514354", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 435, 
          "offsetInEndSection": 576, 
          "text": "Recent studies have demonstrated that both free and embedded Alu RNAs play a major role in post transcriptional regulation of gene expression", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17514354", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 212, 
          "offsetInEndSection": 355, 
          "text": "Alu RNAs transcribed from these elements are present at low levels at normal cell growth but various stress conditions increase their abundance", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16682445", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 357, 
          "offsetInEndSection": 412, 
          "text": "Alu RNAs are known to bind the cognate proteins SRP9/14", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16682445", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 88, 
          "text": "Increased level of polymerase III transcribed Alu RNA in hepatocellular carcinoma tissue", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15593371", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 247, 
          "offsetInEndSection": 411, 
          "text": "we used primer extension analysis to determine the level of polymerase III directed Alu RNA and found an increased expression of Alu RNA in hepatocellular carcinoma", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15593371", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "Widespread RNA editing of embedded alu elements in the human transcriptome", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15342557", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 205, 
          "offsetInEndSection": 282, 
          "text": "Transcribed Alu sequences can alter splicing patterns by generating new exons", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15342557", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 827, 
          "offsetInEndSection": 950, 
          "text": "In the vast majority of edited RNAs, A-to-I substitutions are clustered within transcribed sense or antisense Alu sequences", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15342557", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1098, 
          "offsetInEndSection": 1209, 
          "text": "Alu-associated RNA editing may be a mechanism for marking nonstandard transcripts, not destined for translation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15342557", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 52, 
          "offsetInEndSection": 80, 
          "text": "the case of transcribed Alus", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21987713", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1019, 
          "offsetInEndSection": 1129, 
          "text": "Differential levels of Alu RNA during different conditions of stress also await clear functional understanding", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21987713", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 75, 
          "text": "Alu expression in human cell lines and their retrotranspositional potential", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22716230", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1111, 
          "offsetInEndSection": 1196, 
          "text": "Alu expression likely varies by cell type, growth conditions and transformation state", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22716230", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1324, 
          "offsetInEndSection": 1560, 
          "text": "The vast majority of Alu loci potentially transcribed by RNA pol III lack important sequence features for retrotransposition and the majority of potentially active Alu loci in the genome (scored high ERP) belong to young Alu subfamilies", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22716230", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which are the APOBEC3 protein family members able to inhibit Vif-deficient HIV-1 replication?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24189052", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23427247", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22787460"
      ], 
      "type": "list", 
      "id": "54de15f91388e8454a000002", 
      "snippets": [
        {
          "offsetInBeginSection": 148, 
          "offsetInEndSection": 395, 
          "text": "APOBEC3DE, APOBEC3F, APOBEC3G, and APOBEC3H haplotypes II, V, and VII provide protection against HIV-1\u0394vif through hypermutation of the viral genome, inhibition of reverse transcription, and inhibition of viral DNA integration into the host genome", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24189052", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 625, 
          "offsetInEndSection": 834, 
          "text": "low quantities of IFN-\u03b1 failed to upregulate costimulatory molecules, did not induce IL-12p40 or migration, but significantly induced A3G, A3A, and A3F mRNA expression and restricted viral replication in MDDCs", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23427247", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 304, 
          "offsetInEndSection": 493, 
          "text": "Without Vif, A3 proteins, particularly APOBEC3G (A3G) and APOBEC3F (A3F), inhibit HIV-1 replication by blocking reverse transcription and/or integration and hypermutating nascent viral cDNA", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787460", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which drugs are included in the FEC-75 regimen?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24239210", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22902450", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22772380", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18344024", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18189160", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17647266", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17054108", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16315865", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1988577", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7693420", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8808724", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10963640", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11875727", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12525522", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16282727"
      ], 
      "type": "list", 
      "id": "54df69af1388e8454a000005", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 287, 
          "text": "Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24239210", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 697, 
          "offsetInEndSection": 1272, 
          "text": "Patients randomly assigned to sequential treatment received fluorouracil 500 mg/m(2), epirubicin 75 mg/m(2), and cyclophosphamide 500 mg/m(2) (FEC-75) on day 1 of a 21-day cycle for four cycles followed by paclitaxel 80 mg/m(2) and trastuzumab 2 mg/kg (after a 4 mg/kg loading dose) once per week for 12 weeks, while those randomly assigned to the concurrent treatment group received paclitaxel and trastuzumab once per week for 12 weeks followed by four cycles of FEC-75 (on day 1 of each 21-day cycle) and once-weekly trastuzumab, in the same doses as the sequential group.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24239210", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 112, 
          "offsetInEndSection": 255, 
          "text": "In May 2008, the patient underwent preoperative chemotherapy consisting of 4 courses of FEC 75(fluororracil, epirubicin, and cyclophosphamide).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22902450", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 731, 
          "offsetInEndSection": 1098, 
          "text": "Stage II-IIIC HER2-positive breast cancer patients, including inflammatory disease, were treated with weekly-trastuzumab for 24 weeks administered concurrently with all primary chemotherapy containing paclitaxel (80 mg/m(2)) for 12 weeks and 4 cycles of FEC-75 (fluorouracil 500 mg/m(2), epirubicine 75 mg/m(2), and cyclophosphamide 500 mg/m(2)) followed by surgery. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22772380", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 156, 
          "offsetInEndSection": 610, 
          "text": "Further improvements can be achieved with dose-dense regimens, but densification of fluorouracil/epirubicin/cyclophosphamide (FEC) has proved difficult, with FEC(60) providing little benefit over standard chemotherapy and FEC(100) associated with toxicity. We investigated the feasibility of two intermediate dose-dense FEC regimens. Patients were randomised to six cycles of FEC(75) or FEC(90), with all three drugs given on day 1 of each 14-day cycle. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18189160", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 408, 
          "text": "BACKGROUND: A previously published prospective randomized phase 3 trial showed that administration of 24 weeks of primary systemic chemotherapy (PST) with paclitaxel and FEC(75) (fluorouracil, epirubicin, cyclophosphamide) concurrently with trastuzumab in patients with HER2-positive primary breast cancer resulted in a 60% pathologic complete response rate (PCR) with no associated severe cardiac toxicity. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17647266", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 639, 
          "offsetInEndSection": 796, 
          "text": "Maintenance chemotherapy was FEC 75 (fluorouracil 500 mg/m(2), epirubicin 75 mg/m(2), and cyclophosphamide 500 mg/m(2) on Day 1 every 21 days for 4 cycles). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17054108", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 332, 
          "text": "The French Epirubicin Study Group carried out a randomized trial comparing epirubicin alone 75 mg/m2 with fluorouracil (5FU) 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 50 mg/m2 (FEC 50) and 5FU 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 75 mg/m2 (FEC 75) as first treatment for advanced breast cancer patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1988577", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 711, 
          "offsetInEndSection": 1105, 
          "text": "Patients were randomised to 1 of 3 treatment groups: Group A (n = 207) received FEC 50 (fluorouracil 500 mg/m2, epirubicin 50 mg/m2 plus cyclophosphamide 500 mg/m2) every 21 days for 6 cycles; Group B (n = 193) received FEC 50 every 21 days for 3 cycles; Group C (n = 195) received FEC 75 (fluorouracil 500 mg/m2, epirubicin 75 mg/m2 plus cyclophosphamide 500 mg/m2) every 21 days for 3 cycles.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7693420", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 314, 
          "offsetInEndSection": 852, 
          "text": "Sixty chemotherapy-naive breast cancer patients of 30 to 71 years in age, P.S. = 0-1, receiving 5-fluorouracil-epirubicin-cyclophosphamide (FEC 75) q 21 days or cyclophosphamide-methotrexate-5-fluorouracil (CMF) or 120 mg/m2 epirubicin or high dose mitomycin-methotrexate-mitoxantrone (MMM) q 14 days (+ G-CSF) or 100 mg/m2 epirubicin (+ G-CSF) were randomized to receive, 15 min before chemotherapy, 8 mg i.v. bolus of ondansetron or 3 mg i.v. granisetron or 5 mg i.v. tropisetron and no further antiemetic therapy in the following days.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8808724", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 148, 
          "offsetInEndSection": 670, 
          "text": "PATIENTS AND METHODS: Four hundred seventeen anthracycline-naive MBC patients were randomized to receive one of the following regimens: arm A: 11 cycles of fluorouracil 500 mg/m(2), epirubicin 75 mg/m(2), and cyclophosphamide 500 mg/m(2) (FEC 75) every 21 days; arm B: four cycles of FEC 100 (same regimen but with epirubicin 100 mg/m(2)) then eight cycles of FEC 50 (epirubicin 50 mg/m(2)); and arm C: four cycles of FEC 100 then restart the same regimen at disease progression in case of prior response or stabilization.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10963640", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 339, 
          "text": "The aim of this study, using a Fleming single-stage design, was to explore the efficacy and safety of Taxotere 100 x mg x m(-2) docetaxel and FEC 75 cyclophosphamide 500 mg x m(-2), fluorouracil 500 x mg x m(-2) and epirubicin 75 mg x m(-2), in alternating and sequential schedules for the first-line treatment of metastatic breast cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11875727", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 148, 
          "offsetInEndSection": 609, 
          "text": "PATIENTS AND METHODS: Between 1986 and 1990, 621 patients with operable breast cancer were randomly assigned to receive fluorouracil (Roche SA, Basel, Switzerland) 500 mg/m2, epirubicin (Pharmacia SA, Milan, Italy) 50 mg/m2, and cyclophosphamide (Asta Medica AG, Frankfurt, Germany) 500 mg/m2 every 21 days (FEC 50) for six cycles (6 FEC 50); FEC 50 for three cycles (3 FEC 50); or the same regimen with epirubicin 75 mg/m2 (FEC 75) for three cycles (3 FEC 75).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12525522", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 266, 
          "offsetInEndSection": 471, 
          "text": "We studied the feasibility of FEC (75) (fluorouracil: 500 mg/m(2), epirubicin: 75 mg/m(2), and cyclophosphamide:500 mg/m(2), q 3 w, 6 cycles) as adjuvant chemotherapy for 59 primary breast cancer patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16282727", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List non-surgical treatment modalities that are included in the Stupp protocol.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24111708", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23588276", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23535992", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23453151", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23254891", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25434389", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25201633", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24600235", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24518393", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24287680", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22464950", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22359215", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22141608", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21344976", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21156036", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20870254", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20428822", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20045159", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18808066"
      ], 
      "type": "list", 
      "id": "54df6ed91388e8454a000007", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 283, 
          "text": "OBJECTIVE: It is now accepted that the concomitant administration of temozolomide with radiotherapy (Stupp regime), in the treatment of patients with newly diagnosed glioblastoma multiforme (GBM), significantly improves survival and this practice has been adopted locally since 2004.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24111708", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 225, 
          "text": "BACKGROUND: The introduction of ALA-Fluorescence-guided surgery (FGS) followed by concomitant radiochemotherapy according to the Stupp-protocol is representative of the major changes in glioblastoma therapy in the past years.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23588276", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1485, 
          "offsetInEndSection": 1641, 
          "text": "CONCLUSIONS: FGS and radiochemotherapy according to the Stupp protocol have induced an impressive improvement in overall survival in glioblastoma patients. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23588276", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 330, 
          "text": "Current treatment strategies in patients with newly-diagnosed glioblastoma include surgical resection with post-operative radiotherapy and concomitant/adjuvant temozolomide (the \"Stupp protocol\") or resection with implantation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) wafers in the surgical cavity followed by radiotherapy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23535992", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 184, 
          "offsetInEndSection": 345, 
          "text": "The standard treatment today is maximal surgical resection followed by concomitant chemo-radiation therapy followed by adjuvant TMZ according to Stupp protocol. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23453151", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 273, 
          "offsetInEndSection": 508, 
          "text": "PATIENTS AND METHODS: A total of 191 patients with primary GBM were postoperatively treated with either radiation and concomitant TMZ, followed by adjuvant TMZ (Stupp protocol) (n = 154), or radiation followed by adjuvant TMZ (n = 37).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23254891", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 843, 
          "offsetInEndSection": 935, 
          "text": "Afterward, patients received concomitant radiochemotherapy according to the Stupp protocol. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25434389", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 120, 
          "offsetInEndSection": 228, 
          "text": "The treatment of glioblastoma includes surgery followed by chemoradiation with the protocol of Stupp et al. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25201633", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 595, 
          "offsetInEndSection": 1043, 
          "text": "Since the publication of a study by Stupp et al in 2005, which used a protocol of conventional fractionated irradiation with concomitant TMZ followed by standard TMZ for six cycles, many clinical studies in the People's Republic of China have demonstrated that such a treatment strategy has significantly improved efficacy with limited side effects for newly diagnosed glioblastoma after surgery as compared with strategies that do not contain TMZ.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24600235", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 568, 
          "offsetInEndSection": 739, 
          "text": "Standard chemoradiotherapy as per the Stupp protocol, together with multimodal rehabilitation, resulted in substantial functional improvement within 6 weeks of initiation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24518393", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 186, 
          "text": "BACKGROUND: Patients with glioblastoma treated with BCNU wafer implantation for recurrence frequently receive frontline chemoradiotherapy with temozolomide as part of the Stupp protocol.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24287680", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 137, 
          "offsetInEndSection": 244, 
          "text": "This is followed by concurrent radio-chemotherapy with temozolomide (TMZ) according to the Stupp protocol. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22464950", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1718, 
          "offsetInEndSection": 2045, 
          "text": "CONCLUSIONS: MGMT promoter methylation status and low MGMT expression both were identified as positive prognosticators in patients with newly diagnosed glioblastoma who underwent surgical resection and received Gliadel wafer implants followed by adjuvant radiotherapy and concomitant oral TMZ chemotherapy (the Stupp protocol).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22359215", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 345, 
          "text": "INTRODUCTION: To evaluate the incidence and impact of early post-chemoradiation (cRT) 'pseudoprogression' (PsPD) amongst glioblastoma multiforme (GBM) patients treated with the current standard of care - 60 Gy conformal radiotherapy with concurrent low-dose temozolomide, followed by six cycles of high-dose temozolomide (the 'Stupp protocol'). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22141608", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 280, 
          "text": "In patients with glioblastoma multiforme (GBM), there is no consensus on the sequential use of two existing regimens: post-operative Gliadel implantation into the surgical cavity and concomitant temozolomide with radiotherapy followed by adjuvant temozolomide ('Stupp protocol'). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21344976", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 478, 
          "offsetInEndSection": 727, 
          "text": "We also screened for associations between the level of methylation of CpG sites and overall survival in a cohort of 50 patients uniformly treated by surgery, radiotherapy and chemotherapy with concomitant and adjuvant temozolomide (STUPP protocol). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21156036", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 648, 
          "offsetInEndSection": 777, 
          "text": "Surprisingly, less than half the patients having surgery received concomitant radiochemotherapy according to the Stupp protocol. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20870254", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 365, 
          "offsetInEndSection": 578, 
          "text": "We analyzed MGMT methylation by methylation-specific PCR in 90 GBM patients from four Portuguese hospitals, uniformly treated with radiotherapy combined with concomitant and adjuvant temozolomide (Stupp protocol).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20428822", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 121, 
          "offsetInEndSection": 296, 
          "text": "The current care standards for newly diagnosed glioblastoma consist, when feasible, in surgical resection, radiotherapy, and chemotherapy, as described in the Stupp protocol. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20045159", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 224, 
          "offsetInEndSection": 400, 
          "text": "Moreover, there are no data concerning the effect of concomitant radiochemotherapy according to the STUPP protocol on the course ofMS in patients with coexisting glioblastoma. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18808066", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which micro-RNAs have been associated in the pathogenesis of Rheumatoid Arthritis?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24283221", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24120842", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23649045", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23385088", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23318734", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23280137", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23138379", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22903258", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22823586", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22562984", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22494429", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22161761", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22100329", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21611196", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21600203", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21416408", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21354921", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21339228", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21339227", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21279994", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20870441", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20864373", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20840794", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20459811", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20223711", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19931339", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19404929", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18759964", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18438844", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18383392"
      ], 
      "type": "list", 
      "id": "533c3533c45e133714000004", 
      "snippets": [
        {
          "offsetInBeginSection": 1447, 
          "offsetInEndSection": 1548, 
          "text": "This study provides the first description of increased expression of miRNA miR-155 and miR-146a in RA", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18383392", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 100, 
          "offsetInEndSection": 275, 
          "text": "In this study we investigated the expression, regulation, and function of miR-155 and miR-146a in rheumatoid arthritis (RA) synovial fibroblasts (RASFs) and RA synovial tissue", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18383392", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 199, 
          "offsetInEndSection": 355, 
          "text": "The objective of this study was to identify the expression pattern of microRNA-146 (miR-146) in synovial tissue from patients with rheumatoid arthritis (RA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18438844", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1478, 
          "offsetInEndSection": 1619, 
          "text": "This study shows that miR-146 is expressed in RA synovial tissue and that its expression is induced by stimulation with TNFalpha and IL-1beta", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18438844", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 104, 
          "text": "pregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18759964", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 426, 
          "offsetInEndSection": 707, 
          "text": "Total RNA was isolated from peripheral blood mononuclear cells obtained from patients with rheumatoid arthritis, and healthy and disease control individuals, and the expression of miR-146a, miR-155, miR-132, miR-16, and microRNA let-7a was analyzed using quantitative real-time PCR", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18759964", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 718, 
          "offsetInEndSection": 977, 
          "text": "Rheumatoid arthritis peripheral blood mononuclear cells exhibited between 1.8-fold and 2.6-fold increases in miR-146a, miR-155, miR-132, and miR-16 expression, whereas let-7a expression was not significantly different compared with healthy control individuals", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18759964", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2106, 
          "offsetInEndSection": 2371, 
          "text": "Our data also suggest a possible mechanism contributing to rheumatoid arthritis pathogenesis, whereby miR-146a expression is increased but unable to properly function, leading to prolonged tumor necrosis factor-alpha production in patients with rheumatoid arthritis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18759964", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1299, 
          "offsetInEndSection": 1540, 
          "text": "Repression of TRAF6 and/or IRAK-1 in THP-1 cells resulted in up to an 86% reduction in tumor necrosis factor-alpha production, implicating that normal miR-146a function is critical for the regulation of tumor necrosis factor-alpha production", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18759964", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 170, 
          "text": "icroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19404929", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1051, 
          "offsetInEndSection": 1156, 
          "text": "We found that miR-124a levels significantly decreased in RA synoviocytes as compared with OA synoviocytes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19404929", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1485, 
          "offsetInEndSection": 1597, 
          "text": "Induction of miR-124a in RA synoviocytes significantly suppressed the production of the CDK-2 and MCP-1 proteins", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19404929", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1774, 
          "offsetInEndSection": 1903, 
          "text": "he results of this study suggest that miR-124a is a key miRNA in the posttranscriptional regulatory mechanisms of RA synoviocytes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19404929", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 87, 
          "text": "iR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19931339", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 286, 
          "offsetInEndSection": 627, 
          "text": "Although a multifactorial pathogenesis has been hypothesized, the precise mechanisms leading to the disease are still poorly understood at the molecular level. miRNA expression profile analysis highlighted that miR-223 is the only miRNA that is strikingly deregulated in peripheral T-lymphocytes from RA patients compared with healthy donors", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19931339", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1055, 
          "offsetInEndSection": 1275, 
          "text": "In summary, our data provide a first characterization of the miRNA expression profiles of peripheral T-lymphocytes of RA patients, identifying miR-223 as overexpressed in CD4(+) naive T-lymphocytes from these individuals", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19931339", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 118, 
          "text": "Altered microRNA expression profile with miR-146a upregulation in CD4+ T cells from patients with rheumatoid arthritis", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20459811", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 594, 
          "offsetInEndSection": 692, 
          "text": "The role of miR-146a overexpression in regulating T cell apoptosis was evaluated by flow cytometry", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20459811", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1483, 
          "offsetInEndSection": 1763, 
          "text": "We have detected increased miR-146a in CD4+ T cells of RA patients and its close correlation with TNF-alpha levels. Our findings that miR-146a overexpression suppresses T cell apoptosis indicate a role of miR-146a in RA pathogenesis and provide potential novel therapeutic targets", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20459811", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 92, 
          "text": "icroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20840794", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 936, 
          "offsetInEndSection": 1059, 
          "text": "Six miRNAs, let-7a, miR-26, miR-146a/b, miR-150, and miR-155 were significantly up regulated in the IL-17 producing T cells", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20840794", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1487, 
          "offsetInEndSection": 1601, 
          "text": "These results indicated that miR-146a was associated with IL-17 expression in the PBMC and synovium in RA patients", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20840794", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2, 
          "offsetInEndSection": 163, 
          "text": "polymorphism in the 3'-UTR of interleukin-1 receptor-associated kinase (IRAK1), a target gene of miR-146a, is associated with rheumatoid arthritis susceptibility", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20870441", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 263, 
          "offsetInEndSection": 374, 
          "text": "MicroRNA-146a was found to be increased in synovial fibroblasts, synovial tissue and PBMC from patients with RA", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20870441", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1011, 
          "offsetInEndSection": 1134, 
          "text": "This is the first study that addresses association of a variant in a target of miR-146a, IRAK1 gene, with RA susceptibility", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20870441", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 117, 
          "text": "ltered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21279994", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 115, 
          "offsetInEndSection": 335, 
          "text": "Previously, we described increased expression of miR-155 and miR-146a in rheumatoid arthritis (RA) and showed a repressive effect of miR-155 on matrix metalloproteinase (MMP) expression in RA synovial fibroblasts (RASFs)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21279994", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1575, 
          "offsetInEndSection": 1670, 
          "text": "The current results demonstrate methylation-dependent regulation of miR-203 expression in RASFs", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21279994", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1671, 
          "offsetInEndSection": 1879, 
          "text": " Importantly, they also show that elevated levels of miR-203 lead to increased secretion of MMP-1 and IL-6 via the NF-\u03baB pathway and thereby contribute to the activated phenotype of synovial fibroblasts in RA", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21279994", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 120, 
          "text": "iR-124a as a key regulator of proliferation and MCP-1 secretion in synoviocytes from patients with rheumatoid arthritis", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21339227", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 364, 
          "offsetInEndSection": 498, 
          "text": "Transfection of miR-124a into RA synoviocytes significantly suppressed their proliferation and arrested the cell cycle at the G1 phase", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21339227", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 766, 
          "offsetInEndSection": 911, 
          "text": "It is proposed that miR-124a is a key miRNA in the post-transcriptional regulatory mechanisms of RA synoviocytes, and has a therapeutic potential", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21339227", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 156, 
          "text": "Expression of miR-146a and miR-16 in peripheral blood mononuclear cells of patients with rheumatoid arthritis and their correlation to the disease activity", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21354921", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 960, 
          "offsetInEndSection": 1128, 
          "text": "The elevated expression levels of miR-146a and miR-16 are correlated to RA disease activity, suggesting their value in assessment of the clinical disease activity of RA", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21354921", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 125, 
          "text": "iR-346 controls release of TNF-\u03b1 protein and stability of its mRNA in rheumatoid arthritis via tristetraprolin stabilization", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21611196", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 426, 
          "offsetInEndSection": 650, 
          "text": "Using a microarray, we found two miRNAs, miR-125b and miR-939 predicted to target the 3'-UTR of TNF-\u03b1 mRNA, to be up-regulated in RA FLS in response to LPS, but their repression did not restore mature TNF-\u03b1 expression in FLS", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21611196", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 652, 
          "offsetInEndSection": 781, 
          "text": "We showed previously that miR-346, which is upregulated in LPS-activated FLS, inhibited Btk expression that stabilized TNF-\u03b1 mRNA", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21611196", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 354, 
          "offsetInEndSection": 555, 
          "text": "Different expression patterns of mir-146a, miRNA-155, miRNA-124a, mir-203, mir-223, mir-346, mir-132, mir-363, mir-498, mir-15a, and mir-16 were documented in several tissue sample types of RA patients", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22100329", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 107, 
          "text": "own-regulation of microRNA-34a* in rheumatoid arthritis synovial fibroblasts promotes apoptosis resistance", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22161761", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 848, 
          "offsetInEndSection": 1055, 
          "text": "Basal expression levels of miR-34a* were found to be reduced in synovial fibroblasts from RA patients compared to osteoarthritis patients, whereas levels of miR-34a, miR-34b/b*, and miR-34c/c* did not differ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22161761", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1623, 
          "offsetInEndSection": 1724, 
          "text": "Our data provide evidence of a methylation-specific down-regulation of proapoptotic miR-34a* in RASFs", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22161761", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 170, 
          "text": "dentification of microRNA-221/222 and microRNA-323-3p association with rheumatoid arthritis via predictions using the human tumour necrosis factor transgenic mouse model", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22562984", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 720, 
          "offsetInEndSection": 867, 
          "text": "miR-seq demonstrated that TghuTNF-SF exhibit a distinct pathogenic profile with 22 significantly upregulated and 30 significantly downregulated miR", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22562984", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 869, 
          "offsetInEndSection": 1063, 
          "text": "Validation assays confirmed the dysregulation of miR-223, miR-146a and miR-155 previously associated with human rheumatoid arthritis (RA) pathology, as well as that of miR-221/222 and miR-323-3p", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22562984", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1594, 
          "offsetInEndSection": 1678, 
          "text": "the authors identified miR-221/222 and miR-323-3p as novel dysregulated miR in RA SF", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22562984", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1495, 
          "offsetInEndSection": 1633, 
          "text": "Further association studies may contribute to determining the role of miR-146a single-nucleotide polymorphisms in immune-mediated diseases", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22823586", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 144, 
          "text": "iR-146a polymorphism is associated with asthma but not with systemic lupus erythematosus and juvenile rheumatoid arthritis in Mexican patients.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22823586", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 99, 
          "text": "verexpression of microRNA-223 in rheumatoid arthritis synovium controls osteoclast differentiation", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22903258", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 80, 
          "offsetInEndSection": 159, 
          "text": "MicroRNA-223 (miR-223) is reported to play critical roles in osteoclastogenesis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22903258", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1474, 
          "offsetInEndSection": 1589, 
          "text": "MiR-223 is intensely expressed in RA synovium, and overexpression of miR-223 suppresses osteoclastogenesis in vitro", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22903258", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1591, 
          "offsetInEndSection": 1700, 
          "text": "This study demonstrates the possibility of gene therapy with miR-223 to treat bone destruction in RA patients", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22903258", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 931, 
          "offsetInEndSection": 1085, 
          "text": "MiR-223 was more highly expressed in RA synovium than in osteoarthritis (OA) synovium due to the increased number of miR-223-positive cells in RA synovium", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22903258", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 124, 
          "text": "ssociation of pre-miRNA-146a rs2910164 and pre\u2011miRNA-499 rs3746444 polymorphisms and susceptibility to rheumatoid arthritis", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23138379", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1263, 
          "offsetInEndSection": 1439, 
          "text": "Our findings demonstrated that the hsa-mir-499 rs3746444, but not mir-146a rs2910164, polymorphism is associated with an increased RA risk in a sample of the Iranian population", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23138379", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 139, 
          "text": "umor necrosis factor \u03b1-induced microRNA-18a activates rheumatoid arthritis synovial fibroblasts through a feedback loop in NF-\u03baB signaling", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23280137", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 161, 
          "text": "To elucidate whether the microRNA (miRNA) cluster miR-17-92 contributes to the activated phenotype of rheumatoid arthritis synovial fibroblasts (RASFs", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23280137", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 803, 
          "offsetInEndSection": 895, 
          "text": "We found that TNF\u03b1 induces the expression of miR-17-92 in RASFs in an NF-\u03baB-dependent manner", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23280137", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1151, 
          "offsetInEndSection": 1270, 
          "text": "Using reporter gene assays, we identified the NF-\u03baB pathway inhibitor TNF\u03b1-induced protein 3 as a new target of miR-18a", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23280137", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1431, 
          "offsetInEndSection": 1708, 
          "text": "Our data suggest that the miR-17-92-derived miR-18a contributes to cartilage destruction and chronic inflammation in the joint through a positive feedback loop in NF-\u03baB signaling, with concomitant up-regulation of matrix-degrading enzymes and mediators of inflammation in RASFs", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23280137", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 529, 
          "offsetInEndSection": 774, 
          "text": "As inflammation and joint damage are the main hallmarks of RA, we focused on the three miRNAs, miR-146a, miR-155 and miR-223, whose functions have been studied in both the processes and the pathogenic role investigated in the experimental models", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23318734", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 785, 
          "offsetInEndSection": 979, 
          "text": "Focusing on the role of miR-146a, miR-155 and miR-223 in RA pathogenesis emphasizes the intertwined relationships between bone homeostasis and immunity, and the prominent role of monocytes in RA", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23318734", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 517, 
          "offsetInEndSection": 619, 
          "text": "In a final perspective section we discuss the potential impact of therapeutic miR-155 modulation in RA", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23649045", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 15, 
          "offsetInEndSection": 151, 
          "text": "correlation between whole blood and PBMC expression levels of miR-155 and miR-146a in healthy controls and rheumatoid arthritis patients", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24120842", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 654, 
          "offsetInEndSection": 821, 
          "text": "We demonstrated a highly significant linear correlation between miR-146a and miR-155 expression in PBMC and whole blood, from both healthy individuals and RA patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24120842", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 9, 
          "offsetInEndSection": 183, 
          "text": "expression of specific microRNAs (miRNA) in peripheral blood-derived mononuclear cells (PBMC), particularly miR-146a and miR-155, is associated with rheumatoid arthritis (RA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24120842", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 106, 
          "text": "icroRNA-323-3p with clinical potential in rheumatoid arthritis, Alzheimer's disease and ectopic pregnancy", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24283221", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 332, 
          "offsetInEndSection": 491, 
          "text": "It has been shown that miR-323-3p associates with the pathogenesis of several diseases, such as rheumatoid arthritis, Alzheimer's disease and ectopic pregnancy", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24283221", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "How are lincRNA affecting the regulation of gene expression?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24268656", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24022994", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23597480", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22403033", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24316222", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24080187", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23965803", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23541921", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22841487"
      ], 
      "type": "summary", 
      "id": "533c3571c45e133714000005", 
      "snippets": [
        {
          "offsetInBeginSection": 259, 
          "offsetInEndSection": 483, 
          "text": "We detected a considerable number of cis expression quantitative trait loci (cis-eQTLs) and demonstrated that the genetic regulation of lincRNA expression is independent of the regulation of neighboring protein-coding genes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24268656", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 713, 
          "offsetInEndSection": 930, 
          "text": "We observe biases in lincRNA genomic locations and expression profiles that are consistent with some of these lincRNAs being involved in the regulation of neighboring protein-coding genes with developmental functions.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22403033", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 106, 
          "offsetInEndSection": 337, 
          "text": "In\u00a0this issue of Developmental Cell, Wang et\u00a0al. (2013) find that linc-RoR maintains human embryonic stem cell self-renewal by functioning as a sponge to trap miR-145, thus regulating core pluripotency factors Oct4, Nanog, and Sox2", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23597480", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1008, 
          "offsetInEndSection": 1175, 
          "text": "Enrichment of expressed lincRNA promoters in enhancer marks provides an additional argument for the involvement of lincRNAs in the regulation of transcription in cis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24268656", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 750, 
          "offsetInEndSection": 938, 
          "text": "Together, these findings suggest that lincRNA-p21 is an important player in the regulation of the Warburg effect and also implicate lincRNA-p21 as a valuable therapeutic target for cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24316222", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1387, 
          "offsetInEndSection": 1675, 
          "text": "Our findings implicate a novel RNA gene, lincRNA AC068718.1, as risk factor for PTSD in women and add to emerging evidence that non-coding RNA genes may play a crucial role in shaping the landscape of gene regulation with putative pathological effects that lead to phenotypic differences.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24080187", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1252, 
          "offsetInEndSection": 1466, 
          "text": "Taken together, our results imply that mdig is involved in the regulation of H3K9me3 to influence the heterochromatin structure of the genome and the expression of genes important for cell growth or transformation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23965803", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 110, 
          "text": "ndogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23541921", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 386, 
          "offsetInEndSection": 552, 
          "text": "Here, we demonstrate that a lincRNA, linc-RoR, may function as a key competing endogenous RNA to link the network of miRNAs and core TFs, e.g., Oct4, Sox2, and Nanog.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23541921", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 728, 
          "offsetInEndSection": 848, 
          "text": "We suggest that linc-RoR forms a feedback loop with core TFs and miRNAs to regulate ESC maintenance and differentiation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23541921", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 96, 
          "text": "ammalian long intergenic noncoding RNAs (lincRNAs) are best known for modulating transcription.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22841487", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 785, 
          "offsetInEndSection": 875, 
          "text": "Our findings uncover a role for lincRNA as a posttranscriptional inhibitor of translation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22841487", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the principle of the PAR-CLIP methodology?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20371350", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20644507", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21559008", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21572407", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21816340", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21851591", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22926237", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22885304", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22844102", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22213601", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22152485", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23368412", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24297251", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23706177"
      ], 
      "type": "summary", 
      "id": "533c388dc45e133714000008", 
      "snippets": [
        {
          "offsetInBeginSection": 222, 
          "offsetInEndSection": 371, 
          "text": "We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20371350", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 211, 
          "offsetInEndSection": 567, 
          "text": "To gain insight into the complexity of snoRNA processing and the functional relevance of snoRNA-derived small RNAs, we sequence long and short RNAs, small RNAs that co-precipitate with the Argonaute 2 protein and RNA fragments obtained in photoreactive nucleotide-enhanced crosslinking and immunoprecipitation (PAR-CLIP) of core snoRNA-associated proteins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23706177", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 206, 
          "offsetInEndSection": 441, 
          "text": "A large amount of miRNA-target interactions (MTIs) have been identified by the crosslinking and immunoprecipitation (CLIP) and the photoactivatable-ribonucleoside-enhanced CLIP (PAR-CLIP) along with the next-generation sequencing (NGS)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23368412", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 443, 
          "offsetInEndSection": 584, 
          "text": "PAR-CLIP shows high efficiency of RNA co-immunoprecipitation, but it also lead to T to C conversion in miRNA-RNA-protein crosslinking regions", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23368412", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 150, 
          "offsetInEndSection": 279, 
          "text": "A recent method, PAR-CLIP, uses photoreactive nucleosides to crosslink RBPs to target RNAs in cells prior to immunoprecipitation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22152485", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 421, 
          "offsetInEndSection": 611, 
          "text": "In this article, we review crosslinking and immunoprecipitation (CLIP) methods adapted for large-scale identification of target RNA-binding sites and the respective RNA recognition elements.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22213601", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 612, 
          "offsetInEndSection": 779, 
          "text": "CLIP methods have the potential to detect hundreds of thousands of binding sites in single experiments although the separation of signal from noise can be challenging.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22213601", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 895, 
          "offsetInEndSection": 1184, 
          "text": "We focus on photoactivatable ribonucleoside-enhanced CLIP, which relies on the intracellular incorporation of photoactivatable ribonucleoside analogs into nascent transcripts, and yields characteristic sequence changes upon crosslinking that facilitate the separation of signal from noise.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22213601", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 4, 
          "offsetInEndSection": 184, 
          "text": "Photo-Activatable Ribonucleoside-enhanced CrossLinking and ImmunoPrecipitation (PAR-CLIP) method was recently developed for global identification of RNAs interacting with proteins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22844102", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 185, 
          "offsetInEndSection": 301, 
          "text": "The strength of this versatile method results from induction of specific T to C transitions at sites of interaction.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22844102", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 205, 
          "offsetInEndSection": 343, 
          "text": "PAR-CLIP reveals a collection of RNAs bound to a protein whereas SILAC-based RNA pull-downs identify a group of proteins bound to an RNA. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22885304", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 474, 
          "offsetInEndSection": 743, 
          "text": "Here we present a step-by-step protocol and guidelines for the computational analysis for the large-scale identification of miRNA target sites in cultured cells by photoactivatable ribonucleoside enhanced crosslinking and immunoprecipitation (PAR-CLIP) of AGO proteins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22926237", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 138, 
          "offsetInEndSection": 233, 
          "text": "In particular, PAR-CLIP utilizes a photoactivatable nucleoside for more efficient crosslinking.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21851591", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 136, 
          "text": "rosslinking and immunoprecipitation (CLIP) protocols have made it possible to identify transcriptome-wide RNA-protein interaction sites", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21851591", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 93, 
          "offsetInEndSection": 294, 
          "text": "In this issue of Molecular Cell, Mukherjee et al. (2011) and Lebedeva et al. (2011) identify transcriptome-wide HuR-RNA interactions using PAR-CLIP, unveiling HuR's nuclear role in pre-mRNA processing.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21816340", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 130, 
          "text": "ross-linking and immunoprecipitation (CLIP) is increasingly used to map transcriptome-wide binding sites of RNA-binding proteins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21572407", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 131, 
          "offsetInEndSection": 373, 
          "text": "We developed a method for CLIP data analysis, and applied it to compare CLIP with photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP) and to uncover how differences in cross-linking and ribonuclease digestion affect the identified sites.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21572407", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 752, 
          "offsetInEndSection": 905, 
          "text": "In order to increase the specificity and positional resolution, a strategy referred to as CLIP (UV cross-linking and immunoprecipitation) was introduced.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21559008", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1252, 
          "offsetInEndSection": 1350, 
          "text": "Recently, PAR-CLIP was introduced that uses photoreactive ribonucleoside analogs for cross-linking", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21559008", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 91, 
          "text": "AR-CliP--a method to identify transcriptome-wide the binding sites of RNA binding proteins", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20644507", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1457, 
          "offsetInEndSection": 1716, 
          "text": "We developed a powerful cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs that we term PAR-CliP (Photoactivatable-Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20644507", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1761, 
          "offsetInEndSection": 1943, 
          "text": "The method relies on the incorporation of photoreactive ribonucleoside analogs, such as 4-thiouridine (4-SU) and 6-thioguanosine (6-SG) into nascent RNA transcripts by living cells. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20644507", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2303, 
          "offsetInEndSection": 2477, 
          "text": "One characteristic feature of cDNA libraries prepared by PAR-CliP is that the precise position of crosslinking can be identified by mutations residing in the sequenced cDNA. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20644507", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is an approximate number of CTCF binding sites in the human genome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23707059", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22955980", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22829947", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22709888", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15670593", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15229244", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11854173", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11076856", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8034708"
      ], 
      "type": "factoid", 
      "id": "533c38b3c45e133714000009", 
      "snippets": [
        {
          "offsetInBeginSection": 265, 
          "offsetInEndSection": 384, 
          "text": "To study CTCF multivalency in\u00a0vivo, we define ZF binding requirements at \u223c50,000 genomic sites in primary lymphocytes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23707059", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1436, 
          "offsetInEndSection": 1521, 
          "text": "However, only ~3,700 out of the ~5,700 CTCFL- and ~31,000 CTCF-binding sites overlap.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22709888", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is an acceptable sequence coverage(depth) required for human whole-exome sequencing?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24065236", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23940558", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23728943", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23647072", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23450047", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23357921", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23349227", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23272691", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23015295", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22952768", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22654895", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22156295", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22038007", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21943378", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21499249", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24290377", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23160641", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21654732"
      ], 
      "type": "factoid", 
      "id": "533c390bc45e13371400000b", 
      "snippets": [
        {
          "offsetInBeginSection": 543, 
          "offsetInEndSection": 708, 
          "text": "A total of 5.97 Gb clean data were generated for the two samples, achieving a mean depth of coverage of 31.96 and 32.88 for the AAA and normal samples, respectively.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24065236", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 871, 
          "offsetInEndSection": 970, 
          "text": "The 1.7 Mb targeted regions were sequenced with a coverage ranged from 32\u00d7 to 45\u00d7 for the 28 genes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23940558", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 313, 
          "offsetInEndSection": 425, 
          "text": "We performed whole-exome sequencing on 87 HCCs and matched normal adjacent tissues to an average coverage of 59\u00d7", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23728943", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 793, 
          "offsetInEndSection": 1192, 
          "text": "We performed WES (mean coverage approximately 40\u00d7) on 10 trios comprised of unaffected parents and a child with sporadic epilepsy characterized by difficult-to-control seizures and some combination of developmental delay, epileptic encephalopathy, autistic features, cognitive impairment, or motor deficits. Sequence processing and variant calling were performed using standard bioinformatics tools.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23647072", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 564, 
          "offsetInEndSection": 712, 
          "text": "Whole-exome sequencing achieved a high degree of coverage such that approximately 97% of targeted bases were represented by more than 10 base reads;", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23450047", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 335, 
          "offsetInEndSection": 628, 
          "text": "AbCD is a user-friendly interface providing pre-estimated effective sample sizes, specific to each minor allele frequency category, for designs with arbitrary coverage (0.5-30\u00d7) and sample size (20-10 000), and for four major ethnic groups (Europeans, Africans, Asians and African Americans). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23357921", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 903, 
          "offsetInEndSection": 1031, 
          "text": "Next generation sequencing with mean coverage of 50\u00d7 using the Illumina Hi Seq and whole exome capture processing was performed.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23349227", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1135, 
          "offsetInEndSection": 1571, 
          "text": "mtDNA genome coverage varied depending on the mtDNA:nuclear blend ratio, where a 1:100 ratio provided optimal dual-genome coverage with 10X coverage for over 97.5% of all targeted nuclear regions and 1,000X coverage for 99.8% of the mtDNA genome. mtDNA mutations were reliably detected to at least an 8% heteroplasmy level, as discriminated both from sequencing errors and potential contamination from nuclear mtDNA transcripts (Numts).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23272691", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 900, 
          "offsetInEndSection": 974, 
          "text": "Each sample was sequenced to a mean depth of coverage of greater than 120\u00d7", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23015295", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 810, 
          "offsetInEndSection": 1019, 
          "text": "Long-PCR targeting was more efficient with up to 94% of USH gene regions displaying an overall coverage higher than 25\u00d7, whereas whole exome sequencing yielded a similar coverage for only 50% of those regions.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22952768", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1347, 
          "offsetInEndSection": 1448, 
          "text": "WES reads covered 91% of the target capture region (of size 37.2\u2009MB) with an average coverage of 65\u00d7.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22654895", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 189, 
          "offsetInEndSection": 296, 
          "text": "We captured 162,073 exons of 16,954 genes and sequenced the targeted regions to a mean coverage of 56-fold.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22156295", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 208, 
          "offsetInEndSection": 359, 
          "text": "The specificity of exome enrichment was approximately 80% with 95.6% even coverage of the 34 Mb target region at an average sequencing depth of 33-fold", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22038007", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 629, 
          "offsetInEndSection": 710, 
          "text": "We generated over 4.7 GB of mappable sequence to a 125X read coverage per sample.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21943378", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 143, 
          "offsetInEndSection": 543, 
          "text": "By massively parallel sequencing of a primary hepatitis C virus-positive hepatocellular carcinoma (36\u00d7 coverage) and matched lymphocytes (>28\u00d7 coverage) from the same individual, we identified more than 11,000 somatic substitutions of the tumor genome that showed predominance of T>C/A>G transition and a decrease of the T>C substitution on the transcribed strand, suggesting preferential DNA repair.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21499249", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 832, 
          "offsetInEndSection": 975, 
          "text": "Whole-exome sequencing at a higher sequence depth (>76\u00d7 coverage) revealed a TSC1 nonsense substitution in a subpopulation of the tumor cells. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21499249", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 157, 
          "offsetInEndSection": 354, 
          "text": "We sequenced the exomes of 1,000 Danish cases with common forms of type 2 diabetes (including body mass index\u00a0> 27.5\u00a0kg/m(2) and hypertension) and 1,000 healthy controls to an average depth of 56\u00d7.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24290377", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 299, 
          "offsetInEndSection": 456, 
          "text": "We performed medium-depth (8\u00d7) whole exome sequencing in 1,000 cases with type 2 diabetes, BMI >27.5\u00a0kg/m(2) and hypertension and in 1,000 controls (stage 1)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23160641", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which are the main functions of the human HuR (ELAVL1) protein in fibroblasts?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21164076", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21745814", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21816340", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22201738", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23155001", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23223443", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23837869", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15861128", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15824116", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12730239", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20007147", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19884656", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19345675", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19289500", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19252527", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24152440", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23508105", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23401122", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22446588", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22310293", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21515253", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17392515", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17317627", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17288991", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16639702", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15863502", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15543229", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15036402", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14530362", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12605686", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12242302", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11486028", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10673359", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10075998", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9860962", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9763509", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9628881", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9155038"
      ], 
      "type": "summary", 
      "id": "533c394ec45e13371400000c", 
      "snippets": [
        {
          "offsetInBeginSection": 906, 
          "offsetInEndSection": 1166, 
          "text": "The H(2)O(2)-dependent sGC\u03b21 upregulation was attributable to sGC\u03b21 mRNA stabilization, conditioned by the translocation of the mRNA-binding protein HuR from the nucleus to the cytosol, and the increased mRNA binding of HuR to the sGC\u03b21 3' untranslated region.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21164076", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1167, 
          "offsetInEndSection": 1249, 
          "text": "HuR silencing reversed the effects of H(2)O(2) on sGC\u03b21 levels and cGMP synthesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21164076", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1263, 
          "offsetInEndSection": 1426, 
          "text": "Our results identify H(2)O(2) as an endogenous mediator contributing to the regulation of vascular tone and point to a key role of HuR in sGC\u03b21 mRNA stabilization.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21164076", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 178, 
          "text": "Cytoplasmic export of the RNA-binding protein HuR, a process that critically regulates its function, was recently shown to be inhibited by the AMP-activated protein kinase (AMPK)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12730239", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 593, 
          "offsetInEndSection": 736, 
          "text": "HuR function was previously shown to be implicated in the maintenance of a \"young cell\" phenotype in models of replicative cellular senescence.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12730239", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 870, 
          "offsetInEndSection": 1057, 
          "text": "The in vitro binding selectivity of HuR is indicative of an ARE sequence's ability to destabilize a mRNA in vivo, suggesting a critical role for HuR in the regulation of mRNA degradation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9155038", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 705, 
          "offsetInEndSection": 869, 
          "text": "urification and subsequent analyses demonstrate that this 32 kDa protein is identical to a recently identified member of the Elav-like gene family (ELG) called HuR.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9155038", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1064, 
          "offsetInEndSection": 1219, 
          "text": "We also show that HuR can be induced to redistribute from the nucleus to the cytoplasm and that this redistribution is associated with an altered function.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9628881", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 79, 
          "text": "RNA stabilization by the AU-rich element binding protein, HuR, an ELAV protein.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9628881", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 136, 
          "text": "ELAV protein HuA (HuR) can redistribute between nucleus and cytoplasm and is upregulated during serum stimulation and T cell activation.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9763509", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 611, 
          "offsetInEndSection": 808, 
          "text": " HuR is an RNA-binding protein that can stabilize labile mRNAs containing AU-rich elements in their 3' untranslated regions and has been shown to shuttle between the nucleus and cytoplasm (18, 19).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9860962", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 936, 
          "offsetInEndSection": 1142, 
          "text": "We propose that HuR first may bind AU-rich element-containing mRNAs in the nucleus and then escort them through the nuclear pore, providing protection during and after export to the cytoplasmic compartment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9860962", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1172, 
          "offsetInEndSection": 1355, 
          "text": "Taken together, these data show that a correlation exists between the binding of HuR to the AU-rich motif in vitro and the destabilizing properties conferred by this sequence in vivo.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10075998", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 677, 
          "offsetInEndSection": 870, 
          "text": "HuR interacts with AU-rich elements in the 3'UTR of many protooncogenes, cytokines, and transcription factors, thereby regulating the expression of these mRNAs on the posttranscriptional level.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10673359", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 871, 
          "offsetInEndSection": 1055, 
          "text": "Transfection assays with a CAT reporter construct revealed reduced expression of the reporter, suggesting that HuR may be involved in the fine-tuning of the expression of the NF1 gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10673359", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 426, 
          "offsetInEndSection": 584, 
          "text": "Importantly, overexpression of HuR in senescent cells restored a \"younger\" phenotype, while a reduction in HuR expression accentuated the senescent phenotype.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11486028", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 585, 
          "offsetInEndSection": 676, 
          "text": "Our studies highlight a critical role for HuR during the process of replicative senescence.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11486028", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 74, 
          "offsetInEndSection": 271, 
          "text": "Here, using two models of replicative senescence, we describe the influence of the RNA-binding protein HuR in regulating the expression of several genes whose expression decreases during senescence", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11486028", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 273, 
          "offsetInEndSection": 425, 
          "text": "We demonstrate that HuR levels, HuR binding to target mRNAs encoding proliferative genes, and the half-lives of such mRNAs are lower in senescent cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11486028", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 97, 
          "text": "Loss of HuR is linked to reduced expression of proliferative genes during replicative senescence.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11486028", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 252, 
          "offsetInEndSection": 579, 
          "text": "Although in vitro experiments showed indiscriminate binding of Hu proteins synthesized in bacterial systems to many different AU-rich elements (AREs), in vivo studies have pointed to a cytoplasmic role for HuR protein in antagonizing the rapid decay of some specific ARE-containing mRNAs, depending on physiological situations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12242302", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1682, 
          "offsetInEndSection": 1871, 
          "text": "Our data suggest that the ARE-binding specificity of HuR in vivo is modulated to interact only with and thus regulate specific AREs in a cell type- and physiological state-dependent manner.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12242302", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1183, 
          "offsetInEndSection": 1417, 
          "text": "Overexpression of HuD and HuR in murine fibroblasts caused a striking stabilization of the endogenous MARCKS mRNA even under conditions when the MARCKS mRNA is normally actively degraded, i.e. after treating cells with phorbol ester. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12605686", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1675, 
          "offsetInEndSection": 1824, 
          "text": "Our findings implicate mRNA stabilization in the cytokine-mediated increase in eotaxin expression and strongly suggest a role for HuR in this effect.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14530362", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 141, 
          "text": "Proteasome inhibition increases HuR level, restores heat-inducible HSP72 expression and thermotolerance in WI-38 senescent human fibroblasts.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15036402", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 648, 
          "offsetInEndSection": 782, 
          "text": "This result is consistent with the proposed role of HuR in assisting mRNA export to the cytoplasm and in antagonizing its degradation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15036402", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 926, 
          "offsetInEndSection": 1147, 
          "text": "HuR immunoprecipitations were positive for RhoB mRNA indicating an in vivo association, and Western blot analysis and immunofluorescence demonstrated that HuR rapidly partitions from the nucleus to the cytoplasm after UVL", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15543229", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 224, 
          "offsetInEndSection": 327, 
          "text": "In the cytosol, HuR is thought to function to control stability and translation of its ligand message. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15863502", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "HuR is a ligand for nuclear mRNAs containing adenylate-uridylate-rich (ARE) elements in the 3'-untranslated region.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16639702", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 116, 
          "offsetInEndSection": 229, 
          "text": "Once bound to the mRNA, HuR is recognized by adapter proteins that then facilitate nuclear export of the complex.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16639702", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 230, 
          "offsetInEndSection": 332, 
          "text": "In the cytosol, HuR is thought to function to control stability and translation of its ligand message.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16639702", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 326, 
          "text": "HuR is a ligand for nuclear mRNAs containing adenylate-uridylate rich elements in the 3'-untranslated region. Once bound to the mRNA, HuR is recognized by adapter proteins which then facilitate nuclear export of the complex. In the cytosol HuR is thought to function to control stability and translation of its ligand message.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17288991", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 73, 
          "text": "The RNA binding protein HuR regulates the stability of many target mRNAs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17317627", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 74, 
          "offsetInEndSection": 277, 
          "text": "Here, we report that HuR associated with the 3' untranslated region of the mRNA encoding the longevity and stress-response protein SIRT1, stabilized the SIRT1 mRNA, and increased SIRT1 expression levels.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17317627", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 226, 
          "text": "In this study, we investigated the molecular mechanisms underlying the ATP analogue adenosine-5'-O-(3-thio)triphosphate-induced nucleocytoplasmic shuttling of the mRNA stabilizing factor HuR in human (h) mesangial cells (MC). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17392515", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 325, 
          "offsetInEndSection": 402, 
          "text": "HuR is an essential regulator of mesenchymal responses during lung branching.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21515253", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1176, 
          "offsetInEndSection": 1382, 
          "text": "Our data reveals HuR as the first RBP identified to play a dominant role in lung development and as a key post-transcriptional regulator of networks guiding tissue remodeling during branching morphogenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21515253", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 230, 
          "offsetInEndSection": 338, 
          "text": "Here we demonstrated a relevance for miR-9 in HL pathogenesis and identified two new targets Dicer1 and HuR.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22310293", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 669, 
          "offsetInEndSection": 882, 
          "text": "We show that inhibition of miR-9 leads to derepression of DICER and HuR, which in turn results in a decrease in cytokine production by HL cells followed by an impaired ability to attract normal inflammatory cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22310293", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 88, 
          "text": "A conserved TGF\u03b21/HuR feedback circuit regulates the fibrogenic response in fibroblasts.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22446588", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 623, 
          "offsetInEndSection": 794, 
          "text": "Knockdown of HuR decreased the endogenous expression of TGF\u03b21 under exogenous TGF\u03b21 treatment, simultaneously with the decrease of Col1a, Col3a and fibronectin expression.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22446588", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 795, 
          "offsetInEndSection": 977, 
          "text": "Our study here established a TGF\u03b21/HuR feedback circuit regulating the fibrogenic response in fibroblasts, and targeting this feedback loop is of great potential to control fibrosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22446588", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 272, 
          "offsetInEndSection": 545, 
          "text": "Here, we demonstrated that increased stabilization and subsequent over-expression of HuR mRNA were coupled to TTP deficiency. These findings were observed in breast cancer cell lines with an invasive phenotype and were further confirmed in ZFP36-knockout mouse fibroblasts.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23401122", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 546, 
          "offsetInEndSection": 681, 
          "text": "We show that TTP-HuR imbalance correlated with increased expression of AU-rich element (ARE) mRNAs that code for cancer invasion genes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23401122", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 290, 
          "offsetInEndSection": 472, 
          "text": "Here, we show that an RNA-binding protein, HuR (human antigen R), represses ARF mRNA translation, thereby maintaining the replicative life span of mouse embryonic fibroblasts (MEFs).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23508105", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 647, 
          "offsetInEndSection": 813, 
          "text": "The outcome of this analysis was a list of target genes regulated via HuR for their association (either increased or reduced) with the nuclear hnRNP A1-RNP complexes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24152440", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1045, 
          "offsetInEndSection": 1312, 
          "text": "The differentially enriched mRNAs were found to belong to GO categories relevant to biological processes anticipated for hnRNP A1 and HuR (such as transport, transcription, translation, apoptosis and cell cycle) indicating their concerted function in mRNA metabolism.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24152440", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 128, 
          "offsetInEndSection": 303, 
          "text": "Here, we show that overexpression of RNase L decreases cellular growth and downmodulates the RNA-binding protein, HuR, a regulator of cell-cycle progression and tumorigenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19252527", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1346, 
          "offsetInEndSection": 1607, 
          "text": "In sum, our results indicate that NO stabilizes mRNA subsets in fibroblasts, identify HuR as an RBP implicated in the NO response, reveal that HuR alone is insufficient for stabilizing several mRNAs by NO, and show that HO-1 induction by NO is regulated by HuR.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19289500", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 314, 
          "offsetInEndSection": 515, 
          "text": "Suppression of HuR using siRNA resulted in an attenuation of the 3T3-L1 differentiation program, consistent with HuR control of the expression of mRNA ligand(s) critical to the differentiation process.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19345675", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 908, 
          "offsetInEndSection": 1024, 
          "text": "In mouse embryonic fibroblasts, HuR bound to and stabilized the mRNA for Mdm2, a critical negative regulator of p53.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19884656", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1120, 
          "offsetInEndSection": 1284, 
          "text": "Our results reveal a positive feedback mechanism for the regulation of HuR, which may play an important role in the regulation of HuR during replicative senescence.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20007147", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 192, 
          "text": "In dividing cells, the RNA-binding protein HuR associates with and stabilizes labile mRNAs encoding proliferative proteins, events that are linked to the increased cytoplasmic presence of HuR.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15824116", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 516, 
          "offsetInEndSection": 644, 
          "text": "On the basis of these observations, we postulated a role for HuR in promoting the proliferation of vascular smooth muscle cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15824116", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1180, 
          "offsetInEndSection": 1323, 
          "text": "We propose that HuR contributes to regulating hVSMC growth and homeostasis in pathologies associated with vascular smooth muscle proliferation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15824116", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 85, 
          "text": "Antiapoptotic function of RNA-binding protein HuR effected through prothymosin alpha.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15861128", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 139, 
          "text": "We report the antiapoptotic effect of RNA-binding protein HuR, a critical regulator of the post-transcriptional fate of target transcripts.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15861128", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 961, 
          "offsetInEndSection": 1143, 
          "text": "Together, our data support a regulatory scheme whereby HuR binds the ProTalpha mRNA, elevates its cytoplasmic abundance and translation, and thereby elicits an antiapoptotic program.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15861128", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1293, 
          "offsetInEndSection": 1464, 
          "text": "CARM1 represses replicative senescence by methylating HuR and thereby enhancing HuR's ability to regulate the turnover of cyclin A, cyclin B1, c-fos, SIRT1, and p16 mRNAs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23837869", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 143, 
          "text": "HuR, also known as Elavl1, is an RNA-binding protein that regulates embryonic development, progenitor cell survival, and cell stress responses.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23223443", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1735, 
          "offsetInEndSection": 1912, 
          "text": "Together, these studies reveal an evolutionarily conserved post-transcriptional mechanism involving competitive interactions between HuR and miR-200b that controls angiogenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23223443", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 864, 
          "offsetInEndSection": 1075, 
          "text": "Immunoprecipitation of RNA-protein complexes and luciferase reporter assays indicate that HuR antagonizes the suppressive activity of miR-200b, down-regulates miR-200b expression, and promotes VEGF-A expression.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23223443", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 163, 
          "offsetInEndSection": 373, 
          "text": "Here we present evidence that CUGBP1 and HuR jointly regulate the translation of occludin and play a crucial role in the maintenance of tight junction (TJ) integrity in the intestinal epithelial cell monolayer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23155001", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1034, 
          "offsetInEndSection": 1279, 
          "text": "These findings indicate that CUGBP1 represses occludin translation by increasing occludin mRNA recruitment to P-bodies, whereas HuR promotes occludin translation by blocking occludin mRNA translocation to P-bodies via the displacement of CUGBP1.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23155001", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 289, 
          "offsetInEndSection": 492, 
          "text": "Through its post-transcriptional influence on specific target mRNAs, HuR can alter the cellular response to proliferative, stress, apoptotic, differentiation, senescence, inflammatory and immune stimuli.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22201738", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 835, 
          "offsetInEndSection": 1106, 
          "text": "We focus on HuR's well-recognized implication in cancer and chronic inflammation, and discuss emerging studies linking HuR to cardiovascular, neurological, and muscular pathologies. We also discuss the progress, potential, and challenges of targeting HuR therapeutically.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22201738", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1125, 
          "offsetInEndSection": 1347, 
          "text": "These results indicate that HuR regulates occludin mRNA translation through Chk2-dependent HuR phosphorylation and that this influence is crucial for maintenance of the epithelial barrier integrity in the intestinal tract.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21745814", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 230, 
          "offsetInEndSection": 319, 
          "text": "The RNA-binding protein HuR modulates the stability and translation of many target mRNAs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21745814", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 320, 
          "offsetInEndSection": 459, 
          "text": "Here, we investigated the role of HuR in the regulation of occludin expression and therefore in the intestinal epithelial barrier function.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21745814", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 460, 
          "offsetInEndSection": 552, 
          "text": "HuR bound the 3'-untranslated region of the occludin mRNA and enhanced occludin translation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21745814", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 553, 
          "offsetInEndSection": 640, 
          "text": "HuR association with the occludin mRNA depended on Chk2-dependent HuR phosphorylation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21745814", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are most driver gene mutations synonymous or non-synonymous?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24147068", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23935863", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23819581", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23799614", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23704925", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23694700", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23450047", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23015295", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22893128", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22649506", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22072984", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19633228", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15946860"
      ], 
      "type": "factoid", 
      "id": "534427f8aeec6fbd07000009", 
      "snippets": [
        {
          "offsetInBeginSection": 1649, 
          "offsetInEndSection": 1869, 
          "text": "Therefore, this study highlights the need for multiple biopsies and sequencing during progression of a cancer and combinatorial DNA and RNA sequencing approach for systematic identification of expressed driver mutations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24147068", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 703, 
          "offsetInEndSection": 934, 
          "text": "Whole genome sequencing of the index liver metastasis identified 44 non-synonymous somatic mutations in 42 genes (0.85 mutation/MB) and a large hemizygous deletion in the ATRX gene which has been recently reported in neuroblastoma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24147068", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 543, 
          "offsetInEndSection": 650, 
          "text": "In addition, we show that NetDiseaseSNP discriminates cancer driver and passenger mutations satisfactorily.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23935863", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 651, 
          "offsetInEndSection": 913, 
          "text": "Our method outperforms other state-of-the-art methods on several disease/neutral datasets as well as on cancer driver/passenger mutation datasets and can thus be used to pinpoint and prioritize plausible disease candidates among nsSNPs for further investigation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23935863", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1411, 
          "offsetInEndSection": 1704, 
          "text": "Moreover, we find that a large fraction of the driver mutations are neither located in conserved functional sites, nor responsible for structural stability, but rather regulate protein activity through allosteric transitions, protein-protein interactions, or protein-nucleic acid interactions.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23819581", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 128, 
          "offsetInEndSection": 239, 
          "text": "We used whole-exome sequencing to identify novel non-synonymous somatic mutations in squamous cell lung cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23799614", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 240, 
          "offsetInEndSection": 399, 
          "text": "We identified 101 single-nucleotide variants (SNVs) including 77 non-synonymous SNVs (67 missense and 10 nonsense mutations) and 11 INDELs causing frameshifts.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23799614", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 781, 
          "offsetInEndSection": 1066, 
          "text": "Besides confirming the presence of known melanoma driver mutations (BRAF(V600E), NRAS(Q61R) ), we identified novel mutated genes involved in signalling pathways crucial for melanoma pathogenesis and already addressed by current targeted therapies (such as MAPK and glutamate pathways).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23704925", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 260, 
          "text": "A common goal of tumor sequencing projects is finding genes whose mutations are selected for during tumor development. This is accomplished by choosing genes that have more non-synonymous mutations than expected from an estimated background mutation frequency.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23694700", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are cancer driver genes?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24233780", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24214964", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24084849", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24009526", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23694700", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23416983", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22851646", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21169372", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20707908", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19574499", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19081671", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18339846"
      ], 
      "type": "summary", 
      "id": "534428feaeec6fbd0700000a", 
      "snippets": [
        {
          "offsetInBeginSection": 225, 
          "offsetInEndSection": 493, 
          "text": "We constructed DriverDB (http://ngs.ym.edu.tw/driverdb/), a database which incorporates 6079 cases of exome-seq data, annotation databases (such as dbSNP, 1000 Genome and Cosmic) and published bioinformatics algorithms dedicated to driver gene/mutation identification.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24214964", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 77, 
          "text": "DriverDB: an exome sequencing database for cancer driver gene identification.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24214964", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 135, 
          "text": "With the ability to fully sequence tumor genomes/exomes, the quest for cancer driver genes can now be undertaken in an unbiased manner.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24084849", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 316, 
          "offsetInEndSection": 452, 
          "text": "Here we show that the combination of complementary methods allows identifying a comprehensive and reliable list of cancer driver genes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24084849", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 819, 
          "offsetInEndSection": 964, 
          "text": "In summary, the catalog of driver genes and the methodology presented here open new avenues to better understand the mechanisms of tumorigenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24084849", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 84, 
          "offsetInEndSection": 270, 
          "text": "A subset of these mutations contribute to tumor progression (known as \"driver\" mutations) whereas the majority of these mutations are effectively neutral (known as \"passenger\" mutations)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18339846", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 272, 
          "offsetInEndSection": 421, 
          "text": "The ability to differentiate between drivers and passengers will be critical to the success of upcoming large-scale cancer DNA resequencing projects.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18339846", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 800, 
          "offsetInEndSection": 1263, 
          "text": " In fact, recent sequencing and resequencing (i.e., polymorphism identification) efforts have catalyzed the quest for protein kinase 'driver' mutations (i.e., those genetic alterations which contribute to the transformation of a normal cell to a proliferating cancerous cell) in distinction to kinase 'passenger' mutations which reflect mutations that merely build up in course of normal and unchecked (i.e., cancerous) somatic cell replication and proliferation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19081671", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 913, 
          "offsetInEndSection": 1213, 
          "text": "This method was applied to available breast cancer, colorectal cancer, and glioblastoma sequence data, and identified Wnt/TGF-beta cross-talk, Wnt/VEGF signaling, and MAPK/focal adhesion kinase pathways as targets of rare driver mutations in breast, colorectal cancer, and glioblastoma, respectively.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19574499", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 125, 
          "offsetInEndSection": 314, 
          "text": "Analysis of the frequency of specific mutations across different tumors has been able to identify some, but not all of the mutated genes that contribute to tumor initiation and progression.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19574499", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 251, 
          "text": "We are developing a cross-species comparison strategy to distinguish between cancer driver- and passenger gene alteration candidates, by utilizing the difference in genomic location of orthologous genes between the human and other mammals.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20707908", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 161, 
          "text": "Major tumor sequencing projects have been conducted in the past few years to identify genes that contain 'driver' somatic mutations in tumor samples.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21169372", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 898, 
          "offsetInEndSection": 1115, 
          "text": "At the same time, we determined that some genes previously reported as drivers were not significant by the new analysis because mutations in these genes occurred mainly in tumors with large background mutation rates. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21169372", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 114, 
          "text": "Identifying genomic alterations driving breast cancer is complicated by tumor diversity and genetic heterogeneity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22851646", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 187, 
          "text": "Herein we report a proof-of-principle study illustrating a novel dog-human comparison strategy that addresses a central aim of cancer research, namely cancer driver-passenger distinction.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23416983", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1559, 
          "offsetInEndSection": 1818, 
          "text": "Expansion of this study would make more driver-passenger distinctions for cancers with large genomic amplifications or deletions, and address key questions regarding the relationship between cancer pathogenesis and epithelial cell polarity control in mammals.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23416983", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 102, 
          "text": "Adjusting for background mutation frequency biases improves the identification of cancer driver genes.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23694700", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 79, 
          "text": "The identification of cancer drivers is a major goal of current cancer research", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24009526", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1105, 
          "offsetInEndSection": 1265, 
          "text": "We conclude that zebrafish-human comparative analysis represents a powerful, and broadly applicable, tool to enrich for evolutionarily conserved cancer drivers.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24009526", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Does the CTCF protein co-localize with cohesin?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22780989", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21628529", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20219941", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19109133", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24321385", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24257606", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23945083", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23804403", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23498937", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23295672", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23204437", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23010778", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22952237", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22550178", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22440186", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21970734", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21948239", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21880767", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21876668", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21606361", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21444719", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21106760", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20133600", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19369356", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19308701", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19158269", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18623068", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18550811"
      ], 
      "type": "yesno", 
      "id": "5344310baeec6fbd0700000c", 
      "snippets": [
        {
          "offsetInBeginSection": 348, 
          "offsetInEndSection": 560, 
          "text": "To investigate cohesin-non-CTCF (CNC) binding events in vivo we mapped cohesin and CTCF, as well as a collection of tissue-specific and ubiquitous transcriptional regulators using ChIP-seq in primary mouse liver.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22780989", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 667, 
          "offsetInEndSection": 886, 
          "text": "In contrast to regions of the genome where cohesin and CTCF colocalize, CNC sites coincide with the binding of master regulators and enhancer-markers and are significantly associated with liver-specific expressed genes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22780989", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 415, 
          "offsetInEndSection": 541, 
          "text": "Here we report that cohesins colocalize with CTCF at two additional imprinted loci, the Dlk1-Dio3 and the Kcnq1/Kcnq1ot1 loci.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21628529", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 598, 
          "offsetInEndSection": 834, 
          "text": "By use of human hepatocellular carcinoma cells (HepG2), we found that liver-specific transcription factors colocalize with cohesin independently of CTCF at liver-specific targets that are distinct from those found in breast cancer cells", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20219941", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 687, 
          "offsetInEndSection": 879, 
          "text": "Because cohesin can colocalize with CTCF, we performed chromatin immunoprecipitation for the cohesin subunit Rad21 and found lineage and stage-specific Rad21 recruitment to CTCF in all Ig loci", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19109133", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 323, 
          "offsetInEndSection": 486, 
          "text": "Here we show that zebrafish runx1 is directly bound by cohesin and CCCTC binding factor (CTCF) at the P1 and P2 promoters, and within the intron between P1 and P2.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321385", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 669, 
          "offsetInEndSection": 866, 
          "text": "The intronic binding sites for cohesin and CTCF coincide with histone modifications that confer enhancer-like properties, and two of the cohesin/CTCF sites behaved as insulators in an in vivo assay", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321385", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 868, 
          "offsetInEndSection": 1023, 
          "text": "The identified cohesin and CTCF binding sites are likely to be cis-regulatory elements (CREs) for runx1 since they also recruit RNA polymerase II (RNAPII).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321385", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 157, 
          "offsetInEndSection": 387, 
          "text": "We have found that CTCF and cohesin are highly enriched at the convergent and partially overlapping transcripts for the LMP1 and LMP2A genes, but it is not yet known how CTCF and cohesin may coordinately regulate these transcripts", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24257606", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 124, 
          "text": "haracterization of constitutive CTCF/cohesin loci: a possible role in establishing topological domains in mammalian genomes", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23945083", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 744, 
          "offsetInEndSection": 890, 
          "text": "Our analysis revealed: 1) constitutive CTCF loci were located in constitutive open chromatin and often co-localized with constitutive cohesin loci", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23945083", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 738, 
          "offsetInEndSection": 922, 
          "text": "In brain, a third of CTCF and cohesin binding sites coincide, consistent with the potential for many interactions between cohesin and CTCF but also many instances of independent action", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23804403", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 261, 
          "offsetInEndSection": 389, 
          "text": "Here, we focus on the emerging roles of CTCF and the cohesin in coordinating long-range interactions between regulatory elements", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23498937", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 750, 
          "offsetInEndSection": 1018, 
          "text": "Chromatin immunoprecipitation for CTCF and the cohesin subunits RAD21 and SMC3 reveals evolutionarily conserved binding sites within unmethylated regions \u223c5 kb downstream of the PLAGL1 differentially methylated region and within the PLAGL1 3' untranslated region (UTR)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23295672", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 42, 
          "text": "TCF physically links cohesin to chromatin", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18550811", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 65, 
          "text": "ohesin and CTCF: cooperating to control chromosome conformation?", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18623068", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 222, 
          "offsetInEndSection": 374, 
          "text": "Recently, three groups mapped numerous cohesin-binding sites in mammalian chromosomes and found substantial overlap with the CCCTC-binding factor (CTCF)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18623068", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 516, 
          "offsetInEndSection": 644, 
          "text": "We found that each site contains a conserved CTCF consensus sequence, binds CTCF, and recruits the cohesin subunit Rad21 in vivo", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19158269", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 273, 
          "offsetInEndSection": 408, 
          "text": "Recent experiments have revealed that cohesin binds to the same sites in mammalian genomes as the zinc finger transcription factor CTCF", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19308701", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 579, 
          "offsetInEndSection": 765, 
          "text": "Here we review what is known about the roles of cohesin and CTCF in regulating gene expression in mammalian cells, and we discuss how cohesin might mediate the insulator function of CTCF", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19308701", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 444, 
          "offsetInEndSection": 674, 
          "text": "Previous studies have shown that this major latency control region is occupied by the cellular chromatin boundary factor CTCF and chromosome structural maintenance proteins SMC1, SMC3, and RAD21, which comprise the cohesin complex", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19369356", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 961, 
          "offsetInEndSection": 1070, 
          "text": "Cohesin subunits assembled at the CTCF binding sites and bound CTCF proteins in a cell cycle-dependent manner", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19369356", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1533, 
          "offsetInEndSection": 1788, 
          "text": "We propose that the CTCF-cohesin complex plays a critical role in regulating the cell cycle control of viral gene expression during latency and that failure to maintain cell cycle control of latent transcripts inhibits host cell proliferation and survival", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19369356", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 91, 
          "offsetInEndSection": 298, 
          "text": "We used chromosome conformation capture to determine long-range interactions among CTCF/cohesin sites over 2 Mb on human chromosome 11 encompassing the beta-globin locus and flanking olfactory receptor genes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20133600", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 920, 
          "offsetInEndSection": 1115, 
          "text": "These results support a genome-wide role for CTCF/cohesin sites through loop formation that both influences transcription and contributes to cell-type-specific chromatin organization and function", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20133600", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 741, 
          "offsetInEndSection": 892, 
          "text": "Increased methylation at this promoter triggered the dissociation of the insulator protein CTCF as well as the accompanying cohesin from the BDNF locus", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21106760", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 152, 
          "text": "icotinamide adenine dinucleotide (NAD)-regulated DNA methylation alters CCCTC-binding factor (CTCF)/cohesin binding and transcription at the BDNF locus", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21106760", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 234, 
          "text": "ecent studies have shown that the protein CTCF, which plays an important role in insulation and in large-scale organization of chromatin within the eukaryotic nucleus, depends for both activities on recruitment of the cohesin complex", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21444719", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 236, 
          "offsetInEndSection": 411, 
          "text": "We show here that the interaction of CTCF with the cohesin complex involves direct contacts between the cohesin subunit SA2 and specific regions of the C-terminal tail of CTCF", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21444719", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 743, 
          "offsetInEndSection": 885, 
          "text": "Taken together, our results demonstrate that specific sites on the C terminus of CTCF are essential for cohesin binding and insulator function", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21444719", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 887, 
          "offsetInEndSection": 1004, 
          "text": "The only direct interaction between CTCF and cohesin involves contact with SA2, which is external to the cohesin ring", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21444719", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 626, 
          "offsetInEndSection": 788, 
          "text": "These numerous CTCF/cohesin sites potentially form the bases of the multiloop rosette structures at the Igh locus that compact during Ig heavy chain rearrangement", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21606361", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 153, 
          "offsetInEndSection": 399, 
          "text": "We have previously shown that the Kaposi's Sarcoma-Associated Herpesvirus (KSHV) major latency transcripts encoding LANA, vCyclin, vFLIP, v-miRNAs, and Kaposin are regulated, in part, by a chromatin organizing element that binds CTCF and cohesins", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876668", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 757, 
          "offsetInEndSection": 924, 
          "text": "Mutation of the CTCF-cohesin binding site reduced or eliminated the chromatin conformation linkages, and deregulated viral transcription and genome copy number control", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876668", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1282, 
          "offsetInEndSection": 1483, 
          "text": "Our findings indicate that KSHV genomes are organized into chromatin loops mediated by CTCF and cohesin interactions, and that these inter-chromosomal linkages coordinate latent and lytic gene control.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876668", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 323, 
          "offsetInEndSection": 491, 
          "text": "We show here that GA disrupts an RNA polymerase II (RNAPII) complex that accumulates at the CTCF-cohesin binding site within the first intron of the latency transcript.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880767", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 492, 
          "offsetInEndSection": 638, 
          "text": "GA altered the enrichment of the RNAPII pausing complex, along with pausing factors SPT5 and NELF-A, at the intragenic CTCF-cohesin binding sites.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880767", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 960, 
          "offsetInEndSection": 1116, 
          "text": "GA treatment also inhibited the transcription of some cellular genes, like c-myc, which contain a similar CTCF-cohesin binding site within the first intron.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880767", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1223, 
          "offsetInEndSection": 1499, 
          "text": "These findings suggest that RNAPII pauses at intragenic CTCF-cohesin binding sites and that abrogation of this pausing by GA leads to loss of proper mRNA production and defects in sister chromatid cohesion, a process important for both viral and cellular chromosome stability.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880767", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 120, 
          "text": "TCF and cohesin cooperatively mediate the cell-type specific interchromatin interaction between Bcl11b and Arhgap6 loci", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21948239", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 467, 
          "offsetInEndSection": 648, 
          "text": "Additional experiments verified that the interchromatin interaction between the Bcl11b and Arhgap6 loci was cell-type specific, which was cooperatively mediated by CTCF and cohesin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21948239", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 118, 
          "text": "enome-wide studies of CCCTC-binding factor (CTCF) and cohesin provide insight into chromatin structure and regulation", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22952237", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 315, 
          "offsetInEndSection": 544, 
          "text": "Recent genome-wide studies mapping the binding sites of CTCF and its interacting partner, cohesin, using chromatin immunoprecipitation coupled with deep sequencing (ChIP-seq) revealded that CTCF globally co-localizes with cohesin", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22952237", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 165, 
          "offsetInEndSection": 375, 
          "text": "Here, we show by ChIP-Seq that most human subtelomeres contain a CTCF- and cohesin-binding site within \u223c1-2\u2009kb of the TTAGGG repeat tract and adjacent to a CpG-islands implicated in TERRA transcription control.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23010778", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 974, 
          "offsetInEndSection": 1155, 
          "text": "These findings indicate that CTCF and cohesin are integral components of most human subtelomeres, and important for the regulation of TERRA transcription and telomere end protection", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23010778", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 517, 
          "offsetInEndSection": 731, 
          "text": "In addition, we show that this DNA looping requires specific binding of the CTCF/cohesin complex to two symmetrically aligned binding sites in both the transcriptionally active promoters and in one of the enhancers", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23204437", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the major adverse effect of adriamycin(doxorubicin)?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21295102", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15997091", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15114698", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12445862", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12074691", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3461747", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3459397", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3947104", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7325994"
      ], 
      "type": "factoid", 
      "id": "53551206a0726bee57000001", 
      "snippets": [
        {
          "offsetInBeginSection": 972, 
          "offsetInEndSection": 1158, 
          "text": "It remains to be seen whether inhibition by adriamycin of these systems is related to the severe cardiotoxicity, the major adverse effect of the drug that limits its clinical usefulness.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7325994", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 961, 
          "offsetInEndSection": 1058, 
          "text": "Leukocytopenia was the major adverse effect among patients undergoing systemic THP administration", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3947104", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 536, 
          "offsetInEndSection": 589, 
          "text": "The major adverse effect was bone-marrow suppression;", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3459397", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 813, 
          "offsetInEndSection": 866, 
          "text": "The major adverse effect was bone marrow suppression;", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3461747", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 644, 
          "offsetInEndSection": 746, 
          "text": "Cardiotoxicity is a major adverse effect of the anthracycline antibiotics and can be acute or chronic;", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12074691", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 864, 
          "offsetInEndSection": 1034, 
          "text": "chronic cardiotoxicity represents a serious adverse effect that may be lethal due to the development of irreversible, cumulative dose-dependent, congestive cardiomyopathy", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12074691", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 380, 
          "offsetInEndSection": 642, 
          "text": "Myelosuppression, predominantly neutropenia and leucopenia, is the dose-limiting toxicity; in addition to this, mucositis, nausea, vomiting and alopecia are frequent, whereas hepatopathy, characterised by elevated bilirubin concentrations, occurs less frequently", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12074691", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 115, 
          "offsetInEndSection": 240, 
          "text": "In spite of the routine use of this drug its major adverse effect, the dose-dependent cardiotoxicity, cannot be prevented yet", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12445862", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 389, 
          "offsetInEndSection": 434, 
          "text": "The major adverse effect was myelosuppression", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15114698", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 78, 
          "text": "Cardiac toxicity is a major adverse effect caused by doxorubicin (DOX) therapy", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15997091", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 107, 
          "text": "Antioxidative and cardioprotective effects of Phyllanthus urinaria L. on doxorubicin-induced cardiotoxicity", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15997091", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 55, 
          "offsetInEndSection": 164, 
          "text": "The major adverse effect of DOX treatment in cancer patients is the onset of cardiomyopathy and heart failure", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21295102", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is there increased incidence of incontinence in athletes?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23687004", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23361854", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23122895", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21571270", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21501085", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20890872", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20390664", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19415493", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18506324", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17390923", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16953954", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15385857", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15233598", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11999199", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11689727", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10932809", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8684695", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8041527"
      ], 
      "type": "yesno", 
      "id": "5361677c7d100faa09000008", 
      "snippets": [
        {
          "offsetInBeginSection": 270, 
          "offsetInEndSection": 482, 
          "text": "Urinary incontinence affects women of all ages, including top female athletes, but is often under-reported. The highest prevalence of urinary incontinence is reported in those participating in high impact sports.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23687004", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 29, 
          "offsetInEndSection": 196, 
          "text": "The prevalence of female stress urinary incontinence is high, and young adults are also affected, including athletes, especially those involved in \"high-impact\" sports", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23361854", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1841, 
          "offsetInEndSection": 2074, 
          "text": "Analysis of these data suggests that perineal pressure is decreased in female athletes compared with nonathlete women. A lower perineal pressure correlates with increased symptoms of urinary incontinence and pelvic floor dysfunction.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23122895", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 943, 
          "offsetInEndSection": 1033, 
          "text": "Urinary incontinence is a prevalent condition among athletes that is not openly discussed.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21571270", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1464, 
          "offsetInEndSection": 1564, 
          "text": "High-level sport appears to be a significant independent risk factor for AI in healthy young women. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501085", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 604, 
          "offsetInEndSection": 671, 
          "text": "The prevalence of LUTS was 54.7%, and 30% for urinary incontinence.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20890872", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1528, 
          "offsetInEndSection": 1583, 
          "text": "LUTS and incontinence are prevalent in female athletes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20890872", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 121, 
          "text": "A relationship between sport or fitness activities and urinary incontinence (UI) previously has been described in women. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20390664", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 203, 
          "offsetInEndSection": 294, 
          "text": "studies have also shown a high prevalence of SUI in young, physically fit female athletes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19415493", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 727, 
          "offsetInEndSection": 830, 
          "text": "There was urinary incontinence in female long-distance runners and a correlation with eating disorders.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18506324", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 31, 
          "offsetInEndSection": 136, 
          "text": "young female athletes participating in high-impact sports may be at higher risk for urinary incontinence.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17390923", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 363, 
          "offsetInEndSection": 631, 
          "text": "Results indicated that more than 25% of those completing surveys experienced incontinence and that more than 90% had never told anyone about their problem and had no knowledge of preventive measures; 16% reported incontinence negatively impacted their quality of life.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17390923", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1303, 
          "offsetInEndSection": 1377, 
          "text": "There is a very high prevalence of urinary incontinence in women athletes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16953954", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 697, 
          "offsetInEndSection": 832, 
          "text": "Women athletes should be counseled about the increased risk of urinary incontinence with ultra high-impact sports and eating disorders.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15385857", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 606, 
          "offsetInEndSection": 1036, 
          "text": "Stress urinary incontinence is a barrier to women's participation in sport and fitness activities and, therefore, it may be a threat to women's health, self-esteem and well-being. The prevalence during sports among young, nulliparous elite athletes varies between 0% (golf) and 80% (trampolinists). The highest prevalence is found in sports involving high impact activities such as gymnastics, track and field, and some ball games", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15233598", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1202, 
          "offsetInEndSection": 1330, 
          "text": "Urinary leakage is common among elite athletes and dancers, particularly during training, but also during daily life activities.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11999199", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1850, 
          "offsetInEndSection": 2064, 
          "text": "There is a high prevalence of stress and urge incontinence in female elite athletes. The frequency of SUI and urge incontinence was significantly higher in eating disordered athletes compared with healthy athletes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11689727", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1356, 
          "offsetInEndSection": 1419, 
          "text": "High impact sports activities may produce urinary incontinence.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10932809", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 825, 
          "offsetInEndSection": 906, 
          "text": "Urinary incontinence during physical stresses is common in young nulliparous wome", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8684695", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1307, 
          "offsetInEndSection": 1395, 
          "text": "Incontinence during physical stresses is common in young, highly fit, nulliparous women.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8041527", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Has silicon been used in treatment of  incontinence ?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22933007", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22687358", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20065535", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15582258", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15183554", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12806798", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10838378", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10711555", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9690182"
      ], 
      "type": "yesno", 
      "id": "536172d17d100faa09000009", 
      "snippets": [
        {
          "offsetInBeginSection": 686, 
          "offsetInEndSection": 1026, 
          "text": "an artificial anal sphincter. Worldwide, there are two established devices on the market: the artificial bowel sphincter\u00ae (ABS) from A. M. S. (Minnetonka, MN, USA) and the soft anal band\u00ae from A. M. I. (Feldkirch, Austria). How to implant the artificial anal sphincter? Both devices consist of a silicon cuff which can be filled with fluid.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22933007", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 208, 
          "offsetInEndSection": 326, 
          "text": "The InVance\u2122 system uses a silicon-coated polyester sling positioned under the bulbar urethra via a perineal incision.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22687358", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 658, 
          "offsetInEndSection": 869, 
          "text": "Through a perineal incision three titanium screws with a polipropylene suture were inserted in each ischiopubic rami, and a silicon/polipropylene mesh (Invance) is affixed to them, compressing the bulbar urethra", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20065535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 65, 
          "offsetInEndSection": 450, 
          "text": "surgical treatment of female stress urinary incontinence with a trans-obturator sub-urethral tape of Uratape (Porg\u00e9s). METHODS: Treatment and follow up of their complication were performed at the CHRU of Lille. RESULTS: In both cases, this complication is related to prolonged vaginal exposition of the tape. Vaginal erosion always occurs next to the silicon coated section of the tape", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15582258", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 578, 
          "offsetInEndSection": 705, 
          "text": "A non-elastic, polypropylene tape (UraTape, Mentor-Porg\u00e8s) with a silicon coated central part was placed under the mid-urethra.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15183554", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1441, 
          "offsetInEndSection": 1767, 
          "text": " Stress incontinence is a rare complication in men, usually following prostatic surgery. It can be treated conservatively with pelvic floor training and alpha-adrenergic receptor agonists and if necessary surgically with submucosal collagen or silicon injections in the sphincter area or implantation of a sphincter prosthesis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12806798", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 181, 
          "offsetInEndSection": 339, 
          "text": "The Femassist is a medical-grade silicon dome-shaped device, worn over the urethra and held securely via suction and a commercially available adhesive lotion.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10838378", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 142, 
          "text": "To examine the performance of a silicon urinary control device for nonsurgical management of women with genuine stress incontinence", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10711555", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 168, 
          "offsetInEndSection": 524, 
          "text": "The \"FemAssist\" is a dome-shaped medical grade silicon device intended to be worn over the external urethral meatus and held in place by suction and an adhesive gel. Thirty eight women with varying degrees of genuine stress urinary incontinence (GSUI) or mixed incontinence on multichannel urodynamic testing were fitted with one of two sizes of \"FemAssist", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9690182", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the name for anorexia in gymnasts?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24240086", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10551340"
      ], 
      "type": "factoid", 
      "id": "53617eeb7d100faa0900000a", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 118, 
          "text": "Elite Rhythmic Gymnasts (RGs) constitute a unique metabolic model and they are prone to developing Anorexia Athletica.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240086", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 201, 
          "offsetInEndSection": 273, 
          "text": "We studied 13 female juvenile elite gymnasts with anorexia athletica (AA", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10551340", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are microRNA (miR) regulated through DNA methylation of their promoters?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23658527", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23229728", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18677110", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23707524", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24238656", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23153241", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22715154", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22710432", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19807731"
      ], 
      "type": "yesno", 
      "id": "53636e727d100faa0900000d", 
      "snippets": [
        {
          "offsetInBeginSection": 1121, 
          "offsetInEndSection": 1575, 
          "text": "We found that Tcf3 down-regulation in the context of constitutively active Wnt signaling does not result from promoter DNA methylation but is likely to be caused by a plethora of mechanisms at both the RNA and protein level as shown by the observed decrease in activating histone marks (H3K4me3 and H3-acetylation) and the upregulation of miR-211, a novel Wnt-regulated microRNA that targets Tcf3 and attenuates early neural differentiation in mouse ESCs", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23658527", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 127, 
          "text": "ene silencing of MIR22 in acute lymphoblastic leukaemia involves histone modifications independent of promoter DNA methylation", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19807731", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 878, 
          "offsetInEndSection": 1007, 
          "text": "Whereas a CpG island was identified within the promoter element of MIR22, no promoter DNA methylation was detected in these cells", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19807731", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 139, 
          "text": "xtensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22710432", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 592, 
          "offsetInEndSection": 741, 
          "text": "Integration of DNA methylation and miRNA promoter data led to the identification of 128 recurrent miRNA targets for aberrant promoter DNA methylation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22710432", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1227, 
          "offsetInEndSection": 1461, 
          "text": "Together, our findings characterize the role of epigenetic changes in the regulation of miRNA transcription and create a repository of disease-specific promoter regions that may provide additional insights into the pathogenesis of CLL", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22710432", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 53, 
          "text": "NA methylation of microRNA genes in multiple myeloma", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22715154", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 347, 
          "offsetInEndSection": 511, 
          "text": "Recently, epigenetic dysregulation of tumor-suppressor miRNA genes by promoter DNA methylation has been implicated in human cancers, including multiple myeloma (MM)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22715154", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 41, 
          "text": "ethylation of tumor suppressor microRNAs", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23153241", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 191, 
          "offsetInEndSection": 345, 
          "text": "Dysregulation of miRNA expression involved in cancer can be triggered by multiple mechanisms including aberrant DNA methylation of the miRNA gene promoter", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23153241", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 347, 
          "offsetInEndSection": 443, 
          "text": "Of note, DNA methylation of tumor suppressor miRNAs has been implicated in various human cancers", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23153241", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 445, 
          "offsetInEndSection": 625, 
          "text": "Moreover, miRNA silencing mediated by aberrant promoter DNA methylation can potentially be reversed by hypomethylating agents, and hence may pose a new therapeutic target in cancer", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23153241", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 626, 
          "offsetInEndSection": 838, 
          "text": " In this review, the authors will focus on the aberrant methylation of miRNAs in the pathogenesis of lymphoid malignancies including chronic lymphocytic leukemia, multiple myeloma and acute lymphoblastic leukemia", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23153241", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 707, 
          "offsetInEndSection": 1026, 
          "text": "Here, we review those miRNAs implicated in AD that are regulated by promoter DNA methylation and/or chromatin modifications and, which frequently direct the expression of constituents of the epigenetic machinery, concluding with the delineation of a complex epigenetic-miRNA regulatory network and its alterations in AD", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24238656", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 716, 
          "offsetInEndSection": 943, 
          "text": "Furthermore, we also discuss epigenetic dysregulation of tumor-suppressor miRNA genes by promoter DNA methylation and the interaction of DNA methylation with miRNAs involved in the regulation of HSC activation and liver fibrosi", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23707524", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 974, 
          "offsetInEndSection": 1165, 
          "text": "Instead, the cell type-specific silencing of these genes is due to enhanced p21 mRNA degradation, 14-3-3sigma promoter DNA methylation and reduced processing of the miR-34a primary transcript", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18677110", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 100, 
          "offsetInEndSection": 207, 
          "text": "Some tumor-suppressive miRNAs are known to be epigenetically silenced by promoter DNA methylation in cancer", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229728", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 209, 
          "offsetInEndSection": 339, 
          "text": "In the present study, we aimed to identify miRNA genes that are silenced by DNA hypermethylation in hepatocellular carcinoma (HCC)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229728", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 470, 
          "offsetInEndSection": 806, 
          "text": "It was found that miR-335, which is harbored within an intron of its protein-coding host gene, MEST, was downregulated by aberrant promoter hypermethylation via further methylation assays, including methylation-specific PCR, combined bisulfite and restriction analysis, bisulfite sequencing analysis and 5-aza-2'-deoxycytidine treatment", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229728", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 971, 
          "offsetInEndSection": 1134, 
          "text": "he levels of miR-335/MEST methylation were significantly higher in 18 (90%) out of 20 primary HCC tumors, compared to their non-tumor tissue counterparts (P<0.001)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229728", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1459, 
          "offsetInEndSection": 1568, 
          "text": "In conclusion, our results indicate that expression of miR-335 is reduced by aberrant DNA methylation in HCC.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229728", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which are the most abundant human lincRNA?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24035497", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23243023", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23129630", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23073843", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22916204", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22858678", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22840393", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22718948", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22840402", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22684254", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20459797", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17270048", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12490325", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9886562", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8785513"
      ], 
      "type": "list", 
      "id": "5363bad27d100faa0900000e", 
      "snippets": [
        {
          "offsetInBeginSection": 630, 
          "offsetInEndSection": 817, 
          "text": "One abundant such RNA, ci-ankrd52, largely accumulates to its sites of transcription, associates with elongation Pol II machinery, and acts as a positive regulator of Pol II transcription", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24035497", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 4, 
          "offsetInEndSection": 279, 
          "text": "long noncoding RNA MALAT1 (metastasis-associated lung adenocarcinoma transcript 1), also known as MALAT-1 or NEAT2 (nuclear-enriched abundant transcript 2), is a highly conserved nuclear noncoding RNA (ncRNA) and a predictive marker for metastasis development in lung cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23243023", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 354, 
          "offsetInEndSection": 629, 
          "text": "Because viruses borrow molecular mechanisms from their hosts, we searched highly abundant human long-noncoding RNAs and identified putative ENE-like structures in metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) and multiple endocrine neoplasia-\u03b2 (MEN\u03b2) RNAs. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23129630", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 4, 
          "offsetInEndSection": 173, 
          "text": "MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) locus is misregulated in many human cancers and produces an abundant long nuclear-retained noncoding RNA.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23073843", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 300, 
          "offsetInEndSection": 418, 
          "text": "Many long noncoding RNAs (lncRNAs) appear to have epigenetic regulatory function in humans, including HOTAIR and XIST.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22916204", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 4, 
          "offsetInEndSection": 166, 
          "text": "metastasis-associated lung adenocarcinoma transcript 1, MALAT1, is a long non-coding RNA (lncRNA) that has been discovered as a marker for lung cancer metastasis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22858678", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 167, 
          "offsetInEndSection": 439, 
          "text": "It is highly abundant, its expression is strongly regulated in many tumor entities including lung adenocarcinoma and hepatocellular carcinoma as well as physiological processes, and it is associated with many RNA binding proteins and highly conserved throughout evolution.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22858678", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1203, 
          "offsetInEndSection": 1313, 
          "text": "Thus, loss of the abundant nuclear long ncRNA MALAT1 is compatible with cell viability and normal development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22858678", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 250, 
          "text": "bundant expression of the long noncoding (lnc) PAN (polyadenylated nuclear) RNA by the human oncogenic gammaherpesvirus Kaposi's sarcoma-associated herpesvirus (KSHV) depends on a cis-element called the expression and nuclear retention element (ENE)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22840393", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 162, 
          "text": "alat1 is an abundant long, noncoding RNA that localizes to nuclear bodies known as nuclear speckles, which contain a distinct set of pre-mRNA processing factors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22718948", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 251, 
          "offsetInEndSection": 427, 
          "text": "Malat1 (metastasis associated lung adenocarcinoma transcript 1) is among the most abundant and highly conserved lncRNAs, and it exhibits an uncommon 3'-end processing mechanism", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22840402", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 4, 
          "offsetInEndSection": 249, 
          "text": "H19 large intergenic non-coding RNA (lincRNA) is one of the most highly abundant and conserved transcripts in mammalian development, being expressed in both embryonic and extra-embryonic cell lineages, yet its physiological function is unknown. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22684254", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1643, 
          "offsetInEndSection": 1838, 
          "text": "Our genome-wide screens in two mammalian species reveal no more than three abundant large non-coding polyadenylated RNAs in the nucleus; the canonical large noncoding RNA XIST and NEAT1 and NEAT2", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17270048", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 149, 
          "text": "19, which is one of the most abundantly expressed imprinted genes during mammalian embryonic and foetal development, has been cloned from a ruminant", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12490325", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 767, 
          "offsetInEndSection": 974, 
          "text": "H19 mRNA is highly abundant in most ovine embryonic and foetal tissues of mesodermal and endodermal origins but was not detected in tissues of ectodermal origin such as the trophectoderm and the foetal brain", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12490325", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1170, 
          "offsetInEndSection": 1264, 
          "text": "Abundant expression of H19 was evident in fetal bladder but was absent in normal adult bladder", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9886562", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1639, 
          "offsetInEndSection": 1927, 
          "text": "urthermore, we discuss results showing an abundant expression of H19 gene in some adenocarcinomas of bad prognosis, in the context of the otherwise established tumor-suppressor role of this gene, or the strictly controlled gene dosage, which could be overridden in these particular cases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8785513", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 999, 
          "offsetInEndSection": 1291, 
          "text": "One of the first lncRNA genes discovered was MALAT1, the metastasis-associated lung adenocarcinoma transcript 1,21 later also referred to as NEAT2 for nuclear-enriched abundant transcript 2. MALAT1 is highly abundant and is expressed in many healthy organs, most strongly in pancreas and lung", 
          "beginSection": "sections.0", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22858678", 
          "endSection": "sections.0"
        }
      ]
    }
  ]
}